Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication for Rapid Dissemination of Preliminary Communications on all Aspects of Bioorganic Chemistry, Medicinal Chemistry and Related Disciplines

Editor-in-Chief: **DALE L. BOGER**, *The Scripps Research Institute, La Jolla, CA 92037, USA*
Chairman of the Executive Board of Editors for Tetrahedron Publications: Sir Derek Barton, *Texas A&M University, USA*

SUBJECT INDEX AND AUTHOR INDEX
Volume 2 (1992)

Pergamon Press Oxford New York Seoul Tokyo

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Editor-in-Chief: **PROFESSOR D. L. BOGER**, Department of Chemistry
The Scripps Research Institute, 10666 North Torrey Pines Road
La Jolla, California 92037, USA
Fax: (1) 619 554 6401

Regional Editor for Europe: **Professor L. Ghosez**, Laboratoire de Chimie Organique de Synthèse, Université Catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
Fax: (32) 10 47 41 68

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Chairman: **Professor Sir Derek Barton, FRS,** Department of Chemistry, Texas A & M University, College Station, Texas 77843-3255, USA

Professor J. E. Baldwin, FRS, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Dr S. G. Davies, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Professor S. Ito, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770, Japan
(Associate Editor, Professor Y. Shizuri)

Professor A. R. Katritzky, FRS, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

Professor N. K. Kochetkov, N. D. Zelinsky Institute of Organic Chemistry, Academy of Sciences, Moscow B-334, Russia

Professor Lin Guo-Qiang, Shanghai Institute of Organic Chemistry, Academia Sinica, Shanghai 200032, China

Professor A. McKillop, University of East Anglia, School of Chemical Sciences, University Plain, Norwich, NR4 7TJ, UK

Professor S. F. Martin, Department of Chemistry and Biochemistry, University of Texas, Austin, TX 78712, USA

Professor A. Nickon, Department of Chemistry, The Johns Hopkins University, Baltimore, MD 21218, USA

Professor W. D. Ollis, FRS, Department of Chemistry, University of Sheffield, Sheffield S3 7HF, UK

Professor G. Ourisson, Centre National de la Recherche Scientifique, Centre de Neurochimie, 67084 Strasbourg, Cedex, France
(Associate Editor, Professor G. Solladié)

Professor T. Shioiri, Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya 467, Japan

Professor W. Steglich, Institut für Organische Chemie der Universität München, Karlstr. 23, D-8000 München 2, Germany

Professor H. H. Wasserman, Department of Chemistry, Yale University, PO Box 6666, New Haven, CT 06511, USA

BOARD OF CONSULTING EDITORS

P. Anderson, West Point, PA
M. J. Ashton, Dagenham
S. Bell, Raritan, NJ
R. C. Breslow, New York, NY
P. N. Confalone, Deepwater, NJ
E. J. Corey, Cambridge, MA
S. Danishefsky, New Haven, CT
P. B. Dervan, Pasadena, CA
T. W. Doyle, Wallingford, CT
A. Eschenmoser, Zürich
D. M. Floyd, Princeton, NJ
A. K. Ganguly, Bloomfield, NJ
D. Gani, St Andrews
G. L. Grunewald, Lawrence, KS
H.-J. Hess, Groton, CT
M. Hirobe, Tokyo
D. C. Horwell, Cambridge
W. L. Jorgensen, New Haven, CT
D. Keith, Nutley, NJ
R. Lerner, La Jolla, CA
D. Mansuy, Paris
B. W. Metcalf, King of Prussia, PA
W. H. Moos, Emeryville, CA
K. Mori, Tokyo
K. C. Nicolaou, La Jolla, CA
M. Ohno, Tokyo
H. Pearce, Indianapolis, IN
P. Potier, Gif-sur-Yvette
A. V. Rama Rao, Hyderabad
J. Rebek, Jr, Cambridge, MA
S. L. Schreiber, Cambridge, MA
M. Shibasaki, Tokyo
T. J. Simpson, Bristol
R. V. Wolfenden, Chapel Hill, NC

PUBLISHED MONTHLY

Publishing, Subscription and Advertising Office:
Pergamon Press Ltd, Headington Hill Hall, Oxford, OX3 0BW, UK (Tel: (0865) 794141; Fax: (0865) 60285)

Subscription Rates
Annual Institutional Subscription Rate (1993): £378.00 (US$718.00). Sterling prices are definitive. US dollar prices are quoted for convenience only, and are subject to exchange rate fluctuation. Prices include postage and insurance and are subject to change without notice. Subscription rates for Japan are available on request. Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., 660 White Plains Road, Tarrytown, New York 10591-5153, USA, and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, UK.
Second Class Postage paid at Rahway, NJ. Postmaster send address corrections to *Tetrahedron* c/o Pergamon Press Inc., 660 White Plains Road, Tarrytown, New York 10591-5153, USA.

Copyright © 1993 Pergamon Press Ltd

Subject Index 1992

A
A58365A, angiotensin converting enzyme inhibitor, synthesis anodic amide oxidation 739
A-53612, selective orally active 5-lipoxygenase inhibitor, 1353
Acceptors, for α-L-(1→3) fucosyltransferases, synthesis of 2′-substit β-D-Gal-(1→4)-β-D-Bn 63
AcChE, inhibition, prodrug approach, synthesis 1(2-indolyl)pyridinium salts 123
tacrine derivs, 861
Acetoxy-1-arylalkanes, hydrolysis, synthesis 1-aryl-1-alkanols, 955
Acetylcholine, cognition enhancers, structure-activity pyridinyl pendant groups on cora structures 851
releasing cognition activators urea series, 855
rigid analogs, M1 agonist AF102B, Alzheimers disease therapy, 839
Acridine-peptide, conjugate with ribonucleolytic activity, 303
Activating agent, muramic acid, HBTU, 571
Acyclic guanosine, chiral analogs, synthesis, 677
Acyclonucleotide analogs, synthesis 9-[2-(phosphonomethoxy)ethylamino]adenine and 9-[(phosphonomethoxy)acetamido]adenine anti-HIV agents, 1559
Acyl-2-azetidinones, with enhanced hydrolytic stability, 681
Acyl-CoA, cholesterol, O-acyl transferase, RP 70676 inhibitor, 375
dehydrogenase, inactivation by methylenecyclopropylacetyl-CoA 1423
Adamantane, spiro sultones, synthesis as antiviral agents, 647
Adenosine, , A_1,A_2 affinity, effect 1,3,8-trisubstit xanthines 1199
receptors, action halistanol trisulfate, caution receptor binding assays, marine organism screening, 1631
AdoHey hydroxylase, inhibitors, synthesis 4′,5′-dehydro-5′-fluoro analogs of aristomycin, 1741
AF64A, acetylcholine, chiral piperidine-based analogs, 1551
Agonists, AF102B, Alzheimers disease therapy, 839
arylpiperazine 5-HT_{1a} receptor, metabolically stable, synthesis 1703
azabicyclic muscarinic, N-methoxy imidoyl halide or nitrile function, 791
aza(nor)adamantanes, serotonin 5-HT_4 receptor 1613
imetit, Me deriv, transition to antagonist, histamine H_3 receptors 1231
oxime ether function, design and synthesis, 787
k-opioid, hydrophilic phenylacetylpiperazines activity, reduced access central nervous system, 1275
M1 selective design and synthesis, 821
muscarinic:
functional M_1 selective hexyloxy-TZTP, heterocyclic analogs, synthesis, structure-activity 809
no cholinergic syndrome, SR 46559 and related aminopyridazines 833
SAR azaspirodioxolanes 815
1,4,5,6-tetrahydropyrimidines synthesis 781
UH5, aldehyde, ketone and oxime analogs as cholinergic agents, 803
receptor histamine H_2, S-2-(4-(5)-imidazoylethylthiourea and 4-(4-(5)-

imidazoyl)butyramidine, 77
serotonin 5-HT$_4$ receptor, aza(nor)-adamantanes 1613
Albendazole, sulfoxide and sulfone via benzimidazole derivs, 155
Alcohol-dehydrogenase, from Thermoanaerobacter ethanolicus, asymmetric reduction of ketoesters 619
yeast, inhibition by Cu-complexes of colchiceine and N-deacetyl-deriv 1097
Alcohols, HBTU activated coulping with muramic acid derivs, 571
Alkenyl-α-amino acid esters, enantioselective hydrolysis catalysed by α-chymotrypsin, 387
Alkoxyphenol, leukotriene B$_4$: receptor antagonists 1669
effect chroman carboxylic acid, 1675
Alkylamine, controlled pore glass, long chain, derivatization for solid phase synthesis oligonucleotides, 727
Alkylating agents, substit quinazolinone, design purine nucleoside phosphorylase inhibitors, 1427
Alkylation, properties (+)-, epi-(+)-, ent(-)-, and epi, ent-duocarmycin A, DNA, 759
O-Allylation, β-hydroxy-α-amino acids, entry to conformation-ally constrained dipeptide surrogates, 579
Alzheimers disease, AcCh-releasing agents as cognition enhancers, 851
associated proteases, automated synthesis fluorogenic protease substrates 1665
cholinomimetics 777
therapy, muscarinic ligands based on himbacine, 797
therapy acetylcholine rigid analog AF102B, 839
AMBER, force field parameters, trimethylanilinium cation, 291
Amides, analogs of hygromycin A, 533
Amines, HBTU activated coulping with muramic acid derivs, 571
reaction with etoposide ortho-quinone, 1111
Amino acids, 6-phosphonomethyl-tetrahydro-4-pyrimidine carboxylic acids and acyclic analog competitive N-methyl-D-aspartic acid receptor antagonists 207
analogs, mechanism-based inactivators γ-amino-butyric acid aminotransferase, 1371
fluorescent crosslinked with N-substit dihydrooxopyridine skeleton from bovine elastin, 1767
N-protected, deprotection by D-aminoacylase, 697
N-3 amino derivs thymidine nucleoside analogs, anti-HIV activity, 1469
Amino-chromans, dopamine analogs, prep, 481
Aminoacylase, deprotection N-protected amino acids, 697
Aminobutanoic acid, disubstit derivs from furanoses, 515
Aminobutyric acid, aminotransferase inactivators, mechanism-based α-]amino acid analogs, 1371
Aminocyclitol, analogs, hygromycin A, synthesis, biological activity, 1015, 1043
Aminomethyl-4-substit-4H pyrrolbenzothiazines,, Ca antagonist, 1193
Aminopentanoic acid, disubstit derivs, synthesis from furanoses, 515
Aminopyridazines, 46559 muscarinic agonists with no cholinergic syndrome, 833
Aminotetralins, regioselective chlorination, potential dopaminergic agents, 115
Aminotransferase, γ-aminobutyric acid inactivators, mechanism-based α-amino acid analogs 1371
kynurenine, structure activity relationship human hepatic C-S lyase, 1219
Ammonium ion, binding dipeptidic guests by synthetic receptor 731
Amylase, immobilization into gelatin films with cross linkers 427
Analgesics DuP 747, structure-activity 721
kappa opioid DuP 747, synthesis, pharmacology 715
Anaphylatoxin, C5a receptor binding inhibitor, L-156602 1033
ANF potentiation cyclopentyl glutaryl peptide, rigid bicyclic analogs 1003
Angiotensin converting enzyme inhibitor, A58365A, synthesis, anodic amide oxidations 739
C-linked pyrazole biaryltetrazole antagonist 1243
receptor antagonists, benzothiadiazine dioxides, 1115
Anilines, o-aminophenyl sulfate metabolites oncolytic sulfonylureas, 1013
Anodic oxidations, synthesis angiotensin converting enzyme inhibitor A58365A, 739
Antagonists, 5-HT$_3$ receptors: aza(nor)adamantanes 1613
conformationally restricted naphthalimide derivs 691

synthesis, evaluation azaheteroaromatic ethers as carbonyl bioisosteres 245
tropisetron analog, ligands for 5HT$_4$ receptor, 461
5-HT$_4$, receptors: indazole as indole bioisostere 419
angiotensin II: - C-linked pyrazole biaryltetrazoles 1243
receptor,benzothiadiazine dioxide, new class 1115
substit piperidin-2-one biphenyltetrazoles 1775
calcium: 1-1-aminomethyl-4-substit-4H-pyrrolo[2,1-C]-[1,4]benzothiazines, synthesis, evaluation 1193
diphenylalkylamine-type, role chirality for Ca-channel affinity 1283 B, CCK-B, CCK-B, synthesis, CCK receptor affinities selected carboxylic acid mimics of C1-988, 45 d e
dopamine autoreceptor, AJ-76 synthesis, 1691
glucagon receptor, non-peptide CP-99,711 915
glycine/NMDA, effect 5-membered ring conformation on affinity 2-carboxy indolines, indoles, 1627
first non-peptide, bombesin & gastric releasing-peptide, CP-70,030 & Cp-75,998 333
imetit and N-methyl derivs, transition from agonist at histamine H$_3$ receptors 1231
leukotriene B$_4$ receptor: ortho-alkoxyphenol, effect chroman carboxylic acid, 1675
ortho-alkoxyphenol, 1669
leukotriene D$_4$, orally active, 1141
N-methyl-D-aspartic acid receptor, 6-phosphonomethyltetrahydro-4-pyrimidine carboxylic acids and acyclic analogs 207
NMDA competitive conformational activity due internal H-bonding 1247
nonpeptide substance P, synthesis RP-67,580 37
peptidomimetic cholecystokinin via 1,3,4-trisubstit pyrrolidinones, 1251
phosphonoethylalanine derivs of non-NMDA ionotropic glutamate receptors, 1269
platelet-activating factor, activity L671,284 and analogs, 181
protein kinase C, synthesis and evaluation diacylglycerol 127,131
synthase inhibition thromboxane, dual activity molecules, 979, 985
thromboxane receptors: combined with thromboxane synthase inhibition, 4-substit 3-pyrrolidinyl-alkanoic acids 1619
interphenylene phenyl oxazoles, 937
synthesis interphenylene-7-oxabicyclo[2.2.1]heptane oxazole, 73
thromboxane synthase inhibitor, dual acting thromboxane receptor, heterocyclic 1,3-dioxanes, 1181
TXA$_2$/PGH$_2$ receptors: metabolically stabilized
synthesis
properties, 1069
synthesis and properties 1063
Anthelmintic agents, activity, synthesis 14-O-substit derivs paraherquamide, 1599
avermectin B$_1$-4'',4''a-oxide as precursor 537
Anthracyclines, targeted pro-prodrugs activated by antibody-enzyme conjugates, 1093
Anti-allergic action, 2'-(tetrazole-5-yl)-4-hydroxy-2-methyl-2H-1, 2-benzothiazine-3-carboxanilide 1,1-dioxide, 709
Anti-cholinesterase, activity 1-benzyl-4-(5, 6-dimethoxy-1-indanon-2-yl)methylpiperidine hydrochloride and related compds, 871
Anti-HCMV properties, (±)-7-deazacarbovir, 1279
Anti-herpes, activity 5-trifluorovinyl-2'deoxy uridine 1057
Anti-HIV agents, 2',3'-dideoxy-2',3'-didehydro]nucleoside analogs 315
3'-deoxy-3'-(N-hydroxyamino analogs of nucleosides, 1723
9(2R,5R)-2,5-dihydro-5-(phosphonomethoxy)-2-furanyl -2,6-diaminopurine 307
acyclonucleotide analogs, synthesis 9-[2-(phosphonomethoxy)ethylamino]adenine and 9-[(phosphonomethoxy)-acetamido]adenine, 1559
dideoxynucleosides, nucleotidic prodrugs, 603
evaluation tannins, 1529
N-3 amino substit thymidine nucleoside analogs, 1469
prodrugs, arylphosphate derivs of AZT in HIV kinase-deficient cells, 701
properties, (±)-7-deazacarbovir 1279
synthesis, activity pyrrolo-[1, 2-d]-(1, 4)-benzodiazepin-6-ones 1639
Anti-inflammatory action, 2'-(tetrazole-5-yl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-2-benzothiazine-3-carboxanilide 1,1-dioxide, 709
Antiarrhythmic/anti-

oxidant, quinazolines, 1121
Antibacterials, aminocyclitol analogs hygromycin A, 1043
DNA-gyrase inhibition of fluoro-quinolines, effect of F position, 643
vinyl methyl and amide analogs, hygromycin A modification, 533
Antibiotics, 9-pyrrolo-9-deoxo-erythromycin A analogs, synthesis, activity, 1555
cyclic hexadepsipeptide L-156602 analogs, inhibition C5a receptor binding 1033
synthesis α-(S)-acyl-amino-N-(hydroxy-dioxocyclo-butenyl)-β-lactams 1541
Antibodies, dual catalytic activity, Diels-Alder cycloaddition, 49
enzyme conjugates, anthracycline targeted pro-prodrugs, 1093
phage-alkaline phosphatase conjugates, ELISA's without immun-ization PhoPhabs 1073
Antifungal agents, macrolactam biosynthesis, 575
Antihypertensive agents, labdane diterpenoid, epi-deoxycoleonol from Coleus forskohlii, 249
Antileukemic acivity, etoposide A-ring analogs, 17
Antimalarial agents, 1,2,4-trioxanes, in vivo potent, synthesis, 497
evaluation, 2,3,5-trioxabicyclo [2.2.2]octanes, models for putative pharmacophore of artemisinin, 623
Antineoplastic drugs, hydroxy-amidoanthraquin-ones, 659
Antioxidants, antiarrhythmic quinazolines, 1121
antisense oligo-nucleosides, incorporation methyleneoxy-(methylimino) linked thymidine dimer, 1479
Antithrombin, O-alkylated-O-sulfated pentasaccharides, 905
pentasaccharide with 3-O-methyl iduronic acid unit, 897
tetra-methylated pentasaccharide, 901
Antitumor agents, 1069C effective, drug resistant murine tumour, 1257
antineoplastic bicyclicsulfonylureas, 987
etoposide A-ring analogs, 17
etopsode, teniposide 4'-deshydroxy-4'-methyl analogs, synthesis 1213
Antiviral agents, 9-[2-(phosphonomethoxy)-ethyl]guanine, carbocyclic derivs, synthesis and biological activity, 685 ne
adamantane spiro sultones, 647
synthesis 9-[2-(phosphonomethoxy)-ethylamino]adenine and 9-[(phosphonomethoxy)-acetamido]adenine, 1559
Arecoline, rigid analogs, muscarinic activities of 6-carboxymenthyl-2-azabicyclo-[2.2.1]heptane enantiomers, 501
Arginine, role in interactions, microcystins with protein phosphat-ases 1 and 2A, 673
Aristomycin, 4',5'-dehydro-5'-fluoro analogs, inhibitors rat liver AdoHey hydrolase, 1741
Artemisinin, putative pharmacophore models, antimalarial evaluation 2,3,5-trioxabi-cyclo[2.2.2]octanes, 623
Aryl cyanoguanidine, potassium channel openers, 83
Aryl-1-alkanols, via enzyme hydrolysis 1-acetoxy-1-arylalkanes, 955
Aryl-[1,3]-diones, structural analysis, 5-lipoxygenase inhibitors, 1309
Arylalkanoic acids, arylsulfonylamino pyrrolidinylalkyl substit, thromboxane synthase inhibition combined thromboxane receptor antagonism, 1623
Arylamides, hydroxylated isoquinolines, protein-tyrosine kinase inhibitors, 1771
Arylphosphate, derivs of AZT, inhibitors HIV in kinase-deficient cells, 701
Arylpiperazine, 5-HT_{1a} receptor, metabolically stable agonists, synthesis, 1703
Arylsulfonyl chlorides, Schotten-Baumann reaction with aspartic acid derivs giving oxathiazinone gastrin ligands, 325
Aspartame, like sweeteners containing L-α-Me)Phe, 453
Aspartic acids, derivs, Schotten-Baumann reaction with arylsulfonyl chlorides giving oxathiazinone gastrin ligands, 325
emeriamine enantiomers, stereoselective synthesis, 1029
Assays, for iloprost, stable 9-substit carbacyclin derivs, 439
receptor binding screen marine organisms, caution action halistanol trisulfate on adenosine receptors, 1631
Asymmetry, reduction, ketoesters with alcohol dehydrogenase from Thermoanaerobacter ethanolicus, 619
Avermectin, B_1-4'', 4''a-oxide, precursor

anthelmintic agents 537
Aza-analogs (E)-1-alkylazolylvinyl-pyridinium salts, choline acetyl-transferase, ChAT inhibition, 1493
Aza-L-tryptophans, enzymatic synthesis, 1053
Azabicyclic benzamides, gastric prokinetic agents, 1147
muscarinic agonist, N-methoxy imidoyl halide or nitrile function, 791
oxime ether function, design and synthesis, 787
Azaheteroaromatic ethers, carbonyl bioisosteres, synthesis, evaluation of 5-HT_3 receptor antagonists, 245
Aza(nor)adamantanes, 5-HT_3 receptor antagonists and serotonin 5-HT_4 receptor agonists, 1613
Azapeptide analogs, inhibitors serine, cysteine proteases, synthesis, evaluation, 1375
Azaspirodioxolanes, muscarinic SAR agonists, 815
Azasugar, inhibitors of α-L-fucosidase, 33
Azides, imidazole containing aromatic, photoaffinity probes of lanosterol 14-α-demethylase from Saccharomyces cerevisiae, 383
Azido-L-tyrosine, enzymatic synthesis, 41
AZT, aryl phosphate derivs, inhibitors HIV in kinase-deficient cells 701

B

Baccatin III, 13-(N-(p-chlorobenzoyl)-(2'R,3'S)-3'-phenyl-isoserinate) and 13-(N-benzoyl-(2'R,3'S)-3'(p-chlorophenyl)iso-serinate 295
four taxol analogs, semisynthesis, biological activity, 1751
Bacillus cereus, phosphatidyl inositol specific phospholipase C, inhibition by tetravanadate, 655
Bacteriopheophorbides, pheophorbides related photosensitizers, structure-activity relationships, 491
Benzamides, azabicyclic, gastric prokinetic agents, 1147
hetero-azabicyclo[x.y.0] derivs, gastric prokinetic agents, 1293
Benzimidazoles, derivs, prep albendazole, sulfoxide and sulfone, 155
ribonucleotides, t-butyl nitrite diazo-tizations, unexpected nitration, 1105
Benzo[e]pyrene, K-region arene oxides hydrolysis, enantiomeric composition to trans-dihydrodiols, 1729
Benzoporphyrins, derivs and analogs, photodynamic therapy, 1575
Benzopyranyl, 3-OH group, role in cromakalim and pyridine N-oxide K-channel openers in detn enantiomer biological activity, 229
cyanoguanidine, K-channel openers, 87
Benzothiadiazine dioxides, angiotensin receptor antagonists, 1115
Benzoylamino-4-oxo-quinazolines, synthesis and activity in cognition related tests, 349
Benzyl glycosides, α-glycosylation via methyl 2,3,4,6-tetra-O-(4-methoxybenzyl)-1-thio-β-D-gluco-pyranoside, 1707
Benzylguanine, phosphonate derivs, purine nucleoside phosphorylase inhibitors, 407
Biaryl tetrazoles, C-linked pyrazoles, angiotensin II antagonists, 1243
Bicyclic sulfonylureas, antineoplastic, 987
Bifenthrin, hydroxylated isomers, stereoselective synthesis, 1585
Bioreduction, hydroperoxy fatty acid by Phormidium tenue, 149
Biosynthesis, leukotriene inhibitors, MK0591, 1395
macrolactam antifungal agents, 575
Biphenyltetrazoles, piperidine-2-one substit, angiotensin II antagonists, 1775
Bleomycin A_2, deglyco GABA, GLY-desacetamido-bleomycin A_2 synthetic model 261
isolation purification to deglycobleomycin A_2, 959
Blood, proteins, thiol-induced crosslinking, tumor immunity, humans, 919
BMS180431, inhibitor, synthesis tetrazol-1-yl analogs HMG-CoA reductase, 1085
Bombesin, gastrin releasing peptide, non-peptide CP-70, 030 and CP-75 antag-onists, 998 333
Borinic acids, inhibitors serine proteases subtilisin Carlsberg and α-chymotrypsin, factors controlling binding active sites, 1391
BRL 55834, airways selective potassium channel activator, synthesis, 1161
Bromoacetoarenones, reaction with 3-(N,N)-dimethylamino)propan-1-ol, structure of products, 157

Bromotyrosine, derived metabolite, synthesis psammaplin A from Psammaplysilla sp, 1561
Butanethiol, reactions with β,γ-acetylenic and allenic sulfoxides and sulfones of dehydroepiandrosterone, 933
Butyrylcholinesterase, inhibition, tacrine derivs, 861

C

Caged serine, synthesis, 148
Calcineurin, binding to cyclosporin A, receptor-ligand-receptor interactions, 747
Calcium,
antagonist evaluation 1-aminomethyl-4-substit-4H-pyrrolobenzothiazines, 1193
channel blocker conformationally rigid, synthesis, 95
channel blocker related to potassium channel opener cromakalim 1475
sensitizing activity of cardiotonic EMD 53998 enantiomers, 589
stereoselective channel antagonists, diphenylalkylamine type, 1283
Caracasanamide, hypotensive agent from Verbesina caracasana, 415
Carbacyclin, derivs, stable 9-substit, synthesis and biological use 439
Carbamates, series of juvenoids, 963
Carbamoyl phosphate, synthetase, large subunit from Escherichia coli, mutational analysis two putative domains, 319
Carbocyclic derivs, [9-[2-(phosphonomethoxy)]ethylguanine, synthesis and biological activity, 685
Carbocyclic phosphonate analogs, ddAMP, substrates 5-phosphoribosyl-1-pyrophosphate synthetase, 1483
Carbohydrates, synthesis dihydroxy γ- and δ-amino acids, 515
Carbomethoxymethyl-2-, cyanoimidazolones rearrangement, synthesis [6-carboxyhexahydro]pyrimidines, dihydroorotate dehydrogenase inhibitors, 421
Carbonyl bioisosteres, azaheteroaromatic ethers, synthesis and evaluation of 5-HT_3 receptor antagonists, 245
Carbonylalkyl-acrylate, via lipase-catalyzed regioselective hydrolysis of methoxycarboxyalkyl acrylate, 411
Carboxy-tetrahydroquinolines, cis and trans 4-amido-, affinity ligands, glycine site of NMDA receptor, 371
Carboxyalkyl acrylate, prep via lipase catalyzed regioselective hydrolysis of Me ester, 411
Carboxyhexahydro-pyrimidines, dihydroorotate dehydrogenase inhibitors via [5-carbomethoxymethyl-2-cyano]imidazolones rearrangement, 421
Carboxymenthyl-2-azabicyclo[2.2.1]heptane, enantiomers, rigid analogs of arecoline, muscarinic activities, 501
Cardiotonic drugs, EMD 53998 enantiomers with Ca-sensitizing activity, 589
Catalysts
glycosyltransferase power assessment, glucosylating activity UDPG, 1513
alcalase followed by lipase in BuOH, synthesis N^{α}-protected N-peptidyl-O-acetyl hydroxylamines 1685
antibody with dual activity, Diels-Alder cycloaddition, 49
Cathepsin G, inhibition by isoxazoline derivs, 1571
CCK-B,
antagonist, synthesis and CCK receptor affinities of selected carboxylic acid mimics of Cl-988, 45
receptor dipeptoids, conformational restraint, use of proline ring 403
Cells,
mobility, inhibition by D-erythro-sphingosine-1-phosphate, 973
proliferation prevention, antagonists protein kinase C, synthesis and evaluation diacylglycerol, 127
Cephalostatin, synthesis evaluation nonacyclic and trisdecacyclic pyrazines, 967
Cephem,
4-ketones, keto-enol tautomerism, 1127
sulfones, inactivators human leukocyte elastase, 1127
ChAT inhibitory activity, aza-analogs (E)-4-[2-(1-naphthylvinyl)]-1-substit pyridinium salts 1493
Chelating agents, bifunctional C-backbone modified, 2-p-aminobenzyl-3-methyl- and 2-p-aminobenzyl dérivs DTPA, 1661
Chemical modification, proteins by new reagents, 607
Chirality, role Ca channel diphenylalkylamine antagonists, 1283
Chlorination, 5-OH-2-(alkylamino)tetralins, potential dopaminergic agents, 115
Chloro-L-tryptophans, enzymatic synthesis, 1563
Cholecystokinin, analogs, ergopeptine alkaloid models of active CCK conformation, 9

peptidomimetic antagonists via 1,3,4-trisubstit pyrrolidinones, 1251
Choline acetyltransferase interaction aza-analogs indolylvinylpyridinium salt 1493
Cholinergic agents, muscarinic agonist UH5, aldehyde, ketone and oxime analogs, 803
Cholinomimetics, and Alzheimers disease, 777
Chroman carboxylic acid, effect ortho-alkoxyphenol leukotriene B_4 receptor antagonists, 1675
Chymotrypsin, catalyzed enantioselective hydrolysis, alkenyl-α-amino acid esters, 387
subtilisin, factors controlling binding active sites, borinic acid inhibitors, 1391
Cl-988, CCK-B receptor antagonist, synthesis selected acid mimics, 45
Classification, enzyme inhibitors, 1327
mechanism-based site-directed enzyme inhibitors, 1323
Cleavage, duplex DNA by Fe complex P-3A comparison DNA cleavage Fe complex (-)-desacetamido P3A, 1649
Clostridium perfringens, neuraminidase, inhibitor, synthesis sodium ortho-(difluoromethyl)phenyl α-ketoside of N-acetylneuraminic acid 1361
Cognition, activators urea series as acetylcholine releasing agents, 855
enhancers, structure-activity pyridinyl pendant groups on core structures, 851
related tests, activity 2-benzoylamino-4-oxo-quinazolines, 349
Colchiceine, and N-deacetyl-deriv Cu-complexes, inhibition yeast alcohol dehydrogenase, 1097
Coleus forskohlii, antihypertensive labdane diterpenoid epi-deoxycoleonol, 249
Complexes, shikimate-3-phosphate and glyphosate, design, synthesis EPSP synthase inhibitors, 1435
Computer, alternative model, 3-dimensional structures, micro-cystin-LR and nodularin, reaction with protein phosphatases 299
Configuration, (-)-stypoldione, 391
variants of hydroxyphenylkainoids, depolarizing activities, central nervous system, rat, 743
Conformation, 1-(3,4-dichlorophenyl)-2-aminopropane bound active site PNMT, transferred NOESY, 1681
constrained dipeptide surrogates, entry via acid-catalysed O-allylation, β-hydroxy-α-amino acids 579
constraint, CCK-B receptor dipeptoids, use of proline ring, 403
cyclosporin A bound to cyclophilin, altered after binding to calcineurin, receptor/ligand/receptor interactions 747
2-deoxy-β-D-xylo-thymidinyl-(3,5')-2-deoxy-β-D-xylothymidylate dinucleoside phosphonate 1201
enzyme bound shikimate - 3-phosphate using TRNOE, EPSP synthase inhibitor design 151
NMDA competitive antagonist activity due internal H-bonding, 1247
structure requirements constraint, hydrophobic domain, tetrazole HMG-CoA , reductase inhibitors 99
Copper, complexes, colchiceine and N-deacetyl-deriv, inhibition of yeast alcohol-dehydrogenase, 1097
Corrigenda, Bay S. and Cantacuzene D.: vol2, 423(1992): page 424, second line under drawing corrected, 767
Suzuki Tt and Kasai N: correct specific rotation values for (R)-and (S)-3-chloro-1,2-propanediol vol1, 345(1991), 105
CP-96, 345 SAR study, NK_1 substance P receptor antagonist, 345,559
Cromakalim, K-channel activator, pyrrole analogs pyrrolidinone moiety, relaxants guinea pig trachealis, 159
K-channel openers, role of benzopyranyl 3-OH group, detn enantiomer biological activity, 229
related Ca channel blocker, 1475
Crosslinking, alpha-amylase to gelatin, 427
1-diazo-4-undecyn-2-one, mechanism-based inactivator E.coli β-hydroxydecanoyl thiolester dehydrase, 1381
human blood proteins, thiol-induced, tumor immunity, 919
Cumindysoside A, cytotoxic trisnortriterpene glucoside with 14,18-cycloapoeuphane-type skeleton from Dysoxylum cumingianum, 395
Cyanoguanidines, benzopyranyl and aryl derivs, potassium channel openers, 83, 87
Cycloaddition, nitrile oxides with

dideoxythymidine, 323
Cyclodextrins,
sec-side βCD
hydroxylamine deriv,
H-bonding effects
reactivity
preassociating
α-nucleophile, 1635
substrate selectivity
imidazole appended
dimethyl-
β-cyclodextrin, 1581
Cyclooxygenase,
5-lipoxygenase,
inhibited by
thiazolidine-4-one
analogs meclo-
fenamic acid, 705
5-lipoxygenase dual
inhibitors, synthesis
reversed hydroxamic
acids indomethacin,
1655
inhibitors, conversion
to dual inhibitors of
CO and 5-lipoxy-
genase, 69
Cyclophilin, bound to
cyclosporin A,
conformation altered
after binding to
calcineurin,
receptor-ligand-receptor
interactions, 747
Cyclopropane
carboxamide,
2,3-disubstit as P_3
amino acid
replacement, use
synthesis dipeptide
renin inhibitors, 1405
Cyclosporin A bound to
cyclophilin,
conformation altered
after binding to
calcineurin,
receptor-ligand-receptor
interactions, 747
Cysteine proteases,
inhibitors, synthesis,
evaluation azapeptide
analogs, 1375
Cytomegalovirus, human,
activity, design,
synthesis toyocamycin,
sangivamycin,
thiosangivamycin derivs,
1755
Cytosine nucleosides,
reactions with
2,6-dichlorobenzonitrile
oxide, 941
Cytotoxicity,
enediynes, mechanism of
activation, 1155
ferrocene-intercalator
conjugate, 929
four taxol analogs
baccatin III,
semisynthesis,
biological
activity, 1751
synthesis enantiomeric
pairs duocarmycin A
and 2-epimer, 755
trisnortriterpene
glucoside with 14,
18-cycloapo-
euphane-type
skeleton,
cumindysoside A from
Dysoxylum cumingianum,
395

D

Deacetoxycephalosporin,
C/deacetylcephalosporin
C synthase, high-
level soluble
expression and
purification, 663
soluble recombinant,
substrate
specificity, 669
Deazacarbovir, anti-HIV,
anti-HCMV properties,
1279
Deglyco GABA,
GLY-desacetamidobleo-
mycin A_2, synthetic
model for bleomycin A_2,
261
Deglycobleomycin A_2,
prep, 959
Dehydroepi-androsterone,
β,γ-acetylenic and
allenic sulfoxides,
sulfones, reactions with
1-butanethiol and
glucose-6-phosphate
dehydrogenase, 933
Dehydroquinate synthase,
new interpretation
slowly reversible
inhibition, 1349
Deltorphin 1,
cyclic analog,
biological properties,
547
synthesis and biological
properties, 547
Deoxy analog,
phosphatidylinositol,
synthesis and enzymatic
properties, 171
Deoxy-β-glycosides,
glycosidase catalyzed
synthesis, 423
Deoxymannojirimycin,
synthesis, 1419
Deoxynojirimycin,
glucosidase inhibitor,
synthesis and biological
activity C-6 modified
derivs, 27
Deoxyuridine,
5-trifluorovinyl-,
synthesis and
anti-herpes activity,
1057
Depolarizing action,
central nervous system
rat, configuration
variants of
[hydroxyphenyl]kainoids,
743
Deprotection,
N-protected amino acids
by D-aminoacylase, 697
Derivatization, long
chain alkylamine
controlled pore glass
for solid phase
synthesis oligo-
nucleotides, 727
Dermorphin, Phe
sidechain fixed into
trans conformation, μ-
and δ-opioid activity,
1305
Design, M1 selective
muscarinic agonists, 821
Diacylglycerol,
conformationally
restricted analogs,
synthesis, 131
synthesis and
evaluation, second
messenger antagonists,
127
Diaminopurine, analog
PMEA, anti-HIV activity,
structure activity
relationship, 307
Diaminoquinoline derivs,
potent immunostimulants,
synthesis, 1589
Dianhydrohexitol
nitrate, deriv KF-14124
synthesis stereoisomers,
1187
Diazo-4-undecyn-2-one,
mechanism-based
inactivator E.coli
β-hydroxydecanoyl
thiolester dehydrase,
1381
Diazotization,
benzimidazole
ribonucleotides with
t-butyl nitrite,
unexpected nitration,
1105
Dibenzoyl-guanidines,
synthesis and cognition
effects, analogs of N,
N'-[4(aminocarbonyl)-

phenyl]carbimidoyl]bis-benzamide 345
Dichloro-benzonitrile oxide, reactions with cytosine nucleosides, 941
Dideaza-tetrahydrofolic acid, synthesis and biological activity, 339
Didehydro-dideoxy-thymidine, cycloaddition with nitrile oxides, 323
monophosphate, HIV activity of phosphonate isosteres, 367
Dideoxy-2′,3′-didehydro-nucleoside analogs, anti-HIV agents, 315
Dideoxy-D-erythro-hexa-pyranosyl nucleosides, incorporation oligonucleotides, 945
Dideoxyadenosine-5′-mono phosphate, carbocyclic phosphonate analogs, substrates 5-phosphoribosyl-1-pyro-phosphate synthetase, 1483
Dideoxynucleosides, anti-HIV nucleotidic prodrugs, 603
Diels-Alder, cycloaddition, catalytic antibody with dual activity, 49
Diet, supplementation, iron-saccharide complexes, 997
Difluoro-13-hexadecen-11-ynyl acetate, synthesis, analog sex pheromone of processionary moth, 467
Difluoroacylsilanes, conversion to α,α-difluoroketones, 119
Difluoroketones, synthesis from α,α-]difluoroacylsilanes 119
Dihydrodiol metabolites, dihydro-15H-cyclo-penta[a]phenanthrene, carcinogenic Me and keto derivs, 23
Dihydromevinolin, related HMG-CoA reductase inhibitors, design and biological evaluation, 223
Dihydroorotate, dehydrogenase inhibitors, [6-carboxyhexahydro]pyrimidines via [5-carbo-nethyoxymethyl- 2-cyano]imidazolones rearrangement, 421
Dihydrouracils, substit, inhibition human elastase leukocytes, 1565
Dihydroxy-γ,δ-amino acids synthesis from carbohydrates, 515
α,25-]Dihydroxyvitamin D_3, synthesis (C-11)-substit analogs, 477
3-Dimethylamino-propan-1-ol, reaction with α-bromoacetoarenones, structure of products, 157
Dinucleosides, conformation, 2-deoxy-β-D-xylo-thymidinyl-(3,5′)-2′-deoxy-β-D-xylothymidylate, 1201
phosphodi- and triester of ddC, prodrug of 5-monophosphate nucleoside, 603
phosphonate formation, stereochemical course, 1201
Dioxidosqualene, inhibitor, 2,3-oxidosqualene-lanosterol cyclase rat liver microsomes, 1239
Dipeptides, conformationally constrained surrogates, entry via acid-catalysed O-allylation of β-hydroxy-α-amino acids, 579
guests, ammonium ion binding by synthetic receptor, 731
renin inhibitors, synthesis using 2,3-disubstit cyclopropane carboxamide as P_3 amino acid replacement, 1405
Dipeptoids, CCK-B receptor, conform-ational restraint use of proline ring 403
Diphenylalkylamines, Ca channel antagonists, role chirality, 1283
Dissociation constants, competitive inhibition phospholipase A_2, triton X-100 mixed micelles, 1343
Distamycin, analogs, interaction dodecamer $d(CGCGAATTCGCG)_2$, NMR, 1299
DNA, 2′-O-(o-nitrobenzyloxy-methyl)-protecting monomers, oligoribo-nucleotides synthesis, 1019
alkylation properties (+)-, epi-(+)-, ent(-)-, and epi, ent-duocarmycin A, 759
contained 5-hydroxy-methyluracil, solid phase synthesis, 79
duplex cleavage by Fe complex P-3A comparison DNA cleavage Fe complex (-)-desacetamido P3A, 1649
gyrase inhibition and antibacterial activity of fluoro-quinolines, effect of F position, 643
Dodecamer, $d(CGCGAATTCGCG)_2$, interaction distamycin analogs, NMR, 1299
Dopamine, agents, regioselective chlorination 5-OH-2-alkylaminotetralins, 115
analogs, prep via $\dot{P}D$ catalyzed cyclization, 481
autoreceptor antagonist AJ-76, synthesis, 1691
receptor binding properties of 2,3,4,5-tetrahydro-1H-3-benzazepine-7-ols with non-aromatic substituents in 5-position, 399
Drugs, antineoplastic, hydroxy-amido-anthraquinones, 659
DTPA, 2-p-aminobenzyl-3-methyl- and 2-p-aminobenzyl derivs, bifunct-ional C-backbone modified chelating agents, 1661

Duocarmycins,
(+)-, epi-(+)-, ent(-)-, and epi,ent-duocarmycin A, DNA alkylation properties, 759
A and 2-epimer enantiomeric pairs, synthesis and cytotoxicity, 755
DuP 747,
structure-acivity relationship, 721
synthesis and pharmacology, 715
Dysoxylum cumingianum, isolation cumindysoside A, trisnortriterpene glucoside with 14, 18-cycloapoeuphane-type skeleton, 395

E

Eichhornia crassipes, phenalene metabolites, 311
Elastase, trypsin-like proteases, inhibitors enol lactone derivs, 1399
Elastin, bovine, fluorescent crosslinked amino acids with N-substit dihydro-oxopyridine skeleton, 1767
ELISA, PhoPhabs without immunization, antibody-phage-alkaline phosphatase conjugates, 1073
EMD 53998, enantiomers, cardiotonic with Ca-sensitizing activity, 589
Emeriamine enantiomers, stereoselective synthesis from L-aspartic acid, 1029
Enantiomeric purity, hydroxylated oxotremorine derivs, synthesis, structure activity relationship, 827
Enantiomers,
EMD 53998, cardiotonic with Ca-sensitizing activity, 589
pairs duocarmycin A and 2-epimer synthesis and cytotoxicity, 755
Enantioselectivity, deprotection, N-protected amino acids by D-aminocyclase 697
Endodeoxyribonuclease, restriction, recognition of octadeoxyribo-nucleotides, modulated by purine 8-substit 565
Enediynes, mechanism of cytotoxicity activation, 1155
Enkephalin, potent analogs containing trifluoromethylamino acid residues 219
Enkephalinase, docking inhibition, thiorphan amide bond importance, 949
Enol lactones, derivs, inhibitors human neutrophil elastase and trypsin-like proteases, 1399
Entropy changes, phase transitions, molecular recognition, ligand receptor complementarity, 993
Enzymes,
conversion monocyclic β-lactams to bicyclic β-lactams, 1503
CSL activity, characterized aliphatic/aromatic cysteine conjugates 1219
hydrolysis 1-acetoxy-1-arylalkanes to 1-aryl-1-alkanols, 955
inhibitors:
classification, 1327
pseudo- symmetrical design, use of HIV-1 protease structure 541
mechanism-based, definition, classification, 1323
2,3,6,3′,4′-penta-O-acetyl sucrose, sucralose precursor, 161
phospholipase A_2, interfacial equilibrium constants, binding inhibitors, substrates to active site, 1335
properties:
deoxy analog phosphatidyl-inositol 171
uridine-5′-O-(2-thiodiphospho-glucuronate 197
proteolytic inhibitors, mechanism based, 175
synthesis:
5- and 6-aza-L-tryptophans, 1053
chloro-L-tryptophans, 1563
Epi-deoxycoleonol, from Coleus forskohlii, antihypertensive labdane diterpenoid, 249
Episulfide, inhibitors lipoxygenase, 1385
Epitope mapping, phosphopeptides, α-s1-casein phosphopeptide 59-79 segments, 1153
Epoxide hydrolase, microsomal, meso-K region arene oxides, formation enantiomeric composition trans-dihydrodiols, 1729
EPSP synthase, conformations enzyme boundshikimate-3-phosphate and 5-enolpyruvoyl-shikimate-3-phosphate using TRNOE, 151
inhibitor, design, synthesis, ternary complex with shikimate-3-phosphate and glyphosate, 1435
Ergotamine, inhibition, binding CCK to CCK-A and -B receptors, 9
Erythromycin A, 9-pyrrolo-9-deoxo-analog synthesis, activity, 1555
Escherichia coli, mutational analysis two putative domains in large subunit carbamoyl phosphate synthetase, 319
Ethers, azaheteroaromatic, carbonyl bioisosteres, synthesis and evaluation of 5-HT_3 receptor antagonists, 245
Etoposide, 4′-deshydroxy-4′-methyl analogs, antitumor agents synthesis, 1213
A-ring analogs, synthesis and antileukemic activity, 17

ortho-quinone, reaction with amines and thiols, 1111

F

Ferroceneacridine, conjugate, synthesis, cytotoxicity, 929
Fluoresceinyl-neurokinin-A, synthesis biologically active probe for NK_2 receptors, 609
Fluorine, labelled polymers synthesis, in vivo vascular phenomena with ^{19}F MRI, 527
Fluoro-quinolines, antibacterial activity and DNA-gyrase inhibition, effect of F position, 643
Fluorogenic protease, substrates, automated synthesis, probes Alzheimers disease associated proteases, 1665
Fluoromethyl analog, SC-46275, synthesis, stability, 1761
Fluorescent crosslinked amino acids with N-substit dihydro-oxopyridine skeleton from bovine elastin, 1767
Fucosidase, inhibitors glycal and azasugar, 33
Fucosyltransferase, acceptors, synthesis of 2′-substit β-D-]gal-(1→4)-β-D-GlcAc-1-O-Bn, 63
Furanoses, synthesis dihydroxy γ- and δ-amino acids, 515

G

Gastric prokinetic agents, azabicyclic benzamides, 1147
benzamide hetero-azabi-cyclo[x.y.0] derivs, 1293
Gastrin, ligands, oxathiazinone via Schotten-Baumann reaction, aryl-sulfonyl chlorides with aspartic acid derivs, 325
releasing peptide and bombesin, non-peptide CP-70, 030 and CP-75 antagonists, 998 333
Gelatin, cross-linking alpha-amylase, 427
polyacrylamide gels via urease immobilization, 433
Glucagon, receptor antagonist, non-peptide CP-99, 711 915
α-D-glucopyranosyl, linked oligosaccharide with anomeric 4-nitrophenyl or benzyl group, stereoselective synthesis, 1707
Glucose-6-phosphate dehydrogenase, reactions with β,γ-acetylenic and allenic sulfoxides and sulfones of dehydroepiandrosterone, 933
Glucosylation, mechanism UDPG activity, assessment glycosyltransferase catalysis, 1513
Glutamate, non-NMDA ionotropic receptors, phosphonoethylalanine deriv,antagonist 1269
Glycal, inhibitors of α-L-fucosidase, 33
Glycine, site site of NMDA receptor affinity ligands cis and trans 4- amido-2-carboxytetrahydro-quinolines, 371
glycine/NMDA, antagonists, effect 5-membered ring conformation on affinity 2-carboxy indolines, indoles, 1627
Glycopolymers, synthesis N-acetyl-lactosamine-β-D-(1→6)-α-D-GalNAc-conjugates, 911
Glycosaminoglycan, active heparin-like fragments, pentasaccharide with 3-O-methyl iduronic acid unit, 897
fragments, antithrombin tetra-methylated pentasaccharide, 901
Glycosidase, catalyzed synthesis,2-deoxy-β-glycosides, 423
α-glycosylation, nitrophenyl or benzyl glycosides via methyl 2,3,4,6-tetra-O-(4-methyl-oxybenzyl)-1-thio-β-D-glucopyranoside 1707
Glycosyltransferase, catalytic power, glucosylating activity UDPG 1513
Glyphosate, shikimate-3-phosphate ternary complex, design, synthesis EPSP synthase inhibitors, 1435
Guanosine, acyclic chiral analogs, synthesis, 677

H

Haematoporphyrin, analogs, synthesis and phototoxicity, 343
Halistanol trisulfate, action on adenosine receptors, caution receptor binding assays marine organism screening, 1631
HBTU, activating agent of muramic acid, 571
Heparin, like fragment, glycosaminoglycan, pentasaccharide with 3-O-methyl iduronic acid unit, 897
non-glycosamino glycan structure, O-alkylated O-sulfated penta-saccharides 905
non-glycosaminoglycan structure, tetra-methylated pentasaccharide, 901
Hepatic C-S lyase activity, human structure activity relationship kynurenine aminotransferase, 1219
Herpes simplex, virus type 2 ribonucleotide reductase, substit pentahexapeptide inhibitors, 1297
Hetero-azabicyclo[x.y.0] benzamides, gastric prokinetic agents, 1293
Hexahydroxydiphenyl derivs, potent inhibitors of HIV replication in H9 lymphocytes, 235
Hexyloxy-TZTP, muscarinic agonists, structure-activity

relationship
heterocyclic analogs, 809
Himbacine, muscarinic antagonist, therapy Alzheimers disease, 797
Histamine,
H_3 receptor agonists, S-[2-(4-(5)-imidazoyl) ethyl]isothiourea and 4-(4-(5)-imidazoyl)-butyramidine 77
H_3 receptors, agonist to antagonist imetit, N-methyl derivs, 1231
HIV,
activity, phosphonate isosteres of D4T monophosphonate, synthesis 367
gp120-CD4 interaction, β-lactam peptides as potential inhibitors 331
inhibitors QSARs 1165
non-nucleoside reverse transcriptase inhibitors, greater enzyme affinity than nevirapine 1745
protease, C_2-symmetric inhibitors, synthesis from D-mannitol, 353
proteinase inhibition, phosphonamidate peptides 1047
replication in H9 lymphocytes, hexahydroxydiphenyl derivs as inhibitors 235
structure, use in inhibitor design, 541
tripeptidyl epoxide inactivation, 1441

HMG-CoA,
BMS180431 reductase inhibitor, synthesis tetrazol-1-yl analogs,1085
reductase inhibitors, approach to site specific delivery, 285
HMG-CoA reductase inhibitors,
related to dihydro-mevinolin, design and biological evaluation, 223
tetrazole,conformational constraints and structural requirements at hydrophobic domain, 99
Hormones, carbamate series of juvenoids 963
Hydrogen bonding, effects reactivity preassociating α-nucleophile, secondary-side βCD hydroxylamine, 1635
Hydrolase enzyme, leukotriene A_4 inhibitors, synthesis, pharmacological activity designed compds, 1367
Hydrolysis, alkenyl-α-amino acid esters, catalyzed by α-chymotrypsin, 387
Hydroperoxy fatty acid, bioreduction by Phormidium tenue, 149
Hydrophobic cavities, with anilinium cation as structural element, 291
Hydroxamic acids, vinylogous, 5-lipoxygenase inhibition, 1079
Hydroxy-9,10-anthracenedione derivs, antineoplastic drugs, 659
Hydroxy-α-amino acids, O-allylation, entry to conformationally constrained dipeptide surrogates, 579
Hydroxy-amido-anthraquinones, antineoplastic drugs, 659
Hydroxymethyluracil, containing DNA, solid phase synthesis, 79
Hydroxyphenyl-kainoids, configuration variants, depolarizing activities central nervous system, rat, 743
Hygromycin A, aminocyclitol analogs: synthesis antibacterial activity, 1015
with biological activity, 1043
modification, synthesis and antibacterial activity vinyl methyl and amide analogs, 533
Hypocholesterolaemic agent, RP 70676 inhibitor of acyl-CoA:cholesterol O-acyl transferase, 375
Hypotensive agent, caracasanamide from Verbesina caracasana, 415

I

Iloprost, radio-immune assay, stable 9-substit carbacyclin derivs, 439
Imetit, N-methyl derivs, agonist to antagonist, histamine H_3 receptors, 1231
Imidazo[2',3':6,5]dipyrido[3,2-b:2',3'-e]-[1,4-]diazepine, non-nucleoside reverse transcriptase inhibitors, enzyme affinity greater than nevirapine, 1745
Imidazol-1-ylalkanoate, esters, acids, extrinsic ^{1}NMR probes for intracellular pH, 1717
Imidazole, appended dimethyl-β-cyclodextrin, substrate selectivity 1581
Imidazopyridazine carbamate, effective agent, drug resistant murine tumor 1257
Imidazoylbutyramidine, receptor agonists, 77
Imidazoylethylisothiourea, receptor agonists, 77
Immunoregulating activity, vit D analogs pregnane side chains, 1289
Immunostimulants, synthesis 4,6-diaminoquinoline derivs, 1589
Inactivators,
1-diazo-4-undecyn-2-one, E.coli β-hydroxy-decanoyl thiolester dehydrase 1381
general acyl-CoA dehydrogenase by methylenecyclo-propylacetyl-CoA, 1423
mechanism-based:
mandelate racemase by propargylglycolate, 1411
α-amino acid analogs, γ-aminobutyric acid amino-transferase, 1371

tripeptidyl epoxide, HIV-1 protease, 1441
Indanon-2-yl)methyl]-piperidine, hydrochloride derivs and related compds anti-cholinesterase activity, 871
Indazole, as aromatic bioisostere, imidazole class serotonin 5-HT_3 receptor antagonists, 1509
as indole bioisostere, 5-HT_4 receptor antagonism, 419
Indoles, bioisostere indazole 5-HT_4 receptor antagonism, 419
2-carboxy, glycine/NMDA antagonists, effect 5-membered ring conformation on affinity, 1627
Indolines, 2-carboxy, glycine/NMDA antagonists, effect 5-membered ring conformation on affinity, 1627
as aromatic bioisostere, imidazole class serotonin 5-HT_3 receptor antagonists, 1509
Indolylvinylpyridinium salt, aza-analogs, interaction choline acetyltransferase and ChAT inhibition, 1493
Indomethacin, synthesis reversed hydroxamic acids, cyclooxygenase, 5-lipoxygenase dual inhibitors, 1655
Inhibition, acetylcholinesterase, prodrug approach, synthesis 1-(2-indolyl)pyridinium salts, 123
C5a receptor binding, L-156602 cyclic hexadepsipeptide antibiotic analog, 1033
ChAT, aza-analogs indolylvinylpyridinium salt, 1493
competitive, kinetic analysis, phospholipase A_2, triton X-100 mixed micelles, 1343
DNA-gyrase and antibacterial activity fluoro-quinolines, effect of F position, 643
HIV and reverse transcriptase by tannins, 1529
human leukocyte elastase, cathepsin G, by isoxazoline derivs, 1571
mechanism phospholipase A_2, amino acid residues selectively modified by manoalide analog, 1267
phospholipase A_2, manoalide analog with essential aldehyde groups, 1263
slowly reversible, dehydroquinate synthase, new interpretation, 1349
thromboxane synthase: combined with thromboxane receptor antagonism, 4-substit 3-pyrrolidinyl-alkanoic acid 1619
combined with thromboxane receptor antagonism, arylsulfonylamino pyrrolidinylalkyl substit-aryl-alkanoic acids, 1623
yeast alcoholde-hydrogenase by Cu-complexes of colchiceine and N-deacetyl-deriv, 1097
Inhibitors, 2,3:18,19-dioxido-squalene activity, 2,3-oxidosqualene-lanosterol cyclase, rat liver microsomes, 1239
2-aryl-[1,3]dione compds, 5-lipoxygenase, 1309
7-aminoalkyl-2-amino-1, 2,3,4-tetrahydro-2-naphthoic acids, tryptophan uptake, 1039
A58365A, angiotensin converting enzyme, synthesis anodic amide oxidations, 739
α-hydroxy- and α-ketoester functionalized thrombin 1607
acid stable 5′-O-fluoromethyl phosphonate nucleosides, reverse transcriptase, 145
AdoHey hydrolase, synthesis 4′,5′-dehydro-5′-fluoro analogs aristomycin, 1741
azapeptide-derived, serine, cysteine proteases, synthesis, evaluation, 1375
β-lactam peptides, potential, HIV gp120-CD4 interaction, 331
BMS180431, tetrazol-1-yl analogs HMG-CoA reductase, 1085
borinic acids, serine proteases subtilisin Carlsberg and α-chymotrypsin, factors controlling binding active sites, 1391
C_2-symmetric HIV-1 protease, synthesis from D-mannitol, 353
cathepsin, synthesis N-peptidyl-O-acetyl hydroxylamines catalysed alcalase followed by lipase in t-BuOH, 1685
dihydroorotate dehydrogenase potential, [6-carboxyhexa-hydro]pyrimidines via 5-carbomethoxy-methyl-2-cyano]-imidazolones rearrangement, 421
dipeptide renin, synthesis using 2,3-disubstit cyclopropane carboxamide as P_3 amino acid replacement, 1405
dual, cyclooxygenase, 5-lipoxygenase, synthesis reversed hydroxamic acids indomethacin, 1655
dual balanced, NSAIDS conversion, cyclooxygenase, 5-lipoxygenase, 69

enkephalinase docking, thiorphan amide bond importance, 949
enol lactone derivs, human neutrophil elastase and trypsin-like proteases, 1399
enzyme mechanism-based, definition, classification, 1323 1327
episulfide, lipoxygenase, 1385
EPSP synthase: design, conformations enzyme bound shikimate-3-phosphate 5-enolpyranoyl-shikimate-3-phosphate using TRNOE, 151
synthesis based on ternary complex with shikimate-3-phosphate and glyphosate 1435
glycal, azasugar, of α-L-fucosidase, 33
hexahydrodiphenyl derivs, HIV replication, H9 lymphocytes, 235
HIV: QHSARs 1165
protease structure design, 541
proteinase, phosphonamidate peptides, 1047
HMG-CoA reductase, approach to site specific delivery, 285
L-chiro-inositol 1, 4, 6-trisphosphorothioate of myo-inositol 1, 4, 5-trisphosphate 5-phosphatase, 1523
leukotriene A_4 hydrolase enzyme, synthesis, pharmacological activity designed compds, 1367
lipoxygenase: new class, prototype L-689065 1699
pyridazinone series, structure-activity 1357
selective orally active A-53612, 1353
vinylogous hydroxamic acids, 1079
LY806303, thrombin, 1025
MDL74147, human renin, structure-activity and protease selectivity 651
methylglutaryl coenzyme A reductas, related to dihydromevinolin 223
monocyclic β-lactam, human leukocyte elastase, effect N-acyl substiruents on stability, 681
myo-inositol monophosphatase unrelated to enzyme substrate, 627
neuraminidase Clostridium perfringens, sodium ortho-(difluoro-methyl)phenyl-α-phenyl-α-ketoside N-acetylneuraminic acid 1361
non-nucleoside reverse transcriptase, imidazo[2′,3′:6,5] dipyrido[3,2-b:2′,3′-e]-1,4-diazepine enzyme affinity greater than nevirapine, 1745
penta-, hexapeptides, substit, herpes simplex virus type 2 ribonucleotide reductase, 1207
phenothiazine, phenoxazine derivs, in vitro evaluation, 5-lipoxygenase, iron-dependent lipid peroxidation, 59
[aryl]phosphate derivs AZT, HIV replication, kinase-deficient cells, 701
phosphonate derivs N^9-benzylguanine, purinenucleoside-dephosphorylase, 407
potential, UDP-glucuronosyl transferase, 583
protein kinase C, synthesis from rebeccamycin, 449
protein-tyrosine kinase, arylamides hydroxylated isoquinolines, 1771
proteinase, synthesis peptidyl 2,3-difluoro-3-aminopropionate, 1235
renin, retro-inverso tripeptide, 1089
reversible, interleukin-1β-converting enzyme, 613
RP 70676, acyl-CoA:cholesterol O-acyl transferase, 375
serine proteinases, human leukocyte elastase by substit dihydrouracils, 1565
substance P endopeptidase, peptidomimetics, 1693
tannins, protein kinase C, 239
tetravanadate, phosphatidyl inositol specific phospholipase C from Bacillus cereus, 655
thiazolidine-4-one analogs meclofenamic acid, synthesis cyclooxygenase and 5-lipoxygenase, 705
thromboxane receptor antagonist/synthase, heterocyclic variations, 1181
thromboxane synthase and antagonism dual activity molecules, 979,985
Inositol, 1-phosphate-4,5-pyrophosphate second messenger analog, synthesis via myo-inositol-1-phosphate-4,5-bis-phosphorothioate, 467
monophosphatase inhibitors unrelated to enzyme substrate, 627
Insecticides, synthetic rotenoids with blocked B/C ring system, 593
Interfacial enzymology, phospholipase A_2, 1335
Interleukin-1β, converting enzyme, synthesis of reversible inhibitor, 613
Interphenylene, 7-oxabicyclo[2.2.1] heptane oxazole, thromboxane receptor antagonist synthesis, 73
phenyl oxazoles, thromboxane receptor antagonists, 937
Ion-binding, properties bis-cysteine immobilized peptide, 281

Iron complex P-3A, cleavage duplex DNA comparison DNA cleavage Fe-complex (-)-desacetamido P3A, 1649
Iron-saccharide, complexes, solution stability, 997
Isoquinolines, hydroxylated arylamides, protein-tyrosine kinase inhibitors, 1771
Isoxazoline derivs, human leukocyte elastase, cathepsin G inhibition 1571

J
Juvenoids, carbamate series, 963

K
Kainic acid, synthesis ω-phosphonic acid analog, 1519
Ketoesters, asymmetric reduction with alcohol dehydrogenase from Thermoanaerobacter ethanolicus, 619
KF-14124, [1,4:3,6]-dianhydro-hexitol nitrate deriv, synthesis stereo-isomers, 1187
KH 1060, metabolite identification, 25-dihydroxyvitamin D_3 analog, 1713
Kinetics, competitive inhibition phospholipase A_2, triton X-100 mixed micelles, 1343
Kynurenine, aminotransferase/human hepatic C-S lyase, structure-activity 1219

L
L-156602, cyclic hexadepsipeptide antibiotic analog, inhibition C5a receptor binding, 1033
L-689065, prototype new class lipoxygenase inhibitors, 1699
Labdane diterpenoid, antihypertensive epi-deoxycoleonol from Coleus forskohlii 249
Lactams,
antibiotic potential:
amides of β-lactams,AMI study, tetrahedral intermediates 485
synthesis α-(S)-acylamino-N-(hydroxydioxocyclo-butenyl)-β-lactams, 1541
based, dipeptidyl building blocks 925
monocyclic:
conversion to bicyclic β-lactams 1503
inhibitors, human leukocyte elastase, effect N-acyl substit on stability 681
peptide potential inhibitors, HIV gp120-CD4 interaction 331
Lanosterol, 14α-demethylase, photoaffinity probes, 383
Leukocyte elastase, cephem sulfone inactivators, 1127
effect N-acyl substits stability monocyclic β-lactam inhibitors 681
Leukocytes, human elastase, inhibition by isoxazoline derivs, 1571
inhibition by substit dihydrouracils, 1565
leukotriene, B_4 receptor antagonists, ortho-alkoxyphenol, effect chroman carboxylic acid, 1675
Leukotrienes, A_4, hydrolase enzyme, synthesis, pharmacological activity designed inhibitors, 1367
B_4 receptor antagonists, ortho-alkoxyphenol, 1669
biosynthesis inhibitors, MK0591, 1395
D_4 antagonists, orally active 1141
Lipopolysaccharide, Shigella dysenteriae type 1, O-specific determinant octasaccharide, 255
Lipoxygenase,
dual cyclooxygenase inhibitors:
balanced 69
synthesis reversed hydroxamic acid indomethacin 1655
thiazolidine-4-one analogs meclofenamic acid inhibitors, 705
episuifide inhibitors, 1385
inhibitor, selective orally active A-53612, 1353
inhibitors:
2-aryl-{1,3}-diones. structural analysis 1309
episulfide 1385
new class prototype L-689065, 1699
selective, orally active A-53612 1353
vinylogous hydroxamic acid
structure activity pyridazinone series, 1357
LY806303, selective thrombin inhibition, 1025

M
Macrolactams, antifungal agents, biosynthesis, 575
Mandelate racemase, mechanism-based inactivation by propargylglycolate, 1411
Mannitol, synthesis C_2-symmetric HIV-1 protease inhibitors, 353
Mannose, 5-keto-D-deriv, 1-deoxymannojirimycin synthesis, 1419
Manoalide, aldehyde groups essential inhibition phospholipase A_2, 1263
selectively modified two amino acid residues, phospholipase A_2 inhibition mechanism, 1267
Marine organisms, screening, receptor binding assays, caution action halistanol trisulfate on adenosine receptors, 1631
Mass spectrometry, plasma desorption, 5′ non radioactive multiple

labelled oligodesoxy-ribonucleotides, 267
MDL74147, soluble inhibitor human renin, structure-activity and protease selectivity, 651
Mechanisms,
cytotoxicity activation enediynes, 1155
1-diazo-4-undecyn-2-one inactivator E.coli β-hydroxydecanoyl thiolester dehydrase, 1381
glucosylating activity UDPG, assessment glycosyltransferase catalysis, 1513
inactivation mandelate racemase by propargyl-glycolate, 1411
inhibition phospholipase A_2, selectively modified manoalide analog, 1267
inhibitor, neuraminidase Clostridium perfringens, synthesis sodium ortho-(difluoromethyl)-phenyl-α-ketoside N-acetylneuraminic acid 1361
potential proteolytic enzyme inhibitors, 175
site-directed enzyme inhibitors, classification, 1323
meso-**K region**, arene oxides, enantiomeric composition trans-dihydrodiols formed by microsomal epoxide hydrolase, 1729
Metabolism, resistant, synthesis arylpiperazine 5-HT_{1a} receptor agonists, 1703
Metabolites,
KH 1060 identification, synthesis, 1α, 25-dihydroxyvitamin D_3 analog, 1713
mono-hydroxylated velnacrine, synthesis and activity, 865
o-aminophenyl sulfate, oncolytic sulfonylureas, 1013
synthesis psammaplin A from Psammaplysilla sp, 1561
trans-3,4-dihydrodiol of 16,17-dihydro-15H-cyclopenta[a]-phenanthrene and Me and keto derivs, synthesis, 23
Methoxyimidoyl halide, function azabicyclic muscarinic agonist, 791
Methyl iduronic acid, pentasaccharide, active heparin-like fragments glycosaminoglycan, 897
Methyl-D-aspartic acid, receptor antagonists, 6-phosphonomethyl-tetrahydro-4-pyrimidine caboxylic acids and acyclic analogs 207
Methylenecyclopropyl-acetyl-CoA, general acyl-CoA dehydrogenase inactivation, 1423
Methyleneoxy-(methylimino), linked thymidine dimer, incorporation into antisense oligonucleosides, 1479
Methyoxycarbonylalkyl acrylate, lipase-catalyzed regioselective hydrolysis, prep of carboxyalkyl acrylate, 411
Microcystins,
interactions with protein phosphatases, role of arginine, 673
LR and nodularin, alternative computer model and reaction with protein phosphatases 299
Microtubule assembly assays:
cytotoxicity, biologically taxol analogs, 295
four taxol analogs baccatin III, 1751
Mimetics, type VI β-turn, via natural cis-peptide bond motif, 141
Mimics,
selected carboxylic acid CCK-B, synthesis potent and selective CCK-B antagonist, 45
somatostatin, design, synthesis and binding affinity, 135
MK0591, leukotriene biosynthesis inhibitors, 1395
MK-571(form1), structure at 170K and conformation by molecular modelling, 185
Models,
computer, 3-dimensional structures, microcystin-LR and nodularin and reaction with protein phosphatases 299
putative pharmacophore artemisinin, antimalarial evaluation of 2,3,5-trioxabi-cyclo[2.2.2]octanes, 623
Molecular probes, ^{19}FMRI, in vivo vascular phenomena, synthesis fluorine labelled polymers, 527
Molecular recognition, ligand receptor complementarity, entropy changes in phase transitions, 993
Monophosphatase, myo-inositol inhibitors unrelated to enzyme substrate, 627
Muramic acid, HBTU activating agent, 571
Murine tumour, drug resistant, new antitumour agent 1069C, 1257
Muscarinic agonists,
6-carboxymenthyl-2-aza-bicyclo[2.2.1]heptane enantiomers, rigid analogs of arecoline, 501
azabicyclic, N-methoxy imidoyl halide or nitrile function, 791
oxime ether function, design, synthesis, 787
hexyloxy-TZTP, structure-activity heterocyclic analogs, 809
M1 selective design and synthesis, 821
no cholinergic syndrome, SR 46559 and related amino-pyridazines, 833
SAR azaspirodioxolanes, 815
UH5, aldehyde, ketone and oxime analogs as cholinergic agents, 803
Muscarinic antagonists,

based on himbacine, therapy Alzheimers disease, 797
Muscarinic receptors, 1,4,5,6-tetrahydro-pyrimidines synthesis, activity, behaviour, 781
mustards, chiral phosphorus, serine derived, 1547
probes based on amine congeners of pirenzepine and telenzepine 845

N

NADH, dehydrogenase inhibitor, synthetic rotenoids with blocked B/C ring system 593
Nafazatrom phenothiazine and phenoxazine derivs, in vitro evaluation 5-lipoxygenase and iron-dependent lipid peroxidation inhibitors, 59
Naphthalimide, derivs, conformationally restricted antagonists, 5-HT_3 receptors 691
Neoglycoproteins glycopolymers, synthesis T-antigen and N-acetyl-lactosamine-β-D-(1→6)-α-D-GalNAc conjugates, 911

Nervous system, neural networks, regression analysis QSAR, 213
rat, depolarizing activities configuration variants hydroxyphenyl-kainoids, 743
Neuraminidase, Clostridium perfringens inhibitor, sodium ortho-(difluoromethyl)phenyl-α ketoside N-acetyl-neuraminic acid, 1361
Neurokinin-A fluoresceinyl, synthesis biologically active probe for NK_2 receptors 609
Neuroleptics, with high affinity for sigma receptors, (5S)-3-aryl-5-(1-piperidinylmethyl)-2-oxazolidinones, 165
Neuropeptide Y, functional group mimetics, NPY receptor antagonists 1497
Neurotensin, UK-73093 non-peptide receptor antagonist, 153
Nitration, diazotization benzimidazole ribonucleotides with t-butyl nitrite 1105
Nitriles, function in azabicyclic muscarinic agonist, 791
oxides, cycloaddition 2',3'-didehydro-2',3'-dideoxy]thymidine, 323
Nitrobenzyl serinate, synthesis 'caged serine', 1489
Nitrophenyl glycosides, α-glycosylation via methyl 2,3,4,6-tetra-O-(4-methyoxy-benzyl)-1-thio-β-D-gluco pyranoside, 1707
NMDA, competitive conformational antagonist activity due internal H-bonding, 1247
glycine, antagonists, effect 5-membered ring conformation on affinity 2-carboxy indolines, indoles, 1627
NMR, ^1H, extrinsic probes intracellular pH, imidazol-1-yl-alkanoate esters, acids, 1717
distamycin analogs, interaction dodecamer $d(CGCGAATTCGCG)_2$, 1299
NOESY, transferred, conformation 1-(3,4-]dichlorophenyl)-2-aminopropane bound active site PNMT, 1681
Nor-mefloquine, stereospecific synthesis and biological properties, 53
NPY receptor, antagonists, design, synthesis, 1497
NSAIDS, conversion to inhibitors of cyclooxygenase and 5-lipoxygenase, 69
Nucleosides, 3'-deoxy-3'N-hydroxy-amino analogs, anti-HIV activity, 1723
monophosphates: potential prodrugs dinucleoside phosphodi- and triester of ddC, 603
cyclic phosphonate analog, potent HIV activity, 367
N-3 aminosubstit thymidine analogs, anti-HIV activity, 1469
purine phosphorylase inhibitors, design substit quinazolinone alkylating agents, 1427
pyrimidine analogs, potential anti-HIV agents, 315
synthesis acid stable 5'-O-fluoromethyl phosphonates, inhibitors of reverse transcriptase, 145
Nucleotides, prodrugs of anti-HIV dideoxy-nucleosides, 603

O

Octadeoxyribonucleotides recognition by restriction endodeoxyribonuclease modulated by purine 8-substitution, 565
Octasaccharide, mimics native, O-specific determinant of Shigella dysenteriae type 1 lipopolysaccharide, 255
Odorant, binding protein, affinity of thiazole, selenazole derivs, 1603
Oligodesoxyribo-nucleotides, 5' non radioactive multiple labelled, solid phase synthesis, 267
Oligonucleosides, antisense, incorporation methyleneoxy-methylimino linked thymidine dimer, 1479
Oligonucleotides, incorporation

1-(2,4-dideoxy-β-D-erythrohexa-pyranosyl)-thymine, 945
solid phase synthesis, derivatization long chain alkylamine-controlled pore glass, 727
Oligoribonucleotides, synthesis using 2'-O-(o-nitrobenzyl-oxymethyl)]-protected monomers, 1019
Opioid, activity, dermorphin Phe sidechain fixed trans conformation, 1305
k-agonist hydrophilic phenylacetylpiperazine activity, reduced access central nervous system, 1275
Oxagranatane derivs, serotonin 5-HT_3 receptor antagonists, 519
Oxathiazinone, gastrin ligands via Schotten-Baumann reaction, aryl-sulfonyl chlorides with aspartic acid derivs, 325
Oxaziridines, intermediates lactam-based dipeptide building blocks, 925
Oxazolidinones, 3, 5-disubstit, potential neuroleptics with high affinity for sigma receptors, 165
Oxidosqualene, lanosterol cyclase, rat liver microsomes, synthesis 2,3:18,19-dioxido-squalene inhibitor, 1239
Oxime, ether function, design and synthesis azabicyclic muscarinic agonists, 787
Oxotremorine, enantiomerically pure hydroxylated derivs, synthesis, structure-activity 827
Oxygenation, singlet oxygen, pyrrole derivs of 6-APA and 7-ACA, 1101

P

Paraherquamide, 14-O-substit derivs synthesis, prep paraherquamide-2-O-methyl imidate, 1599
Pasteurella multocida, activity aminocyclitol analogs hygromycin A, 1015
Pentahexapeptides substit inhibitors, herpes simplex virus type 2 ribonucleotide reductase, 1297
Penta-O-acetylsucrose, precursor of sucralose, enzymatic prep, 161
Pentasaccharides, 3-O-methyl iduronic acid unit, active heparin-like fragments of glycosaminoglycan, 897
O-alkylated-O-sulfated, heparin-like fragment with non-glycoamino-glycan structure, 905
tetra-methylated, heparin-like fragment with non-glycosamino glycan structure, 901
Peptides, acridine conjugate with ribonucleolytic activity, 303
bis-cysteine immobilized, synthesis and ion-binding properties 281
bond motif, natural, design mimetic type VI β-turn, 141
cyclopentyl glutaryl, rigid bicyclic analogs, ANF potentiation, 1003
2,3-difluoro-3-aminoprop ionate, synthesis, 1235
HBTU activated coupling with muramic acid derivs, 571
β-lactam, potential inhibitors, HIV gp120-CD4 interaction, 331
lactam-based building blocks, oxaziridine intermediates, 925
N-peptidyl-O-acetyl hydroxylamines synthesis, catalysed alcalase followed by lipase in t-BuOH, cathepsin inhibitors, 1685
Peptidomimetic, cholecystokinin antagonists via 1,3,4-trisubstit pyrrolidinones, 1251
Peptidomimetics, substance P endopeptidase inhibitors, 1693
Perhydroisoindolone, synthesis and resolution, 37
PGE_1, 6-oxo and 9-fluoro derivs, synthesis and biological properties 445
pH, intracellular, imidazol-1-ylalkanoate esters, acids, ^1H NMR extrinsic probes, 1717
Pharmacology, DuP 747 kappa opioid analgesic, 715
Pharmacophore, partial, platelet activating receptor, 597
putative models of artemisinin, antimalarial evaluation 2,3,5-trioxabicyclo[2.2.2]-octanes, 623
Phase transitions, entropy changes, molecular recognition, ligand receptor complementarity, 993
Phenalene, metabolites from Eichhornia crassipes, 311
Phenanthrene, K-region arene oxides hydrolysis. enantiomeric composition trans-dihydrodiols,. 1729
Phenidone, homolog as selective orally active 5-lipoxygenase inhibitor, 1353
Phenothiazine, and phenoxazine derivs of nafazatrom *in vitro* evaluation 5-lipoxygenase and iron-dependent lipid peroxidation inhibitors, 59
Phenylacetylpiperazines, hydrophilic, peripherally selective k-opioid receptor agonists, 1275
Phenylketones, reduction by immobilized baker's yeast, 191
Pheophorbides, and bacteriopheophorbides,

related photosensitizers, structure-activity 491
Pheromones, processionary moth, synthesis of (Z)-10,10-di]fluoro-13-hexadecen-11-ynyl acetate, 467
PhoPhabs, antibody-phage-alkaline phosphatase conjugates, ELISA's without immunization, 1073
Phorbol, 12, 13-bis-lactone, synthesis, 695
Phormidium tenue, bioreduction hydroperoxy fatty acid, 149
Phosphatases, alternative computer model 3-dimensional structures and reaction with microcystin-LR and nodularin, 299
interactions with microcystins, role of arginine, 673
Phosphatidyl inositol, deoxy analog, synthesis and enzymatic properties, 171
specific phospholipase C from Bacillus cereus, inhibition by tetravanadate, 655
Phospholipase A_2, competitive inhibition, tritonX-100 mixed micelles, kinetic analysis, 1343
human synovial fluid, tertiary structure, model substrate binding, 553
interfacial enzymology, 1335
manoalide, analogs, functional groups for inhibition, 1263
mechanism selectively modified manolide analog inhibition, 1267
Phosphonamidate peptides, HIV-1 protease inhibition 1047
phosphonate esters, reversible modulation serine protease activity 1735
Phosphonates, derivs of N^9-benzyl-guanine, purine nucleoside phosphorylase inhibitors, 407
isosteres of D4T monophosphonate, synthesis and HIV activity, 367
Phosphonoethylalanine, derivs, non-NMDA ionotropic glutamate receptor antagonists 1269
ω-Phosphonic acid analog, kainic acid, synthesis, 1519
Phosphonomethoxy-ethyl-amino adenine, 9-[(phosphonomethoxy)acetamido]adenine, antiviral agents, 1559
Phosphonomethyltetrahydro-4-pyrimidine carboxylic acids, and acyclic analog competitive N-methyl-D-aspartic acid receptor antagonists 207
Phosphopeptides, epitope mapping, a[g]-s1-casien phosphopeptide 59-79 segments, 1153
Phosphoribosyl-1-pyrophosphate, synthetase substrate, 5-dideoxy-adenosine-5'-monophosphate, 1483
Phosphorus mustards, chiral, serine derived, 1547
Phosphorylase, purine nucleoside inhibitors, design substit quinazolinone alkylating agents, 1427
Photoaffinity, label, 7-(p-azido benzoyl)]taxol, synthesis and biological evaluation, 735
probes for lanosterol 14α-demethylase, 383
Photochemistry, c caged serine synthesis 1489
reactivity, side-chain of taxol, synthesis 91
Photodynamic therapy, synthesis benzoporphyrin derivs and analogs, 1575
Photosensitizers, related to pheophorbides and bacteriopheophorbides, structure-activity 491
Phototoxicity, haematoporphyrin analogs, 343
Piperidine, based chiral analogs, AF64A, acetylcholine, 1551
Piperidinyl benzamides, conformationally restricted, 5-HT_3 receptor antagonists, 523
Pirenzepine, amine congeners basis for muscarinic receptor probes 845
Plasmodium berghei, in vivo potent antidrugs 1,2,4-trioxanes, 497
Platelets, activating factor antagonist, synthesis and biological activity L671,284 and analogs, 181
activating receptor, partial pharmacophore, 597
PMEG, carbocyclic derivs, synthesis, biological activity, 685
Poly(acrylamide)gelatin, gels via urease immobilization, 433
Polymers, fluorine labelled synthesis, in vivo vascular phenomena with ^{19}F MRI, 527
Porphyrinyl-thymidines, related porphyrins, water soluble, tumoricidal activity, 1645
Potassium channel, activators: airways selective, BRL 55834 synthesis 1161
analogs, synthesis Ro-31-6930, 381
cromakalim, pyrrole analogs 1595
benzopyranyl 3-OH group in cromakalim and pyridine N-oxides in detn enantiomer biological activity 229
benzopyranyl-cyanoguanidine 87
openers: aryl cyanoguanidine, 83
cromakalim, related Ca channel blocker 1475
pyrrolidinone moiety relaxants guinea pig

trachealis 1595
Proclavaminic acid analogs, incubation Streptomyces clavuligerus enzyme prep, conversion monocyclic β-lactams to bicyclic β-lactams-1503
Prodrugs, anthracycline targeted, activated by antibody-enzyme conjugates 1093
approach to acetylcholinesterase inhibition, synthesis 1-(2-indolyl)-pryidinium salts 123
nucleotidic, of anti-HIV dideoxynucleosides, 603
Prokinetic agents, gastric, benzamide hetero-azabicyclo[x.y.0] derivs, 1293
Proline, ring, use as conformational restraint in CCK-B receptor dipeptoids, 403
Propargylglycolate, mechanism-based inactivation mandelate racemase 1411
Prostaglandins, tert allylic alcohol system, stabilization by fluorine, 1761
Proteases, activity serine, reversible modulation by phosphonate esters, 1735
elastase, trypsin-like, inhibitors enol lactone derivs, 1399
fluorogenic substrates, automated synthesis, probes Alzheimers disease associated proteases, 1665
selectivity, MDL74147 soluble inhibitor for human renin, 651
serine, cysteine inhibitors, synthesis, evaluation azapeptide analogs, 1375
serine subtilisin Carlsberg and α-chymotrypsin, factors controlling binding active sites, borinic acid inhibitors, 1391
Protecting groups, 2'-O-(o-nitrobenzyloxymethyl)-monomers, oligoribonucleotide synthesis, 1019
Protein-tyrosine, kinase inhibitors, arylamides hydroxylated isoquinolines, 1771
Proteinase, inhibitor, synthesis peptidyl 2,3-difluoro-3-amino-propionate, 1235
Proteins, chemical modification by new reagents, 607
kinase C, tannin inhibitors, 239
kinase C inhibitors, synthesis from rebeccamycin, 449
odorant-binding, affinity of thiazole, selenazole derivs, 1603
thiamine conjugation, 1007
Psammaplin A, bromotyrosine derived metabolite from Psammaplysilla sp synthesis, 1561
Purification, deacetoxycephalosporin C/deacetylcephalosporin C synthase 663
Purines, 8-substit modulates recognition by restriction endodeoxy-ribonuclease of octadeoxyribo-nucleotides, 565
nucleoside phosphorylase inhibitors, design substit quinazolinone alkylating agents, 1427
phosphonate derivs of N^9-benzylguanine, 407
Pyranoquinolines, Ca channel blocking activity, 1475
Pyrazines, nonacylic and trisdecacyclic, related cephalostatin, synthesis evaluation, 967
Pyrazoles, C-linked biaryl tetrazoles, angiotensin II antagonists, 1243
Pyrene, K-region arene oxides hydrolysis, enantiomeric composition trans-dihydrodiols, 1729
Pyridazinone series, 5-lipoxygenase inhibitors, structure activity 1357
Pyridine, N-oxide potassium channel openers, role of benzopyranyl 3-OH group in detn enantiomer biological activity, 229
Pyridinium salts, 1-(2-indolyl)-, synthesis prodrug approach to acetylcholinesterase inhibition, 123
Pyrroles, analogs, pyrrolidinone moiety K-channel activator cromakalim, relaxants guinea pig trachealis, 1595
derivs of 6-APA and 7-ACA, singlet oxygen oxygenation, 1101
Pyrrolidinone moiety, K-channel activator cromakalim, pyrrole analogs, relaxants guinea pig trachealis, 1595
Pyrrolidinones, 1,3,4-trisubstit, construction peptidomimetic cholecystokinin antagonists, 1251
Pyrrolidinylalkanoic acids, 4-substit, thromboxane synthase inhibition combined with thromboxane receptor antagonism, 1619
Pyrrolidinylalkyl, substit arylsulfonylamino arylalkanoic acids, thromboxane synthase inhibition combined with thromboxane receptor antagonism, 1623
Pyrrolo[1,2-d](1,4)-benzodiazepin-6-ones, anti-HIV agents, 1639

Q

QSARs, HIV inhibitors, 1165
using neural networks, regression analysis, 213
Quinazolines, antiarrhythmic/antioxidant, 1121

Quinazolinone, substit, alkylating agents, design purine nucleoside phosphorylase inhibitors, 1427

R

Reagents, chemical modification of proteins, 607
Rebeccamycin, synthesis of protein kinase C inhibitors, 449
Receptors,
5-HT_3/5-HT_4, design, synthesis of ligands 461
5-HT_3, 3-oxa-granatane derivs, 519
angiotensin-II, antagonists, new class, benzothiadiazine dioxides 1115
antagonists, conformationally restricted piperidinyl benzamides, 523
arylpiperazine 5-HT_{1A} agonists, metabolically stable 1703
bioisostere, 245
indazole 419
CCK-A and -B, binding CCK ergotamine inhibition 9
conformationally CP-99,711, non-peptide glucagon antagonist 915
conformationally restricted:
naphthalimide deriv antagonists 691
piperidinylbenzamides antagonists 523
dual-acting thromboxane, antagonist/synthase inhibitors 1181
effect chroman carboxylic acid 1675
leukotriene B_4 antagonists, ortho-alkoxyphenol, 1669
ligand-receptor interactions, altered conformation cyclosporin A bound to cyclophilin, 747
M_1,1,4,5,6-tetrahydropyrimidine ligands, synthesis, activity, behaviour, 781
muscarinic probes based on amine congeners pirenzepine, telenzepine, 845
NK_2, synthesis fluoresceinyl-neurokinin-A, biologically active probe, 609
NMDA, glycine site, affinity ligands cis and trans [4-amido 2-carboxy]tetrahydroquinolines, 371
non-peptide substance P, CP-96, 345 antagonist, SAR study CP-96, 345 559
NPY antagonists, design, synthesis, 1497
platelet activating factor, partial pharmacophore, 597
serotonin 5-HT_4 agonists and 5-HT_3 antagonists,
substance P NK_1 antagonist, SAR study CP-96, 345 559
synthetic, binding dipeptidic ammonium ion, 731
thromboxane:
antagonism combined synthase inhibition 1619
BMS-180291 antagonist, new pre-clinical lead 73
TXA_2/PGH_2 antagonists, metabolically stabilized synthesis and properties, 1069
UK-73093 neurotensin non-peptide antagonist, 1535
Recognition, by restriction endodeoxyribonuclease of octadeoxyribonucleotides modulated by purine 8-substitution, 565
Reductase, HMG-CoA potential inhibitors, approach to site specific delivery 285
Reduction,
asymmetric, ketoesters with alcohol dehydrogenase 619
phenylketones by immobilized baker's yeast, 191
Regioselection, chlorination 5-OH-2-(alkylamino)-tetralins, potential dopaminergic agents, 115
Relaxants, guinea pig trachealis, pyrrole analogs pyrrolidinone moiety cromakalim, 1595
Renin,
dipeptide inhibitors, synthesis using 2,3-disubstit cyclopropane carboxamide as P, amino acid replacement, 1405
human, soluble inhibitor MDL74147, structure-activity protease selectivity, 651
inhibition, retro-inverso tripeptide, 1089
Restriction, endodeoxyribonuclease, recognition of octadeoxyribonucleotides, modulated by purine 8-substitution, 565
Retinoids, 4-oxygenated, skin-cancer chemopreventatives, 1133
Ribonuclease, activity, acridine-peptide conjugate, 303
Ribonucleotides, benzimidazole, t-butyl nitrite diazotizations, unexpected nitration, 1105
Ro-31-6930, potassium channel activator and analogs, synthesis, 381
Rotenoids,
core structure, modified analogs defining toxophore requirements 13
synthetic, with blocked B/C ring system, 593
RP 70676, inhibitor of acyl-CoA:cholesterol O-acyl transferase, 375
RP-67, 580, synthesis nonpeptide substance P antagonist, 37

S

Saccharomyces cerevisiae, reduction phenylketones, 191
Sangivamycin derivs, design, synthesis activity human cytomegalovirus, 1755
SC-46275, synthesis, stability fluoromethyl analog, 1761

SCF-MO calculation, tetrahedral intermediates of amides of β-lactam antibiotics and MeOH, 485
Schotten-Baumann reaction, arylsulfonyl chlorides with aspartic acid derivs giving oxathiazinone gastrin ligands, 325
Selenazole derivs, affinity for odorant-binding protein, 1603
Serine, derived chiral phosphorus mustards, 1547
photodeprotectable derivs, synthesis 'caged serine', 1489
proteases:
activity reversible modulation by phosphonate esters, 1735
inhibitors, synthesis, evaluation azapeptide analogs, 1375
subtilisin Carlsberg and α-chymotrypsin, factors controlling binding active sites, borinic acid inhibitors, 1391
proteinase inhibitors, human leukocyte elastase by substit dihydrouracils, 1565
Serotonin, 5-HT_3 receptor antagonists, 3-oxagranatane derivs, 519
imidazole class 5-HT_3 receptor antagonists, indazole, indoline as aromatic bioisosteres, 1509
Serpulina hyodysenteriae, activity aminocyclitol analogs hygromycin A, 1015
antibacterial activity of methyl vinyl and amide analogs of hygromycin A, 533
Shigella dysenteriae, type 1 lipopolysaccharide, O-specific determinant octasaccharide, 255
Shikimate-3-phosphate, 5-enolpyruvoylshikimate-3-phosphate, enzyme bound, conformations using TRNOE, EPSP synthase inhibitor design, 151
glyphosate, ternary complex, design, synthesis EPSP synthase inhibitors 1435
Skin, cancer chemopreventatives, 4-oxygenated retinoids, 1133
Solutions, stability iron-saccharide complexes, 997
Somatostatin, nonpeptide mimic, design, synthesis binding affinity 135
Sphingosine-1-phosphate, synthesis and inhibition cell mobility, 973
Spiro adamantane sultones, synthesis as antiviral agents, 647
Stereoisomers, [1,4:3,6]-dianhydro-hexitol nitrate deriv KF-14124 synthesis, 1187
Stereoselectivity, synthesis, hydroxylated bifenthrin isomers, 1585
synthesis emeriamine enantiomers from L-aspartic acid, 1029
Stereospecificity, synthesis, chiral acyclic analogs of guanosine, 677
synthesis and biological properties, nor-mefloquine, 53
Structure activity, analgesic DuP, 747 721 2-aryl-1,3-diones, 5-lipoxygenase inhibitors, 1309
enantiomerically pure hydroxylated oxotremorine derivs, 827
heterocyclic analogs hexyloxy-TZTP muscarinic agonists, 809
kynurenine aminotransferase/human hepatic C-S lyase, 1219
MDL74147 soluble inhibitor for human renin, 651
non-peptide substance P receptor NK_1 antagonist, CP-96, 345 559
photosensitizers related to pheophorbides and bacteriopheophorbides, 491
PMEA analogs, anti-HIV activity, 307
pyridazinone series, 5-lipoxygenase inhibitors, 1357
pyridinyl pendant groups on core structures, acetylcholine cognition enhancers, 851
Structures, MK-571(form1) at 170K conformation by molecular modelling, 185
products, 3-N,N-(dimethylamino)-propan-1-ol reaction with α-bromoaceto-arenones, 157
requirements, hydrophobic domain in tetrazole HMG-CoA reductase inhibitors, 99
tertiary and model of substrate binding, phospholipase A_2 from human synovial fluid, 553
Stypoldione, synthesis and abs configuration, 391
Substance P, peptidomimetics, inhibitors, 1693
Substituent effect, 1,3,8-xanthines, adenosine A_1/A_2 affinity, 1199
Substrates, selectivity, imidazole-appended dimethyl β-cyclo-dextrin 1581
specificity, soluble recombinant deacetoxy-cephalosporin C/deacetyl-cephalosporin C synthase, 669
Subtilisin, Carlsberg and α-chymotrypsin, factors controlling binding active sites, borinic acid inhibitors, 1391
Sucralose, precursor,

enzymatic prep 2,3,6,3′,4′-penta-O-acetyl sucrose 161
Sulfonylureas, oncolytic, o-aminophenyl sulfate metabolites, 1013
Sulfoxides, sulfones, β-γ-acetylenic and allenic dehydroepiandrosterone reactions with 1-butanethiol and glucose-6-phosphate dehydrogenase, 933
Sultones, spiro adamantane, synthesis as antiviral agents, 647
Sweeteners, aspartame-like, containing L-αMe)Phe, 453
Synthetase, carbamoyl phosphate, large subunit from Escherichia coli, mutational analysis two putative domains, 319

T

T-antigen, N-acetyl-lactosamine-β-D (1→6)-α-D-GalNAc conjugates synthesis, 911
Tacrine, derivs synthesis and acetylcholinesterase and butyrylcholinesterase inhibition, 861
Tannins HIV and reverse transcriptase inhibition 1529
selective inhibitors of protein kinase C, 239
Tautomerism, keto-enol, cephem-4-ketones, 1127
Taxol, biologically active analogs, baccatin 111 13-(N-(p-chloro-benzoyl)-(2′R,3′S)-3′-phenylisoserinate) and 13-N-benzoyl-(2′R,3′S)-3′-(p-chlorophenyl)iso-serinate, 295
photoaffinity label, 7-(p-azidobenzoyl)-taxol synthesis and biological evaluation, 735
photoreactive side chain, synthesis, 91
semisynthesis, biological activity four baccatin III analogs, 1751
Telenzepine, amine congeners basis for muscarinic receptor probes, 845
Teleocidin, 5,6-substit synthesis and biological activity, 457
Teniposide, 4′-deshydroxy-4′-methyl analogs, antitumor agents, synthesis 1213
Tetrahedral intermediates, amides of β-lactam antibiotics and MeOH, AMI study, 485
Tetrahydro-1H-3-benza-zepine-7-ols, with non-aromatic substit in 5-position, dopamine receptor binding properties, 399
Tetrahydro-2-naphthoic acids, 7-aminoalkyl-2-amino-, inhibition tryptophan uptake, 1039
Tetrahydrofuran, (L671, 284) and analogs, platelet-activating factor antagonist, 181
Tetrahydronaphthalene, derivs, prep via Pd-catalyzed cyclization, 481
Tetrahydropyrimidines, ligands M1 receptors, synthesis, activity behaviour, 781
Tetrazole-5-yl-4-hydroxy-2-methyl-2H-1, 2-benzothiazine-3-carboxanilide, 1, 1-dioxide, anti-inflammatory, anti-allergic actions 709
Tetrazoles, HMG-CoA reductase inhibitors, conformational constraints and structural requirements at hydrophobic domain, 99
Therapy, Alzheimers disease muscarinic ligands based on himbacine, 797
Thermoanaerobacter ethanolicus, alcohol dehydrogenase, asymmetric reduction of ketoesters, 619
Thiamine, conjugation to proteins, 1007
Thiazole derivs, affinity for odorant-binding protein, 1603
Thiazolidine-4-ones, analogs meclofenamic acid, inhibition of cyclooxygenase and 5-lipoxygenase, 705
Thiols, induced crosslinking human blood proteins, tumor immunity, 919
reaction with etoposide ortho-quinone, 1111
Thiorphan, inhibitor-enkephalinase docking, amide bond importance 949
thiosangivamycin derivs, design, synthesis activity human cytomegalovirus, 1755
Thrombin, selective inhibition, LY806303, 1025
Thromboxane, compds with antagonist and synthase inhibition, 979, 985
dual-acting receptor antagonist/synthase inhibitors 1181
receptor antagonist: BMS-180291, new pre-clinical lead, 73 interphenylene phenyl oxazoles 937
receptors combined synthase inhibition 1619
synthase, inhibition combined with receptor antagonism, pyridinyl-substit sulfonylamino arylalkanoic acids, 1623
Thymidine, linked methyleneoxy(methylimino)incorporation antisense oligonucleosides, 1479
Thymidine nucleoside analogs, 3-amino substit, anti-HIV activity,1469
Topographical requirements, for delta opioid ligands, synthesis and biological properties deltorphin 1 cyclic analog, 547
Toxophore requirements, modified analogs of rotenoid core structure, 13

Toyocamycin, non-phosphorylatable analogs, design, synthesis, activity, human cytomegalovirus, 1755
Trachealis, relaxant, pyrrole analogs pyrrolidinone moiety K-channel activator cromakalim, guinea pig, 1595
Transcriptase, reverse inhibition: tannins, 1529 synthesis acid stable 5′-O-fluoromethyl phosphonate nucleosides, 145
Trifluoromethylamino acid, residue containing enkephalin potent analogs, 219
Trimethylanilinium cation, AMBER force field parameters, 291
Trioxabicyclo-[2.2.2]-octanes, antimalarial evaluation, models for putative pharmacophore of artemisinin, 623
Trioxanes, in vivo potent antimalarials, synthesis, 497
Tripeptide, retro-inverso, renin inhibition, 1089
Tripeptidyl epoxide, inactivation HIV-1 protease, 1441
Trisnortriterpene glucoside with 14,18-cycloapoeuphane-type skeleton, cumindysoside A from Dysoxylum cumingianum, 395
Triton X-100, mixed micelles, kinetic analysis competitive inhibition phospholipase A_2, 1343
Tryptophan, uptake, inhibition by 7-aminoalkyl-2-amino-1, 2,3,4-tetrahydro-2-naphthoic acids, 1039
Tumoricidal activity, water soluble porphyrinyl thymidines and related porphyrins, 1645
Tumors, immunity, thiol-induced crosslinking human blood proteins, 919
TXA_2/PGH_2, metabolically stabilized receptor antagonists synthesis and properties, 1069
receptor antagonists, synthesis and properties, 1063
Tyrosine, enzymatic synthesis of 2-azido-L-tyrosine, 41

U

UDP-glucuronosyltransferase, synthesis potential inhibitor, 583
UDPG, glucosylating activity, assessment glycosyltransferase catalysis, 1513
UK-73093, neurotensin non-peptide receptor antagonist, 1535
Undecapeptide, substance P antagonist, synthesis RP-67, 580 580 37
Urea series, acetylcholine cognition activators, 855
Urease immobilization poly(acrylamide)gelatin gels 433
Uridine-5′-O-(2-thio-diphosphoglucuronate), enzymatic synthesis and properties, 197

V

Vanadate tetramer ion, inhibitor phosphatidyl inositol specific phospholipase C from Bacillus cereus, 655
Vascular phenomena, with ^{19}F MRI, synthesis fluorine labelled polymers, 527
Velnacrine, mono-hydroxy metabolites, synthesis and activity, 865
Verbesina caracasana, hypotensive agent caracasanamide, 415
Vinyl, analogs of hygromycin A, 533
Viruses, type 2 ribonucleotide reductase, herpes simplex penta-, hexapeptide, substit inhibitors, 1297
Vitamins, α, 25-dihydroxyvitamin D_3 analog, identification, synthesis KH 1060 metabolite, 1713
D_3, 1α,25-dihydroxy synthesis (C-11)-substit analogs, 477
D analogs, pregnane side chains, synthesis, immunoregulating activity, 1289

X

Xanthines, 1,3,8-trisubstit substituent effect, adenosine A_1/A_2 affinity, 1199
Xylofuranoses, tetrasubstit, potential nonpeptide mimic somatostatin. 135

Author Index 1992

Abad J.-L. Casas J. Sánchez-Baeza F. and Messeguer A. 2,3:18,19-dioxidosqualene: synthesis and activity as a potent inhibitor of 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes 1239

Adam S. HBTU: a mild activating agent of muramic acid 571

Adam S. Nor-mefloquine: stereospecific synthesis and biological properties 53

Addo M. F. see Murray W. V. 1775

Adlington R. M. see Baldwin J. E. 669

Ahmed S. Z. see Atwal K. S. 1475

Ahmed S. Z. see Atwal K. S. 83

Ahmed S. Z. see Atwal K. S. 87

Akbulut U. see Bayramoglu Z. 427

Akbulut U. see Elçin M. 433

Alberg D. G. see Rosen M. K. 747

Albericio F. see García-Echeverría C. 281

Albert D. H. see Brooks D. W. 1353

Albert D. H. see Brooks D. W. 1357

Alberts A. W. see Bugianesi R. L. 181

Alcalde E. Roca T. Barat A. Ramirez G. Goya P. and Martinez A. (*E*)-1-Alkyl-[2-(1*H*-azol-2-yl)vinyl]pyridinium salts: theoretical analysis, synthesis and evaluation of their interaction with choline acetyltransferase 1493

Ali S. F. see Sieburth S. McN. 1585

Ali S. M. see Liu S. 1741

Alpegiani M. Bissolino P. Borghi D. Corigli R. Del Nero S. Perrone E. Razzano G. and Rizzo V. Cephem sulfones as inactivators of human leukocyte elastase—II. Keto–enol tautomerism in cephem-4-ketones 1127

Amstutz R. see Shapiro G. 815

and McCarthy D. J. Enzymatic synthesis and properties of uridine-5'-*O*-(2-thio-diphosphoglucuronate) 197

Andersen N. R. Buchwald F. A. and Grue-Sørensen G. Identification and synthesis of a metabolite of KH 1060, a new potent 1α,25-dihydroxyvitamin D_3 analogue 1713

Andrianomenjanahary S. Dong X. Florent J.-C. Gaudel G. Gesson J.-P. Jacquesy J.-C. Koch M. Michel S. Mondon M. Monneret C. Petit P. Renoux B. and Tillequin F. Synthesis of novel targeted pro-prodrugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate—I 1093

Andronati S. A. see Mazurov A. A. 649

Angelastro M. R. Bey P. Mehdi S. and Peet N. P. Synthesis of a peptidyl 2,2-difluoro-3-aminopropionate 1235

Antich P. P. see Mehta V. D. 527

Antonello C. see Zagotto G. 659

Ares J. J. Ronkin S. M. and Wallace L. J. Synthesis of 1-(2-indolyl)pyridinium salts: a prodrug approach to acetylcholinesterase inhibition 123

Arison B. H. see Meinke P. T. 537

Arrang J. M. see Ganellin C. R. 1231

Ashe B. M. see Hagmann W. K. 681

Ashton M. J. Bridge A. W. Bush R. C. Dron D. I. Harris N. V. Jones G. D. Lythgoe D. J. Riddell D. and Smith C. RP 70676: a potent systemically available inhibitor of acyl-CoA:cholesterol O-acyl transferase (ACAT) 375

Ashton W. T. see Chang L. L. 1207

Asteriadis G. T. see Schwartz M. E. 1019

Ator M. A. see Graybill T. L. 1375

Attwood M. R. Brown B. S. Dunsdon R. M. Hurst D. N. Jones P. S. and Kay P. B. Synthesis of homochiral potassium channel openers: role of the benzopyranyl 3-hydroxyl group in cromakalim and pyridine N-oxides in determining the biological activities of enantiomers 229

Atwal K. S. McCullough J. R. Hedberg A. Conder M. L. Ahmed S. Z. Cucinotta G. and Normandin D. E. The discovery of a novel calcium channel blocker related to the structure of potassium channel opener cromakalim 1475

Atwal K. S. Moreland S. McCullough J. R. O'Reilly B. C. Ahmed S. Z. and Normandin D. E. Aryl cyanoguanidine potassium channel openers 83

Atwal K. S. Moreland S. McCullough J. R. Ahmed S. Z. and Normandin D. E. Benzopyranyl-cyanoguanidine potassium channel openers 87

Aubé J. and Wolfe M. S. A divergent route toward lactam-based dipeptidyl building blocks 925

Augustyns K. Van Aerschot A. and Herdewijn P. Synthesis of 1-(2,4-dideoxy-β-D-*erythro*-hexopyranosyl)thymine and its incorporation into oligonucleotides 945

Avizonis D. see Conte M. R. 79

Babcock E. E. see Mehta V. D. 527
Babine R. E. Zhang N. Jurgens A. R. Schow S. R. Desai P. R. James J. C. and Semmelhack M. F. The use of HIV-1 protease structure in inhibitor design 541
Baggaley K. H. see Elson S. W. 1503
Baker R. see Fletcher S. R. 627
Baker W. R. Jae H.-S. Martin S. F. Condon S. L. Stein H. H. Cohen J. and Kleinert H. D. Conformationally restricted peptide isosteres—II. Synthesis and *in vitro* potency of dipeptide renin inhibitors employing a 2-alkylsulfonyl-3-phenylcyclopropane carboxamide as a P_3 amino acid replacement 1405
Balachandran S. see Tandon J. S. 249
Balasubramanian N. Brown P. J. Parker R. A. and Wright J. J. HMG-CoA reductase inhibitors—IV. Tetrazole series: conformational constraints and structural requirements at the hydrophobic domain 99
Baldwin J. E. Adlington R. M. Crouch N. P. Heath R. J. Pereira I. A. C. and Sutherland J. D. Substrate specificity of soluble recombinant deacetoxycephalosporin C/deacetylcephalosporin C synthase 669
Baldwin J. E. Blackburn J. M. Heath R. J. and Sutherland J. D. High-level soluble expression and purification of deacetoxycephalosporin C/deacetylcephalosporin C synthase 663
Ball R. G. see Hutchinson J. H. 1699
Ballas L. M. see Kashiwada Y. 239
Ballesteros P. see Gil M. S. 1717
Baltzer S. see Schirlin D. 651
Balzarini J. see Pérez-Pérez M.-J. 647
Bandwar R. P. see Rao C. P. 997
Bang-Andersen B. see Ganellin C. R. 1231
Barak D. see Fisher A. 839
Barat A. see Alcalde E. 1493
Barrere B. see Driguez P.-A. 1361
Barrish J. C. Spergel S. H. Moreland S. and Hedberg S. A. The synthesis of a conformationally rigid calcium channel blocker 95
Barrish J. C. see Misra R. N. 73
Bartus R. T. see Birnberg G. H. 345
Bartus R. T. see Levin J. I. 349
Basavaiah D. and Bhaskar Raju S. Bovine liver acetone powder (BLAP): a crude enzyme for synthesis of optically active 1-aryl-1-alkanols 955
Basha A. see Brooks D. W. 1357
Basten J. Jaurand G. Olde-Hanter B. Duchaussoy P. Petitou M. and van Boeckel C. A. A. Biologically active heparin-like fragments with a 'non-glycosamino' glycan structure—III. O-Alkylated-O-sulphated pentasaccharides 905
Basten J. Jaurand G. Olde-Hanter B. Petitou M. and van Boeckel C. A. A. Biologically active heparin-like fragments with a 'non-glycosamino' glycan structure—II. A tetra-O-methylated pentasaccharide with high affinity for antithrombin III 901
Basten J. see Jaurand G. 897
Baumgold J. see Jacobson K. A. 845
Bause E. see Berger A. 27
Baxter E. W. and Reitz A. B. Concise synthesis of 1-deoxymannojirimycin 1419
Bay S. and Cantacuzène D. Additions and Corrections 767
Bay S. and Cantacuzène D. Glycosidases catalyzed synthesis of 2-deoxy-β-glycosides 423
Bayramoglu Z. Akbulut U. and Sungur S. Immobilization of alpha-amylase into gelatin films with various cross-linkers 427
Bazile S. see Clairefond P. 643
Becker D. P. see Flynn D. L. 1251
Becker D. P. see Flynn D. L. 1613
Bedford C. T. Hickman A. D. and Logan C. J. Mechanistic studies of biological glycosylation. Determination of the glucosylating reactivity of uridine-5'-diphospho-α-D-glucose (UDPG) and assessment of the catalytic power of the glycosyltransferases 1513
Bednar D. L. see Hamilton G. S. 1269
Beer B. see Birnberg G. H. 345
Beer B. see Levin J. I. 349
Begassat F. see Maillard M. 1469
Belley M. see Labelle M. 1141
Belley M. see Prasit P. 1395
Bellinger G. C. A. see Woodburn K. W. 343
Belshaw P. J. see Rosen M. K. 747
Bence L. M. see Suckling C. J. 49
Berg O. see Gelb M. H. 1335
Berger A. Dax K. Gradnig G. Grassberger V. Stütz A. E. Ungerank M. Legler G. and Bause E. Synthesis and biological activity of C-6 modified derivatives of the glucosidase inhibitor 1-deoxynojirimycin 27
Berger J. G. see Chang W. K. 399
Berkowitz D. B. see Dumas D. P. 33
Bermudez J. Gregory J. A. King F. D. Starr S. and Summersell R. J. 3-Oxagranatane (3-oxa-9-azabicyclo[3.3.1]nonane) derivatives as highly potent serotonin 5-HT_3 receptor antagonists 519
Bermudez J. Hadley M. S. King F. D. and Martin R. T. Conformationally restricted piperidinyl benzamides as 5-HT_3 receptor antagonists 523
Bermudez J. King F. D. and Sanger G. J. Indazole and indoline as aromatic bioisosteres in the imidazole class of serotonin 5-HT_3 receptor antagonists 1509
Berner H. see Schricker B. 387
Berry D. R. see Sall D. J. 1025
Bertollini L. see Campiani G. 1193
Bertsch B. see Yu M. J. 59
Bey P. see Angelastro M. R. 1235
Bhagwat S. S. Boswell C. Gude C. Contardo N. Cohen D. S. Mathis J. Dotson R. Lee W. and Shetty S. Thromboxane receptor antagonism combined with thromboxane synthase inhibition—VI. 4-Substituted 3-pyridinylalkanoic acids 1619
Bhagwat S. S. Roland D. M. Main A. J. Gude C. Grim K. Goldstein R. Cohen D. S. Dotson R. Mathis J. and Lee W. Thromboxane receptor antagonism combined with thromboxane synthase inhibition—VII. Pyridinylalkyl-substituted arylsulfonylamino arylalkanoic acids 1623
Bhaskar Raju S. see Basavaiah D. 955

Bhatia P. see Brooks D. W. 1357
Bianchi R. G. see Collins P. W. 1761
Bigge C. F. Wu J.-P. Drummond J. T. Coughenour L. L. and Hanchin C. M. Excitatory amino acids: 6-phosphonomethyltetrahydro-4-pyrimi- dinecarboxylic acids and their acyclic analogues are competitive N-methyl-D-aspartic acid receptor antagonists 207
Birch P. J. Hayes A. G. Johnson M. R. Lee T. A. Murray P. J. Rogers H. and Scopes D. I. C. Preparation and evaluation of some hydrophilic phenylacetylpiperazines as peripherally selective κ-opioid receptor agonists 1275
Birnberg G. H. Fanshawe W. J. Levin J. I. Epstein J. W. Beer B. Bartus R. T. and Dean R. L., III The synthesis and cognition enhancing effects of a series of dibenzoyl guanidines. Analogs of N,N'-[[4-(aminocarbonyl)phenyl]carbon imidoyl]bis-[benzamide] 345
Bissolino P. see Alpegiani M. 1127
Blackburn J. M. see Baldwin J. E. 663
Blagbrough I. S. Buckberry L. D. Bycroft B. W. and Shaw P. N. Kynurenine aminotransferase/human hepatic C-S lyase: preliminary structure–activity relationship studies 1219
Blagbrough I. S. see Buckberry L. D. 1225
Blanckaert N. see Noort D. 583
Blizzard T. A. see Shankaran K. 1555
Blouin M. see Labelle M. 1141
Blum E. Buchheit K. H. Buescher H. H. Gamse R. Kloeppner E. Meigel H. Papageorgiou C. Waelchli R. and Revesz L. Design and synthesis of novel ligands for the 5-HT_3 and the 5-HT_4 receptor 461
Boddeke H. see Shapiro G. 815
Boddeke H. W. G. M. see Pombo-Villar E. 501
Bodner A. J. see Kashiwada Y. 235
Bodner A. J. see Kilkuskie R. E. 1529
Boehm J. C. see Williams J. R. 933
Boesten W. H. J. see Polinelli S. 453
Boger D. L. Menezes R. F. Dang Q. and Yang W. Deglyco GABA,gly-desacetamidobleomycin A_2: a simplified synthetic model for bleomycin A_2 261
Boger D. L. Menezes R. F. and Yang W. A simple method for the purification and isolation of bleomycin A_2 959
Boger D. L. Yun W. Terashima S. Fukuda Y. Nakatani K. Kitos P. A. and Jin Q. DNA Alkylation properties of the duocarmycins: (+)-duocarmycin A, *epi*-(+)-duocarmycin a, *ent*-(–)-duocarmycin a and *epi,ent*-(–)-duocarmycin A 759
Boger D. L. and Yang W. P-3A and (–)-desacetamido P-3A: demonstration and study of their effective functional cleavage of duplex DNA 1649
Boger J. see Durette P. L. 1033
Bohnett M. see Messer, Jr W. S. 781
Boigegrain R. see Wermuth C. G. 833
Bojanic D. see Terrett N. K. 1745
Bolliger G. see Shapiro G. 815
Bondy S. S. see Durette P. L. 1033
Bone E. A. Cunningham E. M. Davidson A. H. Galloway W. A. Lewis C. N. Morrice E. M. Reeve M. M. Todd R. S. and White I. M. The design and biological evaluation of a series of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors related to dihydromevinolin 223
Bonnaffé D. see Lubineau A. 607
Boons G. J. P. H. see Noort D. 583
Borchardt R. T. see Liu S. 1741
Bores G. M. see Gregory Shutske M. 865
Borghi D. see Alpegiani M. 1127
Bornemeier D. A. see Boschelli D. H. 69
Bornemeier D. A. see Kramer J. B. 1655
Borosky S. A. see Hamilton G. S. 1269
Boschelli D. H. Connor D. T. Kuipers P. J. and Wright C. D. Synthesis and cyclooxygenase and 5-lipoxygenase inhibitory activity of some thiazolidene-4-one analogs of meclofenamic acid 705
Boschelli D. H. Connor D. T. Hoefle M. Bornemeier D. A. and Dyer R. D. Conversion of NSAIDS into balanced dual inhibitors of cyclooxygenase and 5-lipoxygenase 69
Boschelli D. H. see Kramer J. B. 1655
Bossuyt X. see Noort D. 583
Boswell C. see Bhagwat S. S. 1619
Boswell G. A. see Earl R. A. 851
Botta B. see Delle Monache G. 415
Botta M. see Campiani G. 1193
Botta M. see Delle Monache G. 415
Bourguignon J.-J. see Wermuth C. G. 833
Bouska J. B. see Brooks D. W. 1353
Bouzard D. see Clairefond P. 543
Boyd R. see Yu M. J. 1121
Brabander H. J. see Trybulski E. J. 827
Bradshaw K. C. see Gregory Shutske M. 865
Brammer N. see Cliffe I. A. 245
Brandeis R. see Fisher A. 839
Breaker R. R. see Schwartz M. E. 1019
Breau A. see Yu M. J. 1121
Brémont B. see Langlois M. 691
Brezina F. see Ulrichová J. 1097
Brideau C. see Prasit P. 1395
Bridge A. W. see Ashton M. J. 375
Briggs J. C. Dawson A. P. Gibson I. Haines A. H. Hook J. and Taylor R. J. K. The synthesis of conformationally-restricted diacyl glycerol analogues 131
Briggs J. C. Dawson A. P. Gibson I. Haines A. H. Hook J. Lloyd A. Meiners S. and Taylor R. J. K. The synthesis and evaluation of diacylglycerol analogues as potential second-messenger antagonists 127
Brittelli D. R. see Earl R. A. 851
Brodin R. see Wermuth C. G. 833
Bromidge S. M. Brown F. Cassidy F. Clark M. S. G. Dabbs S. Hadley M. S. Loudon J. M. Orlek B. S. and Riley G. J. Design and synthesis of azabicyclic muscarinic agonists incorporating an oxime ether functionality 787
Bromidge S. M. Brown F. Cassidy F. Clark M. S. G. Dabbs S. Hawkins J. Loudon J. M. Orlek B. S. and Riley G. J. A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality 791

Bronson J. J. Ferrara L. M. Martin J. C. and Mansuri M. M. Synthesis and biological activity of carbocyclic derivatives of the potent antiviral agent 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG) 685
Bronson J. J. see Kim C. U. 367
Brooks D. W. Albert D. H. Dyer R. D. Bouska J. B. Young P. Rotert G. Machinist J. M. and Carter G. W. 1-Phenyl-[2H]-tetrahydropyridazin-3-one, A-53612, a selective orally active 5-lipoxygenase inhibitor 1353
Brooks D. W. Basha A. Kerdesky F. A. J. Holms J. H. Ratajcyk J. D. Bhatia P. Moore J. L. Martin J. G. Schmidt S. P. Albert D. H. Dyer R. D. Young P. and Carter G. W. Structure–activity relationships of the pyridazinone series of 5-lipoxygenase inhibitors 1357
Brooks D. W. Schmidt S. P. Dyer R. D. Young P. R. and Carter G. W. Structural analysis of 2-aryl-1,3-dione compounds as inhibitors of 5-lipoxygenase 1309
Broughton H. B. see Low C. M. R. 325
Brown B. R. see Misra R. N. 73
Brown B. R. see Misra R. N. 937
Brown B. S. see Attwood M. R. 229
Brown F. see Bromidge S. M. 787
Brown F. see Bromidge S. M. 791
Brown P. J. see Balasubramanian N. 99
Brownlee R. T. C. see Woodburn K. W. 343
Broxterman Q. B. see Polinelli S. 453
Brubaker M. J. see Groutas W. C. 175
Brubaker M. J. see Groutas W. C. 1565
Brubaker M. J. see Groutas W. C. 1571
Bruni G. see Campiani G. 1193
Bruns C. see Papageorgiou C. 135
Buchheit K. H. see Blum E. 461
Buchwald F. A. see Andersen N. R. 1713
Buckberry L. D. Bycroft B. W. Shaw P. N. and Blagbrough I. S. Human hepatic C-S lyase: transamination reactions and significant differences between kynurenine aminotransferase and kynureninase 1225
Buckberry L. D. see Blagbrough I. S. 1219
Buckle D. R. Eggleston D. S. Pinto I. L. Smith D. G. and Tedder J. M. Synthesis of BRL 55834—a novel, potent airways-selective potassium channel activator 1161
Buckle D. R. see Smith D. G. 1595
Buescher H. H. see Blum E. 461
Bugianesi R. L. Ponpipom M. M. Parsons W. H. Hwang S.-B. Doebber T. W. Lam M.-H. Wu M. S. Alberts A. W. and Chabala J. C. Synthesis and biological activity of the platelet-activating factor antagonist (±)-*trans*-2-(3-methoxy-4-phenylsulfonylethoxy-5-*n*-propylsulfonylphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-671,284) and its analogs 181
Bugnicourt A. see Maillard M. 1469
Burke T. R. Ford, Jr H. Osherov N. Levitzki A. Stefanova I. Horak I. D. and Marquez V. E. Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors 1771
Burkholder T. P. Le T.-B. Giroux E. L. and Flynn G. A. Acid-catalyzed O-allylation of β-hydroxy-α-amino acids: an entry into conformationally constrained dipeptide surrogates 579
Burney P. A. see Paul P. K. C. 141
Bush R. C. see Ashton M. J. 375
Butler D. E. see Thomas A. J. 855
Bycroft B. W. see Blagbrough I. S. 1219
Bycroft B. W. see Buckberry L. D. 1225
Bymaster F. P. see Sauerberg P. 809
Byrn S. R. see Stowell J. G. 185

Calabrese J. C. see Seitz S. P. 171
Caldirola P. see Zhang M.-Q. 1283
Caldwell C. G. see Durette P. L. 1033
Camarasa M.-J. see Pérez-Pérez M.-J. 647
Camp N. P. Hawkins P. C. D. Hitchcock P. B. and Gani D. Synthesis of stereochemically defined phosphonamidate-containing peptides: inhibitors for the HIV-1 proteinase 1047
Campbell A. S. and Thatcher G. R. J. Tetravanadate is an inhibitor of phosphatidyl inositol-specific phospholipase C 655
Campbell M. M. see Paul P. K. C. 141
Campiani G. Nacci V. Garofalo A. Botta M. Fiorini I. Tafi A. Bruni G. Romeo M. R. Peres A. and Bertollini L. Synthesis and preliminary biological evaluation of 1-aminomethyl-4-substituted-4H-pyrrolo[2,1-C][1,4]benzothiazines, a new class of calcium antagonists 1193
Camps F. see Feixas J. 467
Cantacuzène D. see Bay S. 423
Cantacuzène D. see Bay S. 767
Capek K. see Tronchet J. M. J. 1723
Carmignani M. see Delle Monache G. 415
Carson D. L. see Curley R. W. 1133
Carter G. W. see Brooks D. W. 1309
Carter G. W. see Brooks D. W. 1353
Carter G. W. see Brooks D. W. 1357
Casara P. J. Jund K. C. Clauss A. Navé J.-F. and Snyder R. D. Synthesis of acid stable 5'-O-fluoromethyl phosphonates of nucleosides. Evaluation as inhibitors of reverse transcriptase 145
Casas J. see Abad J.-L. 1239
Casida J. E. see Josephs J. L. 593
Cassidy F. see Bromidge S. M. 787
Cassidy F. see Bromidge S. M. 791
Casteel D. A. Jung K.-E. Gerena L. and Milhous W. Synthesis and antimalarial evaluation of 2,3,5-trioxabicyclo[2.2.2]octanes, models for the putative pharmacophore of qinghaosu (artemisinin) 623
Castellino S. see Leo G. C. 151
Cayley J. see Crombie L. 13
Cerdán S. see Gil M. S. 1717
Ceszkowski K. and Chollet A. Synthesis of fluoresceinyl-neurokinin-A, a biologically active probe for NK_2 receptors 609
Chabala J. C. see Bugianesi R. L. 181
Chackalamannil S. Wang Y. and Hasianger M. F. Studies in ANF potentiation. Synthesis of rigid bicyclic analogs of

cyclopentyl glutaryl derivatives 1003
Champion E. see Labelle M. 1141
Chan C. see Prasit P. 1395
Chandra S. see Singh C. 497
Chandrasekaran E. V. see Jain R. K. 63
Chang J.-J. see Kashiwada Y. 395
Chang L. L. Hannah J. Ashton W. T. Rasmusson G. H. Ikeler T. J. Patel G. F. Garsky V. Uncapher C. Yamanaka G. McClements W. L. and Tolman R. L. Substituted penta- and hexapeptides as potent inhibitors of herpes simplex virus type 2 ribonucleotide reductase 1207
Chang W. K. Peters M. Fevig V. P. Koziowski J. A. Zhou G. Lowe D. B. Guzik H. McQuade R. D. Duffy R. Coffin V. L. and Berger J. G. Dopamine receptor binding properties of some 2,3,4,5-tetrahydro-1*H*-3-benzazepine-7-ols with non-aromatic substituents in the 5-position 399
Chantegrel B. see Driguez P.-A. 1361
Chapman K. T. Synthesis of a potent, reversible inhibitor of Interleukin-1β converting enzyme 613
Charette L. see Labelle M. 1141
Charleson S. see Hutchinson J. H. 1699
Charleson S. see Prasit P. 1395
Chatterjee A. Williamson J. S. Zjawiony J. K. and Peterson J. R. Synthesis of a photoreactive taxol side chain 91
Cheeseman R. S. see Rajagopalan P. 721
Chen C.-F. see Ong C.-W. 929
Chen H.-P. Wu S.-H. Tsai Y.-C. Yang Y.-B. and Wang K.-T. Enantioselective deprotection of N-protected amino acids by D-aminoacylase 697
Chen I.-S. see Kashiwada Y. 395
Chen S.-T. Lin S.-L. Hsiao S.-C. Wang K.-T. One-pot synthesis of cathepsin inhibitors: Nα-protected N-peptidyl-O-acetyl hydroxylamines catalysed by alcalase followed by lipase in anhydrous *t*-butanol 1685
Chen X. see Siddiqi S. M. 1279
Cheng C. Y. see Rajagopalan P. 721
Cheng Y.-C. see Kilkuskie R. E. 1529
Cheruvallath Z. S. see Georg G. I. 1751
Cheruvallath Z. S. see Georg G. I. 295
Ching T. Y. see Wasserman H. H. 1137
Chollet A. see Ceszkowski K. 609
Chong L. S. see Groutas W. C. 1571
Chong L. S. see Groutas W. C. 175
Choo L. Y. see Hutchinson J. H. 1699
Chorvat R. J. see Earl R. A. 851
Chu S. S. see Doughty M. B. 1497
Cianciarulo D. N. see Durette P. L. 1033
Claesson A. Swahn B.-M. Edvinsson K. M. Molin H. and Sandberg M. Competitive NMDA antagonists that base their activity on a unique conformational effect 1247
Clairefond P. Bouzard D. Ledoussal B. Coroneos E. Bazile S. and Moreau N. DNA-Gyrase inhibition and antibacterial activity of fluoro-quinolones: influence of the position of the fluorine(s) 643
Clare M. see Djuric S. W. 1367
Clark K. L. see Middlemiss D. 1243
Clark M. S. G. see Bromidge S. M. 787
Clark M. S. G. see Bromidge S. M. 791
Clauss A. see Casara P. J. 145
Clay V. see Menear K. A. 285
Cliffe I. A. Brammer N. Middlefell V. Swaminathan P. and White A. C. Azaheteroaromatic ethers as carbonyl bioisosteres. Synthesis and evaluation of a novel class of 5-HT_3 receptor antagonists 245
Cockerham S. L. see Sofia M. J. 1669
Cockerham S. L. see Sofia M. J. 1675
Coffin V. L. see Chang W. K. 399
Coffman W. J. see Sall D. J. 1025
Cohen D. S. see Bhagwat S. S. 1619
Cohen D. S. see Bhagwat S. S. 1623
Cohen J. see Baker W. R. 1405
Cohen R. B. see Weller H. N. 1115
Collins J. L. Dambek P. J. Goldstein S. W. and Faraci W. S. CP-99,711: a non-peptide glucagon receptor antagonist 915
Collins P. W. Shone R. L. Gasiecki A. F. Kramer S. W. Perkins W. E. and Bianchi R. G. Stabilization of a prostaglandin tertiary allylic alcohol system by fluorine: synthesis acid stability studies and pharmacology of a 16-fluoromethyl analog of SC-46275 1761
Conconi M. T. see Zagotto G. 659
Conder M. L. see Atwal K. S. 1475
Condon S. L. see Baker W. R. 1405
Connor D. T. see Boschelli D. H. 69
Connor D. T. see Boschelli D. H. 705
Connor D. T. see Kramer J. B. 1655
Constantinescu A. see Mehta V. D. 527
Contardo N. see Bhagwat S. S. 1619
Conte M. R. Fattorusso E. Paloma L. G. and Mayol L. ^{1}H-NMR Studies of the interactions of two distamycin analogues with the dodecamer $d(CGCGAATTCGCG)_2$ 1299
Conte M. R. Galeone A. Avizonis D. Hsu V. L. Mayol L. and Kearns D. R. Solid phase synthesis of 5-hydroxymethyluracil containing DNA 79
Conway J. see Ojima I. 219
Cook L. see Earl R. A. 851
Cook L. see Rajagopalan P. 721
Cook L. see Rajagopalan P. 715
Cook P. D. see Debart F. 1479
Corelli F. see Delle Monache G. 415
Corigli R. see Alpegiani M. 1127
Coroneos E. see Clairefond P. 643
Cortez C. see Young R. J. 23
Cottens S. see Shapiro G. 815
Coughenour L. L. see Bigge C. F. 207
Coughenour L. L. see Sanders K. B. 803
Craft T. J. see Sall D. J. 1025
Crawley J. N. see Snider R. M. 1535
Creveling C. R. see Hebel D. 41
Crisma M. see Polinelli S. 453
Crombie L. Josephs J. L. Cayley J. Larkin J. and Weston J. B. The rotenoid core structure: modifications to define the requirements of the toxophore 13
Crosswell A. R. see Kadow J. F. 17
Crosswell A. R. see Saulnier M. G. 1213

Crouch N. P. see Baldwin J. E. 669
Cruz F. see Gil M. S. 1717
Cucinotta G. see Atwal K. S. 1475
Cunningham E. M. see Bone E. A. 223
Curley Jr. R. W. and Carson D. L. 4-Oxygenated retinoids: unexpected chemopreventive potential for analogues originally synthesized as affinity labels 1133
Czarniecki M. see Tulshian D. B. 515
Czarnik A. W. see Mortellaro M. A. 1635
Czuchajowski L. Niedbala H. Shultz T. and Seaman W. Synthesis and tumoricidal activity of water soluble porphyrinyl-thymidines and related porphyrins 1645

D'Halleweyn C. Van Haver D. Van der Eycken J. De Clercq P. and Vandewalle M. Synthesis of (C-11)-substituted analogues of 1α,25-dihydroxyvitamin D_3 477
Dabbs S. see Bromidge S. M. 787
Dabbs S. see Bromidge S. M. 791
Dai W. see Katzenellenbogen J. A. 1399
Dai W.-M. see Nicolaou K. C. 1155
Dambek P. J. see Collins J. L. 915
Dang Q. see Boger D. L. 261
Danishefsky S. J. see Dumas D. P. 33
Danzin C. see Halazy S. 407
Darlington W. H. see Romero A. G. 1703
Davidson A. H. see Bone E. A. 223
Davidson R. E. see Snider R. M. 1535
Davies A. J. Taylor R. J. K. Scopes D. I. and Wadsworth A. H. The preparation of novel dopamine analogues via palladium catalysed cyclisation reactions 481
Davis P. see Misicka A. 547
Davis P. see Tourwé D. 1305
Davis R. E. see Sanders K. B. 803
Davis R. E. see Tecle H. 821
Davis R. E. see Thomas A. J. 855
Dawson A. P. see Briggs J. C. 127
Dawson A. P. see Briggs J. C. 131
Dawson J. see Denyer C. V. 1039
Dax K. see Berger A. 27
De Bonnevaux S. C. see Delle Monache G. 415
De Clercq E. see Herdewijn P. 1057
De Clercq E. see Perez-Pérez M.-J. 647
De Clercq P. see D'Halleweyn C. 477
De Luca C. see Delle Monache G. 415
De Lucca G. V. and Otto M. J. Synthesis and anti-HIV activity of pyrrolo-[1,2-*d*]-(1,4)-benzodiazepin-6-ones 1639
De Napoli L. Messere A. Montesarchio D. Piccialli G. and Santacroce C. Synthesis of 2',3'-dideoxy-2',3'-didehydronucleoside analogues as potential anti HIV agents 315
de Villedon de Naide F. see Tronchet J. M. J. 1723
Dean, III R. L. see Birnberg G. H. 345
Dean, III R. L. see Levin J. I. 349
Debart F. Vasseur J.-J. Sanghvi Y. S. and Cook P. D. Synthesis and incorporation of methyleneoxy(methylimino) linked thymidine dimer into antisense oligonucleosides 1479
deBear J. S. see Schwartz M. E. 1019
Deicke P. Klar U. and Vorbrüggen H. Synthesis of chemically stable 9-substituted carbacyclin derivatives and their biological use 439
Deicke P. and Klar U. Syntheses of new TXA_2/PGH_2-receptor antagonists and their biological properties 1063
Deicke P. and Klar U. Syntheses of new metabolically stabilized TXA_2/PGH_2-receptor antagonists and their biological properties 1069
Del Nero S. see Alpegiani M. 1127
Delaney C. L. see Weller H. N. 1115
Delisser V. M. Garratt P. J. Thorn S. N. and Wrigglesworth R. Facile rearrangement of 5-carbomethoxymethyl-2-cyanoimino-imidazolones. Synthesis of 6-carboxyhexahydropyrimidines, potential dihydroorotate dehydrogenase inhibitors 421
Della Greca M. Lanzetta R. Molinaro A. Monaco P. and Previtera L. Phenalene metabolites from *Eichhornia crassipes* 311
Delle Monache F. see Delle Monache G. 415
Delle Monache G. Botta B. Delle Monache F. Espinal R. De Bonnevaux S. C. De Luca C. Botta M. Corelli F. and Carmignani M. Caracasanamide, a novel hypotensive agent from *Verbesina caracasana* 415
DeLuca J. G. see Labelle M. 1141
Dempcy R. O. and Skibo E. B. Rational design of purine nucleoside phosphorylase inhibitors: design of 2-(2'-haloethyl) and 2-ethenyl substituted quinazolinone alkylating agents 1427
Denney M. L. see Sall D. J. 1025
Dennis E. A. see Yu L. 1343
Denyer C. V. Turner-Brown S. J. Knowles R. G. and Dawson J. 7-Aminoalkyl-2-amino-1,2,3,4-tetrahydro-2-naphthoic acids as inhibitors of tryptophan uptake 1039
Desai P. R. see Babine R. E. 541
Deshayes C. see Driguez P.-A. 1361
Devivar R. V. Drach J. C. and Townsend L. B. Benzimidazole ribonucleosides: observation of an unexpected nitration when performing non-aqueous diazotizations with *t*-butyl nitrite 1105
Diaz C. L. see McCarthy P. A. 119
Dickinson K. E. J. see Weller H. N. 1115
DiDonato G. C. see Misra R. N. 73
Dijkstra D. and Grol C. J. A simple, unexpected regioselective chlorination of a series of 5-OH-2-(alkylamino)tetralins: potential dopaminergic agents 115
Djuric S. W. Huff R. M. Penning T. D. Clare M. Swenton L. Kachur J. F. Villani-Price D. Krivi G. G. Pyla E. Y. and Warren T. G. Synthesis and pharmacological activity of rationally designed inhibitors of the Leukotriene A_4 hydrolase enzyme 1367
Doebber T. W. see Bugianesi R. L. 181
Doherty J. B. see Hagmann W. K. 681
Dolle R. E. see Graybill T. L. 1375
Dong X. see Andrianomenjanahary S. 1093
Dooley M. J. and Quinn R. J. An explanation of the

substituent effect of 1,3,8-trisubstituted xanthines on adenosine A_1/A_2 affinity 1199
Dotson R. see Bhagwat S. S. 1619
Dotson R. see Bhagwat S. S. 1623
Dougherty T. J. see Meunier I. 1575
Dougherty T. J. see Pandey R. K. 491
Doughty M. B. Chu S. S. Misse G. A. and Tessel R. Neuropeptide Y (NPY) functional group mimetics: design, synthesis, and characterization as NPY receptor antagonists 1497
Doutheau A. see Driguez P.-A. 1361
Doyle T. W. see Kadow J. F. 17
Doyle T. W. see Saulnier M. G. 1213
Doyle T. W. see Vyas D. M. 1111
Drach J. C. see Devivar R. V. 1105
Drach J. C. see Renau T. E. 1755
Drew G. M. see Middlemiss D. 1243
Driguez P.-A. Barrere B. Chantegrel B. Deshayes C. Doutheau A. and Quash G. Synthesis of sodium salt of *ortho*-(difluoromethyl)phenyl-α-ketoside of N-acetylneuraminic acid: a mechanism-based inhibitor of *Clostridium perfringens* neuraminidase 1361
Dron D. I. see Ashton M. J. 375
Drummond J. T. see Bigge C. F. 207
Drysdale M. J. Pritchard M. C. and Horwell D. C. The synthesis and CCK receptor affinities of selected carboxylic acid mimics of CI-988—a potent and selective CCK-B antagonist 45
Dubreuil D. see Noble N. J. 471
Duchaussoy P. see Basten J. 905
Duffy R. see Chang W. K. 399
Dufresne C. see Labelle M. 1141
Duhamel L. see Monteil T. 949
Duhamel P. see Monteil T. 949
Dumas D. P. Kajimoto T. Liu K. K.-C. Wong C.-H. Berkowitz D. B. and Danishefsky S. J. Azasugar and glycal inhibitors of α-L-fucosidase 33
Dunbar P. G. see Messer, Jr W. S. 781
Dunsdon R. M. see Attwood M. R. 229
Durant G. J. see Messer, Jr W. S. 781
Durette P. L. Kopka I. E. Lanza T. J. Goulet J. L. Kinneary J. F. Caldwell C. G. Hammond M. L. Bondy S. S. Zambias R. A. Boger J. Rollins T. Siciliano S. Cianciarulo D. N. Kobayashi S. V. Springer M. S. and Hagmann W. K. The inhibition of C5a receptor binding by analogs of L-156,602, a cyclic hexadepsipeptide antibiotic 1033
Dyer R. D. see Boschelli D. H. 69
Dyer R. D. see Brooks D. W. 1309
Dyer R. D. see Brooks D. W. 1353
Dyer R. D. see Brooks D. W. 1357
Dyer R. D. see Kramer J. B. 1655

Earl R. A. Myers M. J. Johnson A. L. Scribner R. M. Wuonola M. A. Boswell G. A. Wilkerson W. W. Nickolson V. J. Tam S. W. Brittelli D. R. Chorvat R. J. Zaczek R. Cook L. Wang C. Zhang X. Lan R. Mi B. and Wenting H. Acetylcholine-releasing agents as cognition enhancers. Structure–activity relationships of pyridinyl pendant groups on selected core structures 851
Ebright Y. see Tung C.-H. 303
Edvinsson K. M. see Claesson A. 1247
Eggenspiller A. see Halazy S. 407
Eggleston D. S. see Buckle D. R. 1161
Egyud L. G. see Lipinski B. 919
Ehlhardt W. J. see Toth J. E. 1013
Ehrhard A. see Halazy S. 407
Elçin M. Sungur S. and Akbulut U. Urease immobilization into poly(acrylamide)–gelatin gels 433
Eldred C. see Middlemiss D. 1243
Ellerbrock B. R. see Messer, Jr W. S. 781
Elliott R. L. see Hamilton G. S. 1269
Elson S. W. Baggaley K. H. Holland S. Nicholson N. H. Sime J. T. and Woroniecki S. R. Studies on the substrate specificity of clavaminic acid synthase and associated enzymes 1503
Emmerling M. R. see Gregor V. E. 861
Enz A. see Shapiro G. 815
Epp J. B. see Groutas W. C. 1565
Epp J. B. see Groutas W. C. 1571
Epp J. B. see Groutas W. C. 175
Epstein J. W. see Birnberg G. H. 345
Epstein J. W. see Levin J. I. 349
Ertel P. J. see Yu M. J. 1121
Esmans E. see Herdewijn P. 1057
Espinal R. see Delle Monache G. 415
Evans B. J. see Mount M. E. 155
Evans J. F. see Hutchinson J. H. 1699
Evans J. F. see Prasit P. 1395

Fabre S. Prudhomme M. and Rapp M. Preparation of synthons for the synthesis of protein kinase C inhibitors from Rebeccamycin 449
Fakhoury S. A. see Grant S. K. 1441
Faller A. see Smith D. G. 1595
Fanshaw W. J. see Levin J. I. 349
Fanshawe W. J. see Birnberg G. H. 345
Faraci W. S. see Collins J. L. 915
Fattorusso E. see Conte M. R. 1299
Faull A. W. Gaskin H. Hadfield P. S. Jessup R. Russell K. Watkins W. J. and Wayne M. Dual-acting thromboxane receptor antagonist/synthase inhibitors: heterocyclic variations 1181
Fauq A. H. see Kozikowski A. P. 797
Feixas J. Camps F. and Guerrero A. Synthesis of (*Z*)-10,10-difluoro-13-hexadecen-11-ynyl acetate, new difluoro analogue of the sex pheromone of the processionary moth 467
Ferkany J. W. see Hamilton G. S. 1269
Ferrara L. M. see Bronson J. J. 685
Ferrara L. M. see Kim C. U. 367
Ferrieux C. see Maillard M. 1469
Fevig V. P. see Chang W. K. 399
Fincham C. I. Horwell D. C. Ratcliffe G. S. and Rees D. C. The use of a proline ring as a conformational restraint in CCK-B receptor 'dipeptoids' 403
Finke P. E. see Hagmann W. K. 681
Fiorini I. see Campiani G. 1193

Fisher A. Gurwitz D. Barak D. Haring R. Karton I. Brandeis R. Pittel Z. Marciano D. Meshulam H. Vogel Z. and Heldman E. Rigid analogs of acetylcholine can be M_1-selective agonists: implications for a rational treatment strategy in Alzheimer's disease 839
Fisher M. H. see Meinke P. T. 537
Fisher S. see Sanders K. B. 803
Fletcher S. R. Baker R. Leeson P. D. Teall M. Harley E. A. and Ragan C. I. Inhibitors of myo-inositol monophosphatase unrelated to the enzyme substrate 627
Floersheim P. see Shapiro G. 815
Florent J.-C. see Andrianomenjanahary S. 1093
Florent J.-C. see Maillard M. 1469
Floyd D. M. see Misra R. N. 73
Flynn D. L. Becker D. P. Spangler D. P. Nosal R. Gullikson G. W. Moummi C. and Yang D.-C. New aza(nor)adamantanes are agonists at the newly identified serotonin 5-HT_4 receptor and antagonists at the 5-HT_3 receptor 1613
Flynn D. L. Villamil C. I. Becker D. P. Gullikson G. W. Moummi C. and Yang D.-C. 1,3,4-Trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists 1251
Flynn D. L. see Kramer J. B. 1655
Flynn G. A. see Burkholder T. P. 579
Font J. L. see Marzabadi M. R. 1435
Ford, Jr H. see Burke T. R. 1771
Ford-Hutchinson A. W. see Prasit P. 1395
Ford-Hutchinson A. W. see Labelle M. 1141
Fortin R. see Prasit P. 1395
Foster A. see Rowley M. 1627
Francisco G. see Trybulski E. J. 827
Frenette R. see Labelle M. 1141
Frick J. A. see Jackson J. A. 1547
Friesner R. A. see Thiem H.-J. 291
Froelich L. L. see Sofia M. J. 1669
Froelich L. L. see Sofia M. J. 1675
Fronczek F. R. see Garcia J. G. 157
Frost J. W. see Montchamp J.-L. 1349
Fuchs P. L. see Pan Y. 967
Fujii S. see Katsumura S. 1263
Fujiki H. see Nishiwaki-Matsushima R. 673
Fujiki H. see Taylor C. 299
Fujioka T. see Kashiwada Y. 395
Fujiwara S. see Katsumura S. 1263
Fujiwara S. see Katsumura S. 1267
Fukuda Y. Nakatani K. and Terashima S. Synthesis and cytotoxicity of enanitomeric pairs of duocarmycin A and its 2-epimer 755
Fukuda Y. see Boger D. L. 759
Fukusaki E. Senda S. Nakazono Y. Yuasa H. and Omata T. Preparation of carboxyalkyl acrylate by lipase-catalyzed regioselective hydrolysis of corresponding methyl ester 411
Furlano D. C. see Hebel D. 41

Galeone A. see Conte M. R. 79
Galloway W. A. see Bone E. A. 223
Gamse R. see Blum E. 461
Gandour R. D. see Garcia J. G. 157
Ganellin C. R. Bang-Andersen B. Khalaf Y. S. Tertiuk W. Arrang J. M. Garbarg M. Ligneau X. Rouleau A. and Schwartz J. C. Imetit and N-methyl derivatives. The transition from potent agonist to antagonist at histamine H_3 receptors 1231
Gani D. see Camp N. P. 1047
Ganti V. R. see Rajagopalan P. 721
Garbarg M. see Ganellin C. R. 1231
García J. G. Fronczek F. R. and Gandour R. D. The structure of the products when α-bromoacetoarenones react with 3-(*N,N*-dimethylamino)propan-1-ol 157
García-Echeverría C. Pons M. Giralt E. and Albericio F. Synthesis and ion-binding properties of an immobilized bis-cysteine peptide 281
Garofalo A. see Campiani G. 1193
Garratt P. J. see Delisser V. M. 421
Garret C. see Peyronel J.-F. 37
Garsky V. see Chang L. L. 1207
Gasiecki A. F. see Collins P. W. 1761
Gaskin H. see Faull A. W. 1181
Gaskin H. see Russell K. 979
Gaskin H. see Russell K. 985
Gaudel G. see Andrianomenjanahary S. 1093
Gauthier J. Y. see Labelle M. 1141
Gauvin B. R. see Graybill T. L. 1375
Geetha K. see Rao C. P. 997
Gelb M. H. Jain M. K. and Berg O. Interfacial enzymology of phospholipase A_2 1335
Genc-Sehitoglu E. see Snider R. M. 1535
Georg G. I. Cheruvallath Z. S. Himes R. H. and Mejillano M. R. Semisynthesis and biological activity of taxol analogues: baccatin III 13-(*N*-benzoyl-(2′*R*,3′*S*)-3′-(*p*-tolyl)isoserinate), baccatin III 13-(*N*-(*p*-toluoyl)-(2′*R*,3′*S*)-3′-phenylisoserinate), baccatin III 13-(*N*-benzoyl-(2′*R*,3′*S*)-3′-(*p*-trifluoromethylphenyl)isoserinate), and baccatin III 13-(*N*-(*p*-trifluoromethylbenzoyl)-(2′*R*,3′*S*)-3′-phenylisoserinate) 1751
Georg G. I. Cheruvallath Z. S. Himes R. H. and Mejillano M. R. Novel biologically active taxol analogues: baccatin III 13-(*N*-(*p*-chlorobenzoyl)-(2′*R*,3′*S*)-3′-phenylisoserinate) and baccatin III 13-(*N*-benzoyl-(2′*R*,3′*S*)-3′-(*p*-chlorophenyl)isoserinate) 295
Georg G. I. Harriman G. C. B. Himes R. H. and Mejillano M. R. Taxol photoaffinity label: 7-(*p*-azidobenzoyl)taxol synthesis and biological evaluation 735
Gerena L. see Casteel D. A. 623
Gesson J.-P. see Andrianomenjanahary S. 1093
Gibson I. see Briggs J. C. 127
Gibson I. see Briggs J. C. 131
Gifford-Moore D. S. see Sall D. J. 1025
Gil M. S. Cruz F. Cerdán S. and Ballesteros P. Imidazol-1-ylalkanoate esters and their corresponding acids. A novel series of extrinsic ^{1}H NMR probes for intracellular pH 1717
Gill A. see Murray M. V. 1775
Gillard J. W. see Prasit P. 1395
Giralt E. see García-Echeverría C. 281
Giroux E. L. see Burkholder T. P. 579
Giudice A. see Langlois M. 691
Glaudemans C. P. J. see Pozsgay V. 255
Gmelin G. see Shapiro G. 815
Goldenberg H. J. see Misra R. N. 937

Goldstein R. see Bhagwat S. S. 1623
Goldstein S. W. see Collins J. L. 915
Gosselin G. see Périgaud C. 677
Gosselin G. see Puech F. 603
Gottschlich R. see Prücher H. 165
Gough G. R. see Schwartz M. E. 1019
Goulet J. L. see Durette P. L. 1033
Goya P. see Alcalde E. 1493
Gradnig G. see Berger A. 27
Grant S. K. Moore M. L. Fakhoury S. A. Tomaszek, Jr T. A. and Meek T. D. Inactivation of HIV-1 protease by a tripeptidyl epoxide 1441
Grassberger V. see Berger A. 27
Graybill T. L. Ross M. J. Gauvin B. R. Gregory J. S. Harris A. L. Ator M. A. Rinker J. M. and Dolle R. E. Synthesis and evaluation of azapeptide-derived inhibitors of serine and cysteine proteases 1375
Green A. M. see Wright S. W. 1079
Gregor V. E. Emmerling M. R. Lee C. and Moore C. J. The synthesis and *in vitro* acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivatives 861
Gregory J. A. see Bermudez J. 519
Gregory J. S. see Graybill T. L. 1375
Gregory Shutske M. Bores G. M. Bradshaw K. C. Huger F. P. Kapples K. J. Larsen R. D. Rush D. K. and Tomer J. D. Synthesis and biological activity of putative mono-hydroxylated metabolites of velnacrine 865
Grierson D. S. see Maillard M. 1469
Grim K. see Bhagwat S. S. 1623
Grimm E. see Labelle M. 1141
Grimwood S. see Rowley M. 1627
Grindey G. B. see Mohamadi F. 987
Grindey G. B. see Shih C. 339
Grol C. J. see Dijkstra D. 115
Gros C. see Monteil T. 949
Gross J. L. see Moyer M. P. 1589
Grossman S. J. see Labelle M. 1141
Groutas W. C. Brubaker M. J. Venkataraman R. Epp J. B. Houser-Archield N. Chong L. S. and McClenahan J. J. Potential mechanism-based inhibitors of proteolytic enzymes 175
Groutas W. C. Chong L. S. Epp J. B. Venkataraman R. Brubaker M. J. Stanga M. A. Kim E.-H. and Keller C. E. Inhibition of human leukocyte elastase and cathepsin G by isoxazoline derivatives 1571
Groutas W. C. Huang H. Epp J. B. Brubaker M. J. Keller C. E. and McClenahan J. J. A general approach toward the design of inhibitors of serine proteinases: inhibition of human leukocyte elastase by substituted dihydrouracils 1565
Grue-Sørensen see Andersen N. R. 1713
Grunewald G. L. Palanki M. S. S. and Van der Velde D. Use of transferred nuclear Overhauser effects to determine the conformation of 1-(3 4-dichlorophenyl)-2-aminopropane when bound to the active site of phenylethanolamine *N*-methyltransferase (PNMT) 1681
Gruys K. J. see Marzabadi M. R. 1435
Guard S. see Howson W. 559
Guay D. see Labelle M. 1141
Guay J. see Prasit P. 1395
Gude C. see Bhagwat S. S. 1619
Gude C. see Bhagwat S. S. 1623
Guerrero A. see Feixas J. 467
Gull P. see Shapiro G. 815
Gullikson G. W. see Flynn D. L. 1251
Gullikson G. W. see Flynn D. L. 1613
Gullo V. see Puar M. S. 575
Gundes A. F. see Tulshian D. B. 515
Gunnarsson I. see Puar M. S. 575
Gupta K. C. and Kumar P. A simple method for the derivatisation of long chain alkylamine-controlled pore glass (LCAA–CPG) for solid phase synthesis of oligonucleotides 727
Gurwitz D. see Fisher A. 839
Guzewska M. E. see Hamilton G. S. 1269
Guzik H. see Chang W. K. 399

Haase A. see Prücher H. 165
Haber M. T. Nashed N. T. and Jerina D. M. Enantiomeric composition of *trans*-dihydrodiols formed from *meso*-K-region arene oxides by microsomal epoxide hydrolase 1729
Hackseil U. see Jenmalm A. 1693
Hadfield P. S. see Faull A. W. 1181
Hadley M. S. King F. D. McRitchie B. and Turner D. H. Substituted benzamides with conformationally restricted side chains—IV. Hetero-azabicyclo[x.y.0]derivatives as gastric prokinetic agents 1293
Hadley M. S. King F. D. McRitchie B. Smith D. M. and Turner D. H. Substituted benzamides with conformationally restricted side chains—III. Azabicyclo[x.y.0] derivatives as gastric prokinetic agents 1147
Hadley M. S. see Bermudez J. 523
Hadley M. S. see Bromidge S. M. 787
Hageman D. L. see Valentine J. J. 333
Hagiwara M. see Ojima I. 219
Hagmann W. K. Thompson K. R. Shah S. K. Finke P. E. Ashe B. M. Weston H. Maycock A. L. and Doherty J. B. The effect of N-acyl substituents on the stability of monocyclic β-lactam inhibitors of human leukocyte elastase 581
Hagmann W. K. see Durette P. L. 1033
Hahn R. A. see Yu M. J. 1121
Haines A. H. see Briggs J. C. 127
Haines A. H. see Briggs J. C. 131
Hakomori S. see Ruan F. 973
Halazy S. Eggenspiller A. Ehrhard A. and Danzin C. Phosphonate derivatives of N²-benzylguanine: a new class of potent purine nucleoside phosphorylase inhibitors 407
Halazy S. see Navé J.-F. 1483
Hall S. E. see Misra R. N. 73
Haltiner R. see Papageorgiou C. 135
Hamilton G. S. Huang Z. Patch R. J. Guzewska M. E. Elliott R. L. Borosky S. A. Bednar D. L. Ferkany J. W. and Karbon E. W. Phosphonoethylphenylalanine derivatives as novel antagonists of non-NMDA ionotropic glutamate receptors 1269
Hammond M. L. see Durette P. L. 1033
Han Q. see Katsumura S. 1263
Han Q. see Katsumura S. 1267
Han W.-C. see Misra R. N. 73
Hanchin C. M. see Bigge C. F. 207

Hannah J. see Chang L. L. 1207
Hansch C. and Zhang L. QSAR of HIV inhibitors 1165
Harada K. see Nishiwaki-Matsushima R. 673
Haridas K. see Henderson B. S. 1381
Haring R. see Fisher A. 839
Harley E. A. see Fletcher S. R. 627
Harnden M. R. and Jarvest R. L. Synthesis of 9-[2-(phosphonomethoxy)ethylamino]adenine and 9-[(phosphonomethoxy)acetamido]adenine, analogues of a potent anti-HIV acyclonucleotide 1559
Harriman G. C. B. see Georg G. I. 735
Harrington P. M. see Shih C. 339
Harris A. L. see Graybill T. L. 1375
Harris D. N. see Misra R. N. 937
Harris D. N. see Misra R. N. 73
Harris N. V. see Ashton M. J. 375
Harvey R. G. see Young R. J. 23
Hashimoto K. Horikawa M. Ishida M. Shinozaki H. and Shirahama H. Configurational variants of hydroxyphenylkainoids: their potent depolarizing activities in the rat central nervous system 743
Haslanger M. F. see Chackalamannil S. 1003
Hawkins J. see Bromidge S. M. 791
Hawkins P. C. D. see Camp N. P. 1047
Hay A. J. see McGuigan C. 701
Hayashi H. Ueno H. and Suzuki F. Synthesis of stereoisomers of 1,4:3,6-dianhydrohexitol nitrate derivative, KF-14124 1187
Hayes A. G. see Birch P. J. 1275
Heath R. J. see Baldwin J. E. 663
Heath R. J. see Baldwin J. E. 669
Hebel D. Furlano D. C. Phillips R. S. Koushik S. Creveling C. R. and Kirk K. L. An enzymatic synthesis of 2-azido-L-tyrosine 41
Hecker S. J. Lilley S. C. Minich M. L. and Werner K. M. Semisynthetic modification of hygromycin A—III. Synthesis and antibacterial activity of aminocyclitol analogs 1015
Hecker S. J. Lilley S. C. and Werner K. M. Hygromycin A: preparation of aminocyclitol analogs defining the minimum functionality required for biological activity 1043
Hecker S. J. Minich M. L. and Werner K. M. Semisynthetic modification of hygromycin A—I. Synthesis and antibacterial activity of vinyl methyl and amide analogs 533
Hedberg A. see Atwal K. S. 1475
Hedberg A. see Misra R. N. 73
Hedberg S. A. see Barrish J. C. 95
Hedberg S. A. see Weller H. N. 1115
Hegde V. see Puar M. S. 575
Heidman E. see Fisher A. 839
Henderson B. S. Haridas K. and Schwab J. M. A mechanism-based inactivator of *E. coli* β-hydroxydecanoyl thiolester dehydrase designed to crosslink active site amino acids 1381
Herdewijn P. Kerremans L. Snoeck R. VanAerschot A. Esmans E. and De Clercq E. Synthesis and anti-herpes activity of 5-trifluorovinyl-2'-deoxyuridine 1057
Herdewijn P. see Augustyns K. 945
Herold E. G. see Labelle M. 1141
Hershenson F. M. see Thomas A. J. 855
Hickman A. D. see Bedford C. T. 1513
Hilditch A. see Middlemiss D. 1243
Himes R. H. see Georg G. I. 295
Himes R. H. see Georg G. I. 735
Himes R. H. see Georg G. I. 1751
Hirst G. C. see Middlemiss D. 1243
Hitchcock P. B. see Camp N. P. 1047
Ho P. P. K. see Yu M. J. 1121
Ho P. P. K. see Yu M. J. 59
Hodgkin E. E. Miller A. and Whittaker M. A partial pharmacophore for the platelet activating factor (PAF) receptor 597
Hodgson J. see Howson W. 559
Hodgson S. T. Jenkins D. C. Knick V. Rapson E. and Watts S. D. M. Synthesis and biological properties of 1069C: a new synthetic antitumour agent with very low cross-resistance potential 1257
Hoefle M. see Boschelli D. H. 69
Hoffmann R. see Wermuth C. G. 833
Holland S. see Elson S. W. 1503
Holms J. H. see Brooks D. W. 1357
Honek J. F. see Wright G. D. 383
Hook J. see Briggs J. C. 127
Hook J. see Briggs J. C. 131
Hopkins M. H. and Silverman R. B. α-Amino acid analogues as mechanism-based inactivators of γ-amino-butyric acid aminotransferase 1371
Horak I. D. see Burke T. R. 1771
Horikawa M. see Hashimoto K. 743
Horvath R. see Misicka A. 547
Horwell D. C. see Drysdale M. J. 45
Horwell D. C. see Fincham C. I. 403
Hoshino O. Murakata M. and Yamada K. A convenient synthesis of a bromotyrosine derived metabolite, psammaplin A, from *Psammaplysilla* sp. 1561
Hosoya M. see Pérez-Pérez M.-J. 647
Hoss W. see Messer, Jr W. S. 781
Houser-Archield N. see Groutas W. C. 175
Howes C. see Menear K. A. 285
Howson W. Hodgson J. Richardson R. Walton L. Guard S. and Watling K. An SAR study for the non-peptide substance P receptor (NK_1) antagonist, CP-96,345 559
Howson W. Parsons M. E. Raval P. and Swayne G. T. G. Two novel, potent and selective histamine H_3 receptor agonists 77
Hruby V. J. see Misicka A. 547
Hruby V. J. see Tourwé D. 1305
Hsi J. D. see Murray M. V. 1775
Hsiao S.-C. see Chen S.-T. 1685
Hsu V. L. see Conte M. R. 79
Huang H. see Groutas W. C. 1565
Huang L. see Kashiwada Y. 235
Huang Z. see Hamilton G. S. 1269
Hubbard T. see Middlemiss D. 1243
Huff R. M. see Djuric S. W. 1367
Huger F. P. see Gregory Shutske M. 865
Huh N. and Thompson C. M. Chiral, piperidine-based analogues of AF64A and acetylcholine 1551
Hurst D. N. see Attwood M. R. 229

Hutchinson J. H. Prasit P. Choo L. Y. Riendeau D. Charleson S. Evans J. F. Piechuta H. and Ball R. G. Development of L-689,065—the prototype of a new class of potent 5-lipoxygenase inhibitors 1699
Hutchinson J. H. see Prasit P. 1395
Hwang S.-B. see Bugianesi R. L. 181

Ichikawa T. see Komatsu H. 565
Igarashi Y. see Ruan F. 973
Iimura Y. see Sugimoto H. 871
Ikeda H. Ikeda T. and Toda F. Substrate selectivity of imidazole-appended dimethyl-β-cyclodextrin 1581
Ikeda K. see Katsumura S. 1263
Ikeda K. see Katsumura S. 1267
Ikeda T. Kakegawa H. Miyataka H. Matsumoto H. and Satoh T. Anti-allergic and anti-inflammatory actions of 2'-(tetrazole-5-yl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxanilide 1,1-dioxide 709
Ikeda T. see Ikeda H. 1581
Ikeler T. J. see Chang L. L. 1207
Imbach J.-L. see Périgaud C. 677
Imbach J. L. see Puech F. 603
Inoue S. see Katsumura S. 1267
Irvine J. I. see Suckling C. J. 49
Isaac J. W. see Moyer M. P. 1589
Ishida M. see Hashimoto K. 743
Isoe S. see Katsumura S. 1263
Isoe S. see Katsumura S. 1267
Iwanowicz E. J. Lin J. Roberts D. G. M. Michel I. M. and Seiler S. M. α-Hydroxy- and α-ketoester functionalized thrombin inhibitors 1607

Jackson J. A. Frick J. A. and Thompson C. M. Synthesis of chiral phosphorus mustards derived from serine 1547
Jackson W. T. see Sofia M. J. 1669
Jackson W. T. see Sofia M. J. 1675
Jackson W. T. see Yu M. J. 1121
Jacobson K. A. Karton Y. and Baumgold J. Muscarinic receptor probes based on amine congeners of pirenzepine and telenzepine 845
Jacquesy J.-C. see Andrianomenjanahary S. 1093
Jadhav P. K. and Woerner F. J. Synthesis of C_2-symmetric HIV-1 protease inhibitors from D-mannitol 353
Jae H.-S. see Baker W. R. 1405
Jaen J. C. Moos W. H. and Johnson G. INTRODUCTION: Cholinomimetics and Alzheimer's disease 777
Jain M. K. see Gelb M. H. 1335
Jain R. K. Locke R. D. Chandrasekaran E. V. and Matta K. L. Synthesis of 2'-O-substituted β-D-Gal-(1→)-β-D-GlcNAc-1-O-Bn as specific acceptors for α-L-(1→3)fucosyltransferases 63
Jain R. K. and Matta K. L. Methyl 2,3,4,6-tetra-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside—a novel reagent for α-glycosylation towards nitrophenyl or benzyl glycosides 1707
Jain R. K. see Roy R. 911
Jamelson F. A. see Ojima I. 219
James J. C. see Babine R. E. 541
Janaki S. see Mount M. E. 155
Janzen W. P. see Kashiwada Y. 239
Jarvest R. L. and Jennings L. J. β-Lactam peptides as potential inhibitors of the HIV gp120–CD4 interaction 331
Jarvest R. L. see Harnden M. R. 1559
Jaurand G. Basten J. Lederman I. van Boeckel C. A. A. and Petitou M. Biologically active heparin-like fragments with a 'non-glycosamino' glycan structure—I. A pentasaccharide containing a 3-O-methyl iduronic acid unit 897
Jaurand G. see Basten J. 901
Jaurand G. see Basten J. 905
Jayamani M. and Low P. S. An efficient method for conjugation of thiamine to proteins 1007
Jefferies I. Synthesis of the ω-phosphonic acid analogue of kainic acid 1519
Jeng J.-Y. see Ong C.-W. 929
Jenkins D. C. see Hodgson S. T. 1257
Jenmalm A. Luthman K. Lindeberg G. Nyberg F. Terenius L. and Hacksell U. Novel peptidomimetics: inhibitors of substance P endopeptidase 1693
Jennings L. J. see Jarvest R. L. 331
Jeong N. see Yoo S. 381
Jerina D. M. see Haber M. T. 1729
Jessup R. see Faull A. W. 1181
Jessup R. see Russell K. 979
Jiang J. B. see Kashiwada Y. 239
Jin Q. see Boger D. L. 759
Joekes I. see Sorrilha A. E. P. M. 191
Johnson A. L. see Earl R. A. 851
Johnson A. L. see Rajagopalan P. 721
Johnson G. see Jaen J. C. 777
Johnson M. R. see Birch P. J. 1275
Jonas R. Klockow M. and Lues I. Preparation of the enantiomers of the novel Ca-sensitizer EMD 53 998 589
Jones G. D. see Ashton M. J. 375
Jones J. B. see Simpelkamp J. 1391
Jones P. S. see Attwood M. R. 229
Jones T. R. see Labelle M. 1141
Josephs J. L. and Casida J. E. Novel synthetic rotenoids with blocked B/C ring systems 593
Josephs J. L. see Crombie L. 13
Juang S.-S. see Ong C.-W. 929
Jund K. C. see Casara P. J. 145
Jung K.-E. see Casteel D. A. 623
Jurgens A. R. see Babine R. E. 541

Kabanov V. M. see Mazurov A. A. 649
Kachur J. F. see Djuric S. W. 1367
Kadono H. see Katsumura S. 1263
Kadow J. F. MinTun M. Crosswell A. R. Rose W. C. Vyas D. M. and Doyle T. W. Synthesis and antileukemic activity of etoposide A-ring analogs 17
Kadow J. F. see Vyas D. M. 1111
Kajimoto T. see Dumas D. P. 33
Kakegawa H. see Ikeda T. 709
Kalindjian S. B. see Low C. M. R. 325
Kaltenbach,III R. F. see Seitz S. P. 171
Kamphuis J. see Polinelli S. 453
Kan J.-P. see Wermuth C. G. 833
Kapples K. J. see Gregory Shutske M. 865

Karbon E. W. see Hamilton G. S. 1269
Karton I. see Fisher A. 839
Karton Y. see Jacobson K. A. 845
Kasai N. see Suzuki T. 105
Kashiwada Y. Fujioka T. Chang J.-J. Chen I.-S. Mihashi K. and Lee K.-H. Cumindysoside A, a novel cytotoxic trisnortriterpene glucoside with a 14,18-cycloapoeuphane-type skeleton from *Dysoxylum cumingianum* 395
Kashiwada Y. Huang L. Kilkuskie R. E. Bodner A. J. and Lee K.-H. New hexahydroxydiphenyl derivatives as potent inhibitors of HIV replication in H9 lymphocytes 235
Kashiwada Y. Nonaka G. Nishioka I. Ballas L. M. Jiang J. B. Janzen W. P. and Lee K.-H. Tannins as selective inhibitors of protein kinase C 239
Kashiwada Y. see Kilkuskie R. E. 1529
Kato K. see Ojima I. 219
Katsumura S. Han Q. Fujiwara S. Isoe S. Nishimura H. Inoue S. and Ikeda K. Toward elucidation of the inhibition mechanism of phospholipase A_2 by manoalide: selectively modified amino acid residues by manoalide analogues 1267
Katsumura S. Han Q. Kadono H. Fujiwara S. Isoe S. Fujii S. Nishimura H. and Ikeda K. Phospholipase A_2 inhibition by manoalide: development of simple analogues and necessary functional groups for inhibition 1263
Katzenellenbogen J. A. Rai R. and Dai W. Enol lactone derivatives as inhibitors of human neutrophil elastase and trypsin-like proteases 1399
Kaumann A. J. King F. D. and Young R. C. Indazole as an indole bioisostere: 5-HT_4 receptor antagonism 419
Kay P. B. see Attwood M. R. 229
Kearns D. R. see Conte M. R. 79
Kellam M. L. see Sall D. J. 1025
Keller C. E. see Groutas W. C. 1565
Keller C. E. see Groutas W. C. 1571
Kelly M. Sessions R. B. and Muirhead H. A prediction of the tertiary structure of human Phospholipase A_2 from synovial fluid and a model of substrate binding 553
Kendrick D. A. Ryder H. Semple G. and Szelke M. Cholecystokinin analogues: the ergopeptine alkaloids as models of the active conformation of CCK 9
Kennedy J. A. see Kramer J. B. 1655
Kenyon G. L. see Landro J. A. 1411
Kerdesky F. A. J. see Brooks D. W. 1357
Kerremans L. see Herdewijn P. 1057
Kester J. A. see Thomas A. J. 855
Kezar H. S. see Rajagopalan P. 721
Khalaf Y. S. see Ganellin C. R. 1231
Kilkuskie R. E. Kashiwada Y. Nonaka G. Nishioka I. Bodner A. J. Cheng Y.-C. and Lee K.-H. HIV and reverse transcriptase inhibition by tannins 1529
Kilkuskie R. E. see Kashiwada Y. 235
Kim C. U. Bronson J. J. Ferrara L. M. and Martin J. C. Synthesis and HIV activity of phosphonate isosteres of D4T monophosphate 367
Kim C. U. Luh B. Y. and Martin J. C. Synthesis and anti-HIV activity of 9-[(2*R*,5*R*)-2,5-dihydro-5-(phosphono-methoxy)-2-furanyl]-2,6-diaminopurine 307
Kim E.-H. see Groutas W. C. 1571
Kim J. N. Ryu E. K. No Z. and Lee I. Y. 1,3-Dipolar cycloaddition reactions of nitrile oxides with 2',3'-didehydro-2',3'-dideoxythymidine (d4T) 323
Kim J. N. and Ryu E. K. The reactions of 2,6-dichlorobenzonitrile oxide with the 5,6-double bond of cytosine nucleosides 941
Kim S.-G. see Komatsu H. 565
King F. D. see Bermudez J. 1509
King F. D. see Bermudez J. 519
King F. D. see Bermudez J. 523
King F. D. see Hadley M. S. 1147
King F. D. see Hadley M. S. 1293
King F. D. see Kaumann A. J. 419
Kinneary J. F. see Durette P. L. 1033
Kirk K. L. see Hebel D. 41
Kitos P. A. see Boger D. L. 759
Klar U. Pietsch A. Skuballa W. and Vorbrüggen H. Synthesis of potent 6-oxo and 9-fluoro-PGE_1-derivatives and their biological properties 445
Klar U. see Deicke P. 1063
Klar U. see Deicke P. 1069
Klar U. see Deicke P. 439
Kleinert H. D. see Baker W. R. 1405
Klinger M. M. and McCarthy D. J. Enzymatic synthesis and properties of uridine-5'-*O*-(2-thidiphosphoglucuronate 197
Klockow M. see Jonas R. 589
Kloeppner E. see Blum E. 461
Knick V. see Hodgson S. T. 1257
Knowles R. G. see Denyer C. V. 1039
Kobayashi S. V. see Durette P. L. 1033
Koch M. see Andrianomenjanahary S. 1093
Koga Y. see Mori K. 391
Kogan T. P. see Rawson T. E. 695
Komatsu H. Kim S.-G. Sakabe I. Ichikawa T. Nakai M. and Takaku H. Purine 8-substitution modulates the recognition by restriction endodeoxy-ribonuclease EcoRI of octadeoxyribonucleotides (dGGAATTCC) 565
Kopka I. E. see Durette P. L. 1033
Kostlan C. R. see Kramer J. B. 1655
Kotera M. see Monteil T. 949
Koushik S. see Hebel D. 41
Kovach I. M. and McKay L. Reversible modulation of serine protease activity by phosphonate esters 1735
Kozarich J. W. see Landro J. A. 1411
Kozikowski A. P. Fauq A. H. Miller J. H. and McKinney M. Alzheimer's therapy: an approach to noyel muscarinic ligands based upon the naturally occurring alkaloid himbacine 797
Kozlowski J. A. see Chang W. K. 399
Krafft G. A. see Wang G. T. 1665
Kramer J. B. Boschelli D. H. Connor D. T. Kostlan C. R. Flynn D. L. Dyer R. D. Bornemeier D. A. Kennedy J. A. Wright C. D. and Kuipers P. J. Synthesis of reversed hydroxamic acids of indomethacin: dual inhibitors of cyclooxygenase and 5-lipoxygenase 1655
Kramer S. W. see Collins P. W. 1761

Kramer T. H. see Misicka A. 547
Kramss R. H. see Trybulski E. J. 827
Krantz A. A classification of enzyme inhibitors 1327
Krivi G. G. see Djuric S. W. 1367
Kubodera N. see Murayama E. 1289
Kuipers P. J. see Boschelli D. H. 705
Kuipers P. J. see Kramer J. B. 1655
Kulkarni P. V. see Mehta V. D. 527
Kumar P. see Gupta K. C. 727

Labelle M. Prasit P. Belley M. Blouin M. Champion E. Charette L. DeLuca J. G. Dufresne C. Frenette R. Gauthier J. Y. Grimm E. Grossman S. J. Guay D. Herold E. G. Jones T. R. Lau C. K. Leblanc Y. Léger S. Lord A. McAuliffe M. McFarlane C. Masson P. Metters K. M. Ouimet N. Patrick D. H. Perrier H. Pickett C. B. Piechuta H. Roy P. Williams H. Wang Z. Xiang Y. B. Zamboni R. J. Ford-Hutchinson A. W. and Young R. N. The discovery of a new structural class of potent orally active leukotriene D_4 antagonists 1141
Lahti R. A. see Romero A. G. 1703
Lai M.-T. Oh E. and Liu H.-W. Studies of the inactivation of general acyl-CoA dehydrogenase by (1*R*)- and (1*S*)-(methylenecyclopropyl)acetyl-CoA 1423
Laitinen K. see Snider R. M. 1535
Lalan P. see Murray M. V. 1775
Lam M.-H. see Bugianesi R. L. 181
Lan R. see Earl R. A. 851
Landro J. A. Kenyon G. L. and Kozarich J. W. Mechanism-based inactivation of mandelate racemase by propargyl-glycolate 1411
Langevine C. M. see Sieburth S. McN. 1585
Langlois M. Soulier J. L. Brémont B. Shen S. Rampillon V. and Giudice A. Derivatives of naphthalimide: new potent conformationally restricted antagonists of 5-HT_3 receptors 691
Lanza T. J. see Durette P. L. 1033
Lanzetta R. see Della Greca M. 311
Larkin J. see Crombie L. 13
Larsen R. D. see Shutske G. M. 865
Lau C. K. see Labelle M. 1141
Lauffer D. J. see Tecle H. 821
Le T.-B. see Burkholder T. P. 579
Lea T. A. see Birch P. J. 1275
Leblanc Y. see Labelle M. 1141
LeBoulluec K. L. see Saulnier M. G. 1213
LeBoulluec K. L. see Vyas D. M. 1111
Lecomte J. M. see Monteil T. 949
Lederman I. see Jaurand G. 897
Ledoussal B. see Clairefond P. 643
Lee C. see Gregor V. E. 861
Lee D. K. H. see Murray M. V. 1775
Lee H. see Young R. J. 23
Lee I. Y. see Kim J. N. 323
Lee J.-G. see Thiem H.-J. 291
Lee K.-H. see Kashiwada Y. 235
Lee K.-H. see Kashiwada Y. 239
Lee K.-H. see Kashiwada Y. 395
Lee K.-H. see Kilkuskie R. E. 1529
Lee M. and Phillips R. S. Enzymatic synthesis of chloro-L-tryptophans 1563
Lee S. J. see Yoo S. 381
Lee W. see Bhagwat S. S. 1619
Lee W. see Bhagwat S. S. 1623
Leeson P. D. see Fletcher S. R. 627
Leeson P. D. see Rowley M. 1627
Leeson P. D. see Stevenson G. I. 371
Lefebvre I. see Puech F. 603
Léger S. see Labelle M. 1141
Léger S. see Prasit P. 1395
Legler G. see Berger A. 27
Lehr G. S. see Resch J. F. 271
Leiby J. A. see Romero A. G. 1691
Lemaître M. see Maillard M. 1469
Leo G. C. Castellino S. Sammons R. D. and Sikorski J. A. EPSP Synthase inhibitor design—I. Conformations of enzyme bound shikimate-3-phosphate and 5-enolpyruvoylshikimate-3-phosphate using TRNOE 151
Lerner R. A. see Light J. 1073
Levin J. I. Fanshaw W. J. Epstein J. W. Beer B. Bartus R. T. and Dean R. L., III Synthesis and activity in cognition-related tests of novel 2-benzoylamino-4-oxoquinazolines 349
Levin J. I. see Birnberg G. H. 345
Levitzki A. see Burke T. R. 1771
Lewis C. N. see Bone E. A. 223
Lewis J. M. see Murray M. V. 1775
Leysen D. C. see Zhang M.-Q. 1283
Li G. and Still W. C. Dipeptidic ammonium ion binding by a synthetic receptor 731
Light J. and Lerner R. A. PhoPhabs: antibody–phage–alkaline phosphatase conjugates for one step ELISA's without immunization 1073
Ligneau X. see Ganellin C. R. 1231
Lilley S. C. see Hecker S. J. 1015
Lilley S. C. see Hecker S. J. 1043
Lin J. see Iwanowicz E. J. 1607
Lin S.-L. see Chen S.-T. 1685
Lindeberg G. see Jenmalm A. 1693
Lindstrom T. D. see Yu M. J. 1121
Lindstrom T. D. see Yu M. J. 59
Lipinski B. and Egyud L. G. Thiol-induced crosslinking of human blood proteins: implications for tumor immunity 919
Lipkowski A. W. see Misicka A. 547
Lipshutz B. H. see Wasserman H. H. 1137
Liu C. Safrany S. T. Nahorski S. R. and Potter B. V. L. Synthesis of L-*chiro*-inositol 1,4,6-trisphosphorothioate, a potent and selective inhibitor of *myo*-inositol 1,4,5-trisphosphate 5-phosphatase 1523
Liu H.-W. see Lai M.-T. 1423
Liu K. K.-C. see Dumas D. P. 33
Liu S. Wolfe M. S. Yuan C. Ali S. M. and Borchardt R. T. Synthesis and evaluation of 4′,5′-dehydro-5′-fluoroaristeromycins as *S*-adenosyl-L-homocysteine (AdoHcy) hydrolase inhibitors 1741
Livingstone D. J. and Salt D. W. Regression analysis for QSAR using neural networks 213
Lloyd A. see Briggs J. C. 127
Lobasyuk B. A. see Mazurov A. A. 649
Locke R. D. see Jain R. K. 63
Logan C. J. see Bedford C. T. 1513
Long B. H. see Saulnier M. G. 1213
Longo K. P. see Snider R. M. 1535
Lord A. see Labelle M. 1141
Loudon J. M. see Bromidge S. M. 787

Loudon J. M. see Bromidge S. M. 791
Low C. M. R. Broughton H. B. Kalindjian S. B. and McDonald I. M. Novel oxathiazinones as gastrin ligands: unexpected products from the Schotten–Baumann reaction of arylsulphonyl chlorides with derivatives of aspartic acid 325
Low P. S. see Jayamani M. 1007
Lowe D. B. see Chang W. K. 399
Lubineau A. Bonnaffé D. and Thérisod M. A new class of reagents for the chemical modification of proteins 607
Ludwig M. S. see Renau T. E. 1755
Lues I. see Jonas R. 589
Luh B. Y. see Kim C. U. 307
Luna E. see Young R. J. 23
Luthman K. see Jenmalm A. 1693
Lythgoe D. J. see Ashton M. J. 375

Machinist J. M. see Brooks D. W. 1353
Magolda R. L. see Wright S. W. 1079
Mahmood N. see McGuigan C. 701
Maillard M. Florent J.-C. Lemaître M. Begassat F. Bugnicourt A. Ferrieux C. Rombi C. Pacaud E. Thierry D. Zerial A. Monneret C. and Grierson D. S. Preparation and anti-HIV activity of N-3 amino substituted thymidine nucleoside analogs 1469
Main A. J. see Bhagwat S. S. 1623
Mangano R. M. see Trybulski E. J. 827
Mansuri M. M. see Bronson J. J. 685
Marciani Magno S. see Zagotto G. 659
Marciano D. see Fisher A. 839
Marder P. see Sofia M. J. 1675
Marques M. see Sorrilha A. E. P. M. 191
Marquez V. E. see Burke T. R. 1771
Marriott J. G. see Thomas A. J. 855
Martin J. C. see Bronson J. J. 685
Martin J. C. see Kim C. U. 307
Martin J. C. see Kim C. U. 367
Martin J. G. see Brooks D. W. 1357
Martin R. T. see Bermudez J. 523
Martin S. F. see Baker W. R. 1405
Martinez A. see Alcalde E. 1493
Marzabadi M. R. Font J. L. Gruys K. J. Pansegrau P. D. and Sikorski J. A. Design and synthesis of a novel EPSP synthase inhibitor based on its ternary complex with shikimate-3-phosphate and glyphosate 1435
Mason R. P. see Mehta V. D. 527
Masson P. see Labelle M. 1141
Mathis J. see Bhagwat S. S. 1619
Mathis J. see Bhagwat S. S. 1623
Matsumoto H. see Ikeda T. 709
Matsuyama H. see Wasserman H. H. 1137
Matta K. L. see Jain R. K. 1707
Matta K. L. see Jain R. K. 63
Matta K. L. see Roy R. 911
Mattei P. L. see Rajagopalan P. 721
Maycock A. L. see Hagmann W. K. 681
Mayol L. see Conte M. R. 1299
Mayol L. see Conte M. R. 79
Mazurov A. A. Andronati S. A. Lobasyuk B. A. Kabanov V. M. and Mokhovikov A. N. Peptides inducing psychosis 649
McAuliffe M. see Labelle M. 1141
McCarthy D. J. see Klinger M. M. 197
McCarthy P. A. Wint L. T. and Diaz C. L. Synthesis of α,α-difluoroketones: novel synthesis of α,α-difluoroketones from α,α-difluoroacylsilanes 119
McClements W. L. see Chang L. L. 1207
McClenahan J. J. see Groutas W. C. 1565
McClenahan J. J. see Groutas W. C. 175
McCowan J. R. see Yu M. J. 1121
McCowan J. R. see Yu M. J. 59
McCulloch R. see Taylor C. 299
McCullough J. R. see Atwal K. S. 1475
McCullough J. R. see Atwal K. S. 83
McCullough J. R. see Atwal K. S. 87
McDonald I. M. see Low C. M. R. 325
McFarlane C. see Labelle M. 1141
McGuigan C. Pathirana R. N. Mahmood N. and Hay A. J. Aryl phosphate derivatives of AZT inhibit HIV replication in cells where the nucleoside is poorly active 701
McKay L. see Kovach I. M. 1735
McKinney M. see Kozikowski A. P. 797
McQuade R. D. see Chang W. K. 399
McRitchie B. see Hadley M. S. 1293
McRitchie B. see Hadley M. S. 1147
Meek T. D. see Grant S. K. 1441
Mehdi S. see Angelastro M. R. 1235
Mehta V. D. Kulkarni P. V. Mason R. P. Babcock E. E. Constantinescu A. and Antich P. P. Novel molecular probes for ^{19}F magnetic resonance imaging: synthesis and characterization of fluorinated polymers 527
Meigel H. see Blum E. 461
Meiners S. see Briggs J. C. 127
Meinke P. T. Sinclair P. Mrozik H. O'Connor S. Ostlind D. A. Shoop W. L. Arison B. H. and Fisher M. H. Synthesis of avermectin B_1-4",4"a-oxide: a precursor of potent anthelmintic agents 537
Mejillano M. R. see Georg G. I. 1751
Mejillano M. R. see Georg G. I. 295
Mejillano M. R. see Georg G. I. 735
Menear K. A. Patel D. Clay V. Howes C. and Taylor P. W. A novel approach to the site specific delivery of potential HMG–CoA reductase inhibitors 285
Menezes R. F. see Boger D. L. 261
Menezes R. F. see Boger D. L. 959
Merriman R. L. see Pan Y. 967
Merson J. R. see Terrett N. K. 1745
Meshulam H. see Fisher A. 839
Messeguer A. see Abad J.-L. 1239
Messer, Jr W. S. Dunbar P. G. Rho T. Periyasamy S. Ngur D. Ellerbrock B. R. Bohnett M. Ryan K. Durant G. J. and Hoss W. Synthesis, biochemical activity and behavioral effects of a series of 1,4,5,6-tetrahydropyrimidines as novel ligands for M_1 receptors 781
Messere A. see De Napoli L. 315
Metters K. M. see Labelle M. 1141
Meunier I. Pandey R. K. Walker M. M. Senge M. O. Dougherty T. J. and Smith K. M. New syntheses of benzoporphyrin derivatives

and analogues for use in photodynamic therapy 1575
Mi B. see Earl R. A. 851
Michel I. M. see Iwanowicz E. J. 1607
Michel I. M. see Misra R. N. 937
Michel S. see Andrianomenjanahary S. 1093
Middlefell V. see Cliffe I. A. 245
Middlemiss D. Ross B. C. Eldred C. Montana J. G. Shah P. Hirst G. C. Watson S. P. Panchal T. A. Paton J. M. S. Hubbard T. Drew G. M. Robertson M. J. Hilditch A. and Clark K. L. C-Linked pyrazole biaryl tetrazoles as antagonists of angiotensin—II 1243
Mihashi K. see Kashiwada Y. 395
Mikkilineni A. see Ueda Y. 1541
Miles B. W. see Raushel F. M. 319
Milhous W. see Casteel D. A. 623
Miller A. see Hodgkin E. E. 597
Miller A. V. see Weller H. N. 1115
Miller J. H. see Kozikowski A. P. 797
Minich M. L. see Hecker S. J. 533
Minich M. L. see Hecker S. J. 1015
MinTun M. see Kadow J. F. 17
Mirzadegan T. see Tecle H. 821
Misicka A. Nikiforovich G. Lipkowski A. W. Horvath R. Davis P. Kramer T. H. Yamamura H. I. and Hruby V. J. Topographical requirements for delta opioid ligands: the synthesis and biological properties of a cyclic analogue of deltorphin I 547
Misiti D. Santaniello M. and Zappia G. A stereoselective synthesis of both enantiomers of emeriamine from a single precursor: L-aspartic acid 1029
Misra D. see Singh C. 497
Misra R. N. Brown B. R. Sher P. M. Patel M. M. Hall S. E. Han W.-C. Barrish J. C. Floyd D. M. Sprague P. W. Morrison R. A. Ridgewell R. E. White R. E. DiDonato G. C. Harris D. N. Hedberg A. Schumacher W. A. Webb M. L. and Ogletree M. L. Thromboxane receptor antagonist BMS-180291: a new pre-clinical lead 73
Misra R. N. Harris D. N. Michel I. M. Goldenberg H. J. Webb M. L. and Brown B. R. Interphenylene phenyl oxazoles: novel, potent thromboxane receptor antagonists 937
Misse G. A. see Doughty M. B. 1497
Mitch C. H. see Sauerberg P. 809
Miyamae T. see Ojima I. 219
Miyamoto K. see Murayama E. 1289
Miyataka H. see Ikeda T. 709
Moeller K. D. and Wong P. L. Anodic amide oxidations: a novel synthesis of the angiotensin-converting enzyme inhibitor A58365A 739
Mohamadi F. Spees M. M. and Grindey G. B. Antineoplastic bicyclicsulfonylureas 987
Mohammadpour H. see Quadri S. M. 1661
Mokhovikov A. N. see Mazurov A. A. 649
Molin H. see Claesson A. 1247
Molinaro A. see Della Greca M. 311
Monaco P. see Della Greca M. 311
Mondon M. see Andrianomenjanahary S. 1093
Moni R. W. Willis R. J. and Quinn R. J. A note of caution in the use of receptor binding assays to screen marine organisms: the action of halistanol trisulphate on adenosine receptors 1631
Monneret C. see Andrianomenjanahary S. 1093
Monneret C. see Maillard M. 1469
Montana J. G. see Middlemiss D. 1243
Montchamp J.-L. Piehler L. T. Tolbert T. J. and Frost J. W. The basis for slowly reversible inhibition of dehydroquinate synthase: a case of mistaken identity? 1349
Monteil T. Kotera M. Duhamel L. Duhamel P. Gros C. Noël N. Schwartz J. C. and Lecomte J. M. Importance of the amide bond of thiorphan in the inhibitor–enkephalinase docking process demonstrated with some thiorphan isosteres 949
Montesarchio D. see De Napoli L. 315
Moore C. J. see Gregor V. E. 861
Moore J. L. see Brooks D. W. 1357
Moore M. L. see Grant S. K. 1441
Moos W. H. see Jaen J. C. 777
Moos W. H. see Sanders K. B. 803
Moos W. H. see Tecle H. 821
Moos W. H. see Thomas A. J. 855
Moquin R. V. see Weller H. N. 1115
Moran P. J. S. see Somlha A. E. P. M. 191
Moreau N. see Clairefond P. 643
Moreland D. W. see Tecle H. 821
Moreland S. see Atwal K. S. 83
Moreland S. see Atwal K. S. 87
Moreland S. see Barrish J. C. 95
Moreland S. see Weller H. N. 1115
Mori K. and Koga Y. Synthesis and absolute configuration of (−)-stypoldione 391
Morimoto T. see Murakami N. 149
Morrice E. M. see Bone E. A. 223
Morrison R. A. see Misra R. N. 73
Mortellaro M. A. and Czarnik A. W. Hydrogen bonding effects on the reactivity of a preassociating α-nucleophile. The secondary-side βCD hydroxylamine 1635
Moummi C. see Flynn D. L. 1251
Moummi C. see Flynn D. L. 1613
Mount M. E. Evans B. J. Janaki S. and Musker W. K. Preparation of functionalized derivatives of benzimidazole: albendazole and its sulfoxide and sulfone 155
Moutonnier C. see Peyronel J.-F. 37
Moyer M. P. Weber F. H. Gross J. L. Isaac J. W. and Saint Fort R. The synthesis and identification of 4,6-diaminoquinoline derivatives as potent immunostimulants 1589
Mrozik H. see Meinke P. T. 537
Mrozik H. see Sinclair P. J. 1599
Muirhead H. see Kelly M. 553
Mulder G. J. see Noort D. 583
Murakami N. Morimoto T. Shirahashi H. Ueda T. Nagai S. Sakakibara J. and Yamada N. Bioreduction of hydroperoxy fatty acid by cyanobacterium *Phormidium tenue* 149
Murakata M. see Hoshino O. 1561
Murayama E. Miyamoto K. Ochi K. and Kubodera N. Synthesis and immunoregulating activity of vitamin D analogues bearing pregnane side chains 1289
Murphy A. see Yu M. J. 1121
Murray M. V. Lalan P. Gill A. Addo M. F. Lewis J. M. Lee

D. K. H. Rampulla R. Wachter M. P. Hsi J. D. and Underwood D. C. Substituted piperidin-2-one biphenyltetrazoles as angiotensin II antagonists 1775
Murray P. J. see Birch P. J. 1275
Musker W. K. see Mount M. E. 155
Myers M. J. see Earl R. A. 851
Myers S. L. see Sanders K. B. 803

Nacci V. see Campiani G. 1193
Nagai S. see Murakami N. 149
Nahm K. AM1 Study on tetrahedral intermediates of the amides of β-lactam antibiotics and methanol 485
Nahorski S. R. see Liu C. 1523
Nakahashi K. see Ojima I. 219
Nakai M. see Komatsu H. 565
Nakamura F. see Suyama K. 1767
Nakanishi S. see Valentine J. J. 333
Nakatani K. see Boger D. L. 759
Nakatani K. see Fukuda Y. 755
Nakazono Y. see Fukusaki E. 411
Napolitano E. and Pelosi P. Synthesis of thiazole and selenazole derivatives with affinity for the odorant-binding protein 1603
Nashed N. T. see Haber M. T. 1729
Navé J.-F. Wolff-Kugel D. and Halazy S. Carbocyclic phosphonate analogs of 2',3'-dideoxyadenosine-5'-monophosphate as substrates of 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetase 1483
Navé J.-F. see Casara P. J. 145
Nelson M. J. see Wright S. W. 1385
Ngur D. see Messer, Jr W. S. 781
Nicholson N. H. see Elson S. W. 1503
Nickolson V. J. see Earl R. A. 851
Nicolaou K. C. Dai W.-M. Tsay S.-C. and Wrasidlo W. On the mechanism of activation of designed enediynes with selective cytotoxicity 1155
Niedbala H. see Czuchajowski L. 1645
Nikiforovich G. see Misicka A. 547
Nishimura H. see Katsumura S. 1263
Nishimura H. see Katsumura S. 1267
Nishioka I. see Kashiwada Y. 239
Nishioka I. see Kilkuskie R. E. 1529
Nishiwaki-Matsushima R. Fujiki H. Harada K. Taylor C. and Quinn R. J. The role of arginine in interactions of microcystins with protein phosphatases 1 and 2A 673
Nishiwaki-Matsushima R. see Taylor C. 299
Niu C. see Wasserman H. H. 1101
No Z. see Kim J. N. 323
Noble N. J. Dubreuil D. and Potter B. V. L. Total synthesis of *myo*-inositol-1-phosphate-4,5-pyrophosphate, a novel second messenger analogue, via *myo*-inositol-1-phosphate-4,5-bis-phosphorothioate 471
Noël N. see Monteil T. 949
Nonaka G. see Kashiwada Y. 239
Nonaka G. see Kilkuskie R. E. 1529
Noort D. van Straten N. C. R. Boons G. J. P. H. van der Marel G. A. Bossuyt X. Blanckaert N. Mulder G. J. and van Boom J. H. Synthesis of a potential inhibitor of UDP-glucuronosyltransferase 583
Normandin D. E. see Atwal K. S. 1475
Normandin D. E. see Atwal K. S. 83
Normandin D. E. see Atwal K. S. 87
Nosal R. see Flynn D. L. 1613
Nunn D. S. see Pirrung M. C. 1489
Nyberg F. see Jenmalm A. 1693

O'Connor S. see Meinke P. T. 537
O'Reilly B. C. see Atwal K. S. 83
Ochi K. see Murayama E. 1289
Ogletree M. L. see Misra R. N. 73
Oh E. see Lai M.-T. 1423
Ojima I. Kato K. Jamelson F. A. Conway J. Nakahashi K. Hagiwara M. Miyamae T. and Radunz H. E. New potent enkephalin analogs containing trifluoromethyl-amino acid residues 219
Olde-Hanter B. see Basten J. 901
Olde-Hanter B. see Basten J. 905
Olesen P. H. see Sauerberg P. 809
Omata T. see Fukusaki E. 411
Ong C.-W. Jeng J.-Y. Juang S.-S. and Chen C.-F. A ferrocene–intercalator conjugate with a potent cytotoxicity 929
Ong G.-T. Wu S.-H. and Wang K.-T. Additions and Corrections 631
Ong G.-T. Wu S.-H. and Wang K.-T. Preparation of 2,3,6,3',4'-penta-O-acetyl sucrose, the precursor of sucralose, by enzymatic methods 161
Orlek B. S. see Bromidge S. M. 787
Orlek B. S. see Bromidge S. M. 791
Osguthorpe D. J. see Paul P. K. C. 141
Osherov N. see Burke T. R. 1771
Ostlind D. A. see Meinke P. T. 537
Otto M. J. see De Lucca G. V. 1639
Ouimet N. see Labelle M. 1141

Pacaud E. see Maillard M. 1469
Palanki M. S. S. see Grunewald G. L. 1681
Paloma L. G. see Conte M. R. 1299
Palumbo M. see Zagotto G. 659
Pan Y. Merriman R. L. Tanzer L. R. and Fuchs P. L. Synthesis and pharmacological evaluation of nonacyclic and trisdecacyclic pyrazines related to cephalostatin 967
Panchal T. A. see Middlemiss D. 1243
Pandey R. K. Shiau F.-Y. Sumlin A. B. Dougherty T. J. and Smith K. M. Structure/activity relationships among photosensitizers related to pheophorbides and bacteriopheophorbides 491
Pandey R. K. see Meunier I. 1575
Pansegrau P. D. see Marzabadi M. R. 1435
Papageorgiou C. Haltiner R. Bruns C. and Petcher T. J. Design, synthesis, and binding affinity of a nonpeptide mimic of somatostatin 135
Papageorgiou C. see Blum E. 461
Parker R. A. see Balasubramanian N. 99
Parker R. A. see Sit S. Y. 1085
Parsons M. E. see Howson W. 77
Parsons W. H. see Bugianesi R. L. 181
Partyka R. A. see Ueda Y. 1541
Patch R. J. see Hamilton G. S. 1269
Patel D. see Menear K. A. 285

Patel D. V. and Ryono D. E. Retro–inverso tripeptide renin inhibitors 1089
Patel G. F. see Chang L. L. 1207
Patel M. see Puar M. S. 575
Patel M. M. see Misra R. N. 73
Pathirana R. N. see McGuigan C. 701
Paton J. M. S. see Middlemiss D. 1243
Patrick D. H. see Labelle M. 1141
Paul P. K. C. Burney P. A. Campbell M. M. and Osguthorpe D. J. Design of a natural *cis* peptide bond motif to form type VI β-turn mimetic 141
Pavia M. R. see Sanders K. B. 803
Pavia M. R. see Tecle H. 821
Peet N. P. see Angelastro M. R. 1235
Pelosi P. see Napolitano E. 1603
Pennev P. see Rajagopalan P. 721
Pennev P. see Rajagopalan P. 715
Penning T. D. see Djuric S. W. 1367
Pereira D. A. see Snider R. M. 1535
Pereira I. A. C. see Baldwin J. E. 669
Peres A. see Campiani G. 1193
Pérez-Pérez M.-J. Balzarini J. Hosoya M. De Clercq E. and Camarasa M.-J. Synthesis of adamantane spiro sultones as potential antiviral agents 647
Perich J. W. and Reynolds E. C. The use of synthetic phosphopeptides for epitope mapping of the α_{s1}-casein phosphopeptide segment 59–79 1153
Périgaud C. Gosselin G. and Imbach J.-L. Stereospecific synthesis of chiral acyclic analogues of guanosine 677
Periyasamy S. see Messer W. S. 781
Perkins W. E. see Collins P. W. 1761
Perrella F. W. see Seitz S. P. 171
Perrier H. see Labelle M. 1141
Perrone E. see Alpegiani M. 1127
Petcher T. J. see Papageorgiou C. 135
Peters M. see Chang W. K. 399
Peterson J. R. see Chatterjee A. 91
Petit P. see Andrianomenjanahary S. 1093
Petitou M. see Basten J. 901
Petitou M. see Basten J. 905
Petitou M. see Jaurand G. 897
Peyronel J.-F. Truchon A. Moutonnier C. and Garret C. Synthesis of RP-67,580, a new potent nonpeptide Substance P antagonist 37
Pham V. T. see Zheng C. 619
Phebus L. A. see Yu M. J. 1121
Phebus L. A. see Yu M. J. 59
Phillips D. R. see Woodburn K. W. 343
Phillips R. S. see Hebel D. 41
Phillips R. S. see Lee M. 1563
Phillips R. S. see Sloan M. J. 1053
Phillips R. S. see Zheng C. 619
Piccialli G. see De Napoli L. 315
Pickett C. B. see Labelle M. 1141
Piechuta H. see Hutchinson J. H. 1699
Piechuta H. see Labelle M. 1141
Piehler L. T. see Montchamp J.-L. 1349
Piercey M. F. see Romero A. G. 1703
Pieriot C. and Sergheraert C. Solid phase synthesis of 5' non radioactive multiple labelled oligodesoxyribonucleotides 267
Pinto D. J. see Wright S. W. 1079
Pinto I. L. see Buckle D. R. 1161
Pinto I. L. see Smith D. G. 1595
Pirrung M. C. and Nunn D. S. Synthesis of photodeprotectable serine derivatives. 'Caged serine' 1489
Piskorz C. F. see Roy R. 911
Pittel Z. see Fisher A. 839
Pletsch A. see Klar U. 445
Polinelli S. Broxterman Q. B. Schoemaker H. E. Boesten W. H. J. Crisma M. Valle G. Toniolo C. and Kamphuis J. New aspartame-like sweeteners containing L-(αMe)Phe 453
Pollock G. D. see Yu M. J. 1121
Pombo-Villar E. Supavilai P. Weber H. P. and Boddeke H. W. G. M. 6-Carboxymethyl-2-azabicyclo[2.2.1]heptane enantiomers: muscarinic activities of rigid analogues of arecoline 501
Pompon A. see Puech F. 603
Ponpipom M. M. see Bugianesi R. L. 181
Pons M. see García-Echeverría C. 281
Porreca F. see Tourwé D. 1305
Post D. J. see Raushel F. M. 319
Post L. E. see Raushel F. M. 319
Potter B. V. L. see Liu C. 1523
Potter B. V. L. see Noble N. J. 471
Pozsgay V. Glaudemans C. P. J. Robbins J. B. and Schneerson R. A synthetic octasaccharide mimics the native, O-specific determinant of the *Shigella dysenteriae* type 1 lipopolysaccharide 255
Prasit P. Belley M. Brideau C. Chan C. Charleson S. Evans J. F. Fortin R. Ford-Hutchinson A. W. Gillard J. W. Guay J. Hutchinson J. H. Léger S. Riendeau D. Young R. N. and Zamboni R. A new class of leukotriene biosynthesis inhibitors: the discovery of MK0591 1395
Prasit P. see Hutchinson J. H. 1699
Prasit P. see Labelle M. 1141
Pratt R. F. On the definition and classification of mechanism-based enzyme inhibitors 1323
Previtera L. see Della Greca M. 311
Pritchard M. C. see Drysdale M. J. 45
Prücher H. Gottschlich R. Haase A. Stohrer M. and Seyfried C. (5S)-3-Aryl-5-(1-piperidinylmethyl)-2-oxazolidinones, a new class of potential neuroleptics with a high affinity for sigma receptors 165
Prudhomme M. see Fabre S. 449
Puar M. S. Gullo V. Gunnarsson I. Hegde V. Patel M. and Schwartz J. Biosynthesis of macrolactam antifungal agents 575
Puech F. Pompon A. Lefebvre I. Gosselin G. and Imbach J. L. Nucleotidic prodrugs of anti-HIV dideoxynucleosides 603
Pyla E. Y. see Djuric S. W. 1367

Quadri S. M. and Mohammadpour H. Synthesis of 2-*p*-aminobenzyl-3-methyl- and 2-*p*-aminobenzyl-3-benzyl derivatives of diethylenetriaminepentaacetic acids (DTPA): carbon backbone modified bifunctional chelating agents 1661
Quash G. see Driguez P.-A. 1361
Quimby S. J. see Sauerberg P. 809
Quinn R. J. see Dooley M. J. 1199

Quinn R. J. see Moni R. W. 1631
Quinn R. J. see Nishiwaki-Matsushima R. 673
Quinn R. J. see Taylor C. 299

Radunz H. E. see Ojima I. 219
Ragan C. I. see Fletcher S. R. 627
Rai R. see Katzenellenbogen J. A. 1399
Rajagopalan P. Scribner R. M. Pennev P. Schmidt W. K. Tam S. W. Steinfels G. F. and Cook L. DuP 747: a new potent, kappa opioid analgesic. Synthesis and pharmacology 715
Rajagopalan P. Scribner R. M. Pennev P. Mattei P. L. Kezar H. S. Cheng C. Y. Cheeseman R. S. Ganti V. R. Johnson A. L. Wuonola M. A. Schmidt W. K. Tam S. W. Steinfels G. F. and Cook L. DuP 747: SAR study 721
Ramirez G. see Alcalde E. 1493
Rampillon V. see Langlois M. 691
Rampulla R. see Murray M. V. 1775
Rao C. P. Geetha K. and Bandwar R. P. Solution stability of iron–saccharide complexes 997
Rapp M. see Fabre S. 449
Rapson E. see Hodgson S. T. 1257
Rasmusson G. H. see Chang L. L. 1207
Ratajczyk J. D. see Brooks D. W. 1357
Ratcliffe G. S. see Fincham C. I. 403
Raushel F. M. Miles B. W. Post L. E. and Post D. J. Mutational analysis of two putative domains within the large subunit of carbamoyl phosphate synthetase from *Escherichia coli* 319
Raval P. see Howson W. 77
Rawson T. E. and Kogan T. P. The synthesis of a phorbol 12,13-bis-lactone 695
Ray J. see Toth J. E. 1013
Razzano G. see Alpegiani M. 1127
Rees D. C. see Fincham C. I. 403
Reeve M. M. see Bone E. A. 223
Reiss J. A. see Woodburn K. W. 343
Reitz A. B. see Baxter E. W. 1419
Rejzek M. Zarevucká M. and Wimmer Z. Carbamate series of juvenoids 963
Rémy J. M. see Schirlin D. 651
Renau T. E. Ludwig M. S. Drach J. C. and Townsend L. B. Design, synthesis and activity against human cytomegalovirus of non-phosphorylatable analogs of toyocamycin sangivamycin and thiosangivamycin 1755
Renoux B. see Andrianomenjanahary S. 1093
Resch J. F. Lehr G. S. and Wischik C. M. Additions and Corrections 271
Revesz L. see Blum E. 461
Reynolds E. C. see Perich J. W. 1153
Rho T. see Messer W. S. 781
Richardson R. see Howson W. 559
Riddell D. see Ashton M. J. 375
Ridgewell R. E. see Misra R. N. 73
Riendeau D. see Hutchinson J. H. 1699
Riendeau D. see Prasit P. 1395
Riley G. J. see Bromidge S. M. 787
Riley G. J. see Bromidge S. M. 791
Rinker J. M. see Graybill T. L. 1375
Rizzo V. see Alpegiani M. 1127
Robbins J. B. see Pozsgay V. 255
Roberts D. G. M. see Iwanowicz E. J. 1607
Robertson M. J. see Middlemiss D. 1243
Roca T. see Alcalde E. 1493
Rodrigues J. A. R. see Sorrilha A. E. P. M. 191
Rogers H. see Birch P. J. 1275
Roland D. M. see Bhagwat S. S. 1623
Rollins T. see Durette P. L. 1033
Romanowska A. see Roy R. 911
Rombi C. see Maillard M. 1469
Romeo M. R. see Campiani G 1193
Romero A. G. Darlington W. H. Piercey M. F. and Lahti R. A. Synthesis of metabolically stable arylpiperazine 5-HT_{1A} receptor agonists 1703
Romero A. G. and Leiby J. A. An improved synthesis of the dopamine autoreceptor antagonist (+)-*cis*-8-methoxy-1-methyl-2-(dipropylamino)tetralin (AJ-76) 1691
Ronkin S. M. see Ares J. J. 123
Rose W. C. see Kadow J. F. 17
Rosemeyer H. Strodtholz I. and Seela F. 2'-Deoxy-β-D-xylothymidinyl-(3',5')-2'-deoxy-β-D-xylothymidylate: stereochemical course of dinucleoside phosphonate formation and conformational properties 1201
Rosen M. K. Belshaw P. J. Alberg D. G. and Schreiber S. L. The conformation of cyclosporin a bound to cyclophilin is altered (once again) following binding to calcineurin: an analysis of receptor=ligand-receptor interactions 747
Ross B. C. see Middlemiss D. 1243
Ross M. J. see Graybill T. L. 1375
Rotert G. see Brooks D. W. 1353
Rouleau A. see Ganellin C. R. 1231
Rowley M. Leeson P. D. Grimwood S. Foster A. and Saywell K. 2-Carboxy indolines and indoles as potential glycine/NMDA antagonists: effect of five-membered ring conformation on affinity 1627
Rowley M. see Stevenson G. I. 371
Roy P. see Labelle M. 1141
Roy R. Tropper F. D. Romanowska A. Jain R. K. Piskorz C. F. and Matta K. L. Direct access to neoglycoproteins and glycopolymers from single precursors. Synthesis of T-antigen and N-acetyl-lactosamine-β-D-(1→6)-α-D-GalNAc conjugates 911
Roy R. see Tandon J. S. 249
Ruan F. Sadahira Y. Hakomori S. and Igarashi Y. Chemical synthesis of D-*erythro*-sphingosine-1-phosphate, and its inhibitory effect on cell motility 973
Rush D. K. see Gregory Shutske M. 865
Russell K. Gaskin H. and Jessup R. Discovery of dual activity molecules with thromboxane antagonist and thromboxane synthase inhibitory activity 979
Russell K. and Gaskin H. Synthesis of dual activity molecules with thromboxane antagonist and thromboxane synthase inhibitory activity 985
Russell K. see Faull A. W. 1181
Ruterbories K. J. see Yu M. J. 59
Ruterbories K. J. see Yu M. J. 1121
Ryan K. see Messer, Jr W. S. 781
Ryder H. see Kendrick D. A. 9
Ryono D. E. see Patel D. V. 1089
Ryu E. K. see Kim J. N. 323

Ryu E. K. see Kim J. N. 941

Sadahira Y. see Ruan F. 973
Sadek M. see Woodburn K. W. 343
Safrany S. T. see Liu C. 1523
Saint Fort R. see Moyer M. P. 1589
Sakabe I. see Komatsu H. 565
Sakakibara J. see Murakami N. 149
Sall D. J. Berry D. R. Coffman W. J. Craft T. J. Denney M. L. Gifford-Moore D. S. Kellam M. L. and Smith G. F. Characterization of LY806303 as a potent and selective inhibitor of thrombin 1025
Salt D. W. see Livingstone D. J. 213
Sammons R. D. see Leo G. C. 151
Sánchez-Baeza F. see Abad J.-L. 1239
Sandberg M. see Claesson A. 1247
Sanders K. B. Thomas A. J. Pavia M. R. Davis R. E. Coughenour L. L. Myers S. L. Fisher S. and Moos W. H. Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5 803
Sanderson I. see Stevenson G. I. 371
Sanger G. J. see Bermudez J. 1509
Sanghvi Y. S. see Debart F. 1479
Santacroce C. see De Napoli L. 315
Santaniello M. see Misiti D. 1029
Satoh T. see Ikeda T. 709
Sauerberg P. Olesen P. H. Suzdak P. D. Sheardown M. J. Mitch C. H. Quimby S. J. Ward J. S. Bymaster F. P. Sawyer B. D. and Shannon H. E. Synthesis and structure–activity relationships of heterocyclic analogues of the functional M_1 selective muscarinic agonist hexyloxy-TZTP 809
Saulnier M. G. LeBoulluec K. L. Long B. H. Vyas D. M. Crosswell A. R. and Doyle T. W. Synthesis and biological evaluation of 4'-deshydroxy-4'-methyl etoposide and teniposide analogs 1213
Saulnier M. G. see Vyas D. M. 1111
Saussy D. L. see Sofia M. J. 1669
Saussy, Jr D. L. see Sofia M. J. 1675
Sawyer B. D. see Sauerberg P. 809
Saxena G. see Singh C. 497
Saywell K. see Rowley M. 1627
Schaeffer J. M. see Sinclair P. J. 1599
Schirlin D. Tarnus C. Baltzer S. and Rémy J. M. MDL 74147, A novel selective and soluble inhibitor of human renin. Synthesis, structure–activity relationship, species and protease selectivities 651
Schmidt S. P. see Brooks D. W. 1309
Schmidt S. P. see Brooks D. W. 1357
Schmidt W. K. see Rajagopalan P. 715
Schmidt W. K. see Rajagopalan P. 721
Schneerson R. see Pozsgay V. 255
Schneller S. W. see Siddiqi S. M. 1279
Schoemaker H. E. see Polinelli S. 453
Schow S. R. see Babine R. E. 541
Schreiber S. L. see Rosen M. K. 747
Schricker B. Thirring K. and Berner H. α-Chymotrypsin catalyzed enantioselective hydrolysis of alkenyl-α-amino acid esters 387
Schumacher W. A. see Misra R. N. 73
Schwab J. M. see Henderson B. S. 1381
Schwartz J. see Puar M. S. 575
Schwartz J. C. see Ganellin C. R. 1231
Schwartz J. C. see Monteil T. 949
Schwartz M. E. Breaker R. R. Asteriadis G. T. deBear J. S. and Gough G. R. Rapid synthesis of oligoribonucleotides using 2'-*O*-(*o*-nitrobenzyloxy-methyl)-protected monomers 1019
Schwarz R. D. see Tecle H. 821
Schwarz R. D. see Thomas A. J. 855
Scopes D. I. see Davies A. J. 481
Scopes D. I. C. see Birch P. J. 1275
Scribner R. M. see Rajagopalan P. 715
Scribner R. M. see Earl R. A. 851
Scribner R. M. see Rajagopalan P. 721
Scully F. E. see Wasserman H. H. 1137
Seaman W. see Czuchajowski L. 1645
Searle M. S. and Williams D. H. Consequences for molecular recognition and ligand–receptor complementarity of entropy changes in phase transitions 993
Seela F. see Rosemeyer H. 1201
Seiler S. M. see Iwanowicz E. J. 1607
Seitz S. P. Kaltenbach R. F., III Vroekamp R. H. Calabrese J. C. and Perrella F. W. Synthesis and enzymatic properties of a deoxy analog of phos- phatidylinositol 171
Semmelhack M. F. see Babine R. E. 541
Semple G. see Kendrick D. A. 9
Senda S. see Fukusaki E. 411
Senge M. O. see Meunier I. 1575
Sergheraert C. see Pierlot C. 267
Sessions R. B. see Kelly M. 553
Seyfried C. see Prücher H. 165
Shah P. see Middlemiss D. 1243
Shah S. K. see Hagmann W. K. 681
Shankaran K. and Blizzard T. A. Synthesis and activities of 9-pyrrolo-9-deoxoerythromycin A analogs 1555
Shannon H. E. see Sauerberg P. 809
Shapiro G. Floersheim P. Amstutz R. Boddeke H. Bolliger G. Cottens S. Enz A. Gmelin G. Gull P. and Supavilai P. Muscarinic agonist SAR of azaspirodioxolanes 815
Shaw P. N. see Blagbrough I. S. 1219
Shaw P. N. see Buckberry L. D. 1225
Sheardown M. J. see Sauerberg P. 809
Shen S. see Langlois M. 691
Shen X. see Tung C.-H. 303
Sher P. M. see Misra R. N. 73
Sherk S. R. see Wright S. W. 1079
Shetty S. see Bhagwat S. S. 1619
Shiau F.-Y. see Pandey R. K. 491
Shih C. Grindey G. B. Taylor E. C. and Harrington P. M. Synthesis and biological activity of nor- and homo-5,10-dideazatetrahydro-folic acid 339
Shinozaki H. see Hashimoto K. 743
Shirahama H. see Hashimoto K. 743
Shirahashi H. see Murakami N. 149
Shone R. L. see Collins P. W. 1761
Shoop W. L. see Meinke P. T. 537

Shoop W. L. see Sinclair P. J. 1599
Shultz T. see Czuchajowski L. 1645
Siciliano S. see Durette P. L. 1033
Siddiqi S. M. Chen X. and Schneller S. W. (±)-7-Deazacarbovir as a compound with potential anti-HIV and anti-HCMV properties 1279
Sieburth S. McN. Ali S. F. Langevine C. M. and Tuliman R. H. Stereoselective synthesis of hydroxylated bifenthrin isomers 1585
Sikorski J. A. see Leo G. C. 151
Sikorski J. A. see Marzabadi M. R. 1435
Silbaugh S. A. see Sofia M. J. 1669
Silbaugh S. A. see Sofia M. J. 1675
Silverman R. B. see Hopkins M. H. 1371
Šimánek V. see Ulrichová J. 1097
Sime J. T. see Elson S. W. 1503
Simpelkamp J. and Jones J. B. Borinic acid inhibitors as probes of the factors involved in binding at the active sites of subtilisin Carlsberg and α-chymotrypsin 1391
Simpson P. J. see Yu M. J. 59
Sinclair P. see Meinke P. T. 537
Sinclair P. J. Schaeffer J. M. Shoop W. L. and Mrozik H. The preparation and utilization of paraherquamide-2-O-methyl imidate in the synthesis of 14-O-substituted paraherquamide derivatives 1599
Singh C. Misra D. Saxena G. and Chandra S. Synthesis of *in vivo* potent antimalarial 1,2,4-trioxanes 497
Sit S. Y. Parker R. A. and Wright J. J. Synthesis of tetrazol-1-yl analogs of HMG–CoA reductase inhibitor BMS180431 (formerly BMY21950) 1085
Skibo E. B. see Dempcy R. O. 1427
Skuballa W. see Klar U. 445
Skwish S. see Weller H. N. 1115
Sloan M. J. and Phillips R. S. Enzymatic synthesis of aza-L-tryptophans: the preparation of 5- and 6-aza-L-tryptophan 1053
Smallwood J. K. see Yu M. J. 59
Smith C. see Ashton M. J. 375
Smith D. G. Buckle D. R. Faller A. and Pinto I. L. Pyrrole analogues of the pyrrolidinone moiety of the potassium channel activator cromakalim as relaxants of guinea pig trachealis 1595
Smith D. G. see Buckle D. R. 1161
Smith D. M. see Hadley M. S. 1147
Smith G. F. see Sall D. J. 1025
Smith K. M. see Meunier I. 1575
Smith K. M. see Pandey R. K. 491
Snider R. M. Pereira D. A. Longo K. P. Davidson R. E. Vinick F. J. Laitinen K. Genc-Sehitoglu E. and Crawley J. N. UK-73,093: A non-peptide neurotensin receptor antagonist 1535
Snider R. M. see Valentine J. J. 333
Snoeck R. see Herdewijn P. 1057
Snyder R. D. see Casara P. J. 145
Sofia M. J. Jackson W. T. Saussy D. L. Jr Silbaugh S. A. Froelich L. L. Cockerham S. L. and Stengel P. W. *ortho*-Alkoxyphenol leukotriene B_4 receptor antagonists 1669
Sofia M. J. Saussy, Jr D. L. Jackson W. T. Marder P. Silbaugh S. A. Froelich L. L. Cockerham S. L. and Stengel P. W. *ortho*-Alkoxyphenol leukotriene B_4 receptor antagonists: effect of a chroman carboxylic acid 1675
Sorriiha A. E. P. M. Marques M. Joekes I. Moran P. J. S. and Rodrigues J. A. R. Reduction of phenylketones by immobilized baker's yeast 191
Soubrié P. see Wermuth C. G. 833
Soulier J. L. see Langlois M. 691
Spangler D. P. see Flynn D. L. 1613
Spees M. M. see Mohamadi F. 987
Spencer C. J. see Thomas A. J. 855
Spencer R. W. see Valentine J. J. 333
Spergel S. H. see Barrish J. C. 95
Sprague P. W. see Misra R. N. 73
Springer M. S. see Durette P. L. 1033
Stanga M. A. see Groutas W. C. 1571
Stansfield I. see Stevenson G. I. 371
Starr S. see Bermudez J. 519
Stefanova I. see Burke T. R. 1771
Stein H. H. see Baker W. R. 1405
Stein S. see Tung C.-H. 303
Steinberg M. I. see Yu M. J. 1121
Steinfels G. F. see Rajagopalan P. 715
Steinfels G. F. see Rajagopalan P. 721
Stengel P. W. see Sofia M. J. 1669
Stengel P. W. see Sofia M. J. 1675
Stephenson P. T. see Terrett N. K. 1745
Stevenson G. I. Leeson P. D. Rowley M. Sanderson I. and Stansfield I. Synthesis of *cis* and *trans* 4-amido 2-carboxytetrahydroquinolines, high affinity ligands at the glycine site of the NMDA receptor 371
Still W. C. see Li G. 731
Stimson W. H. see Suckling C. J. 49
Stohrer M. see Prücher H. 165
Stowell J. G. Toma P. H. and Byrn S. R. The structure of MK-571 (Form I) at 170 K and conformational analysis by molecular modeling 185
Strodtholz I. see Rosemeyer H. 1201
Stütz A. E. see Berger A. 27
Suckling C. J. Tedford M. C. Bence L. M. Irvine J. I. and Stimson W. H. An antibody with dual catalytic activity 49
Sugimoto H. Iimura Y. Yamanishi Y. and Yamatsu K. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds 871
Suh J. H. see Yoo S. 381
Sumlin A. B. see Pandey R. K. 491
Summersell R. J. see Bermudez J. 519
Sungur S. see Bayramoglu Z. 427
Sungur S. see Elçin M. 433
Supavilai P. see Pombo-Villar E. 501
Supavilai P. see Shapiro G. 815
Sutherland J. D. see Baldwin J. E. 663
Sutherland J. D. see Baldwin J. E. 669
Suyama K. and Nakamura F. Two fluorescent crosslinking amino acids having N-substituted dihydrooxopyridine skeleton isolated from bovine elastin 1767
Suzdak P. D. see Sauerberg P. 809

Suzuki F. see Hayashi H. 1187
Suzuki T. and Kasai N. Additions and Corrections 105
Swahn B.-M. see Claesson A. 1247
Swaminathan P. see Cliffe I. A. 245
Swayne G. T. G. see Howson W. 77
Swenton L. see Djuric S. W. 1367
Symons J. P. see Thomas A. J. 855
Szelke M. see Kendrick D. A. 9

Tafi A. see Campiani G. 1193
Takaku H. see Komatsu H. 565
Tam S. W. see Rajagopalan P. 715
Tam S. W. see Earl R. A. 851
Tam S. W. see Rajagopalan P. 721
Tandon J. S. Roy R. Balachandran S. and Vishwakarma R. A. epi-Deoxycoleonol, a new antihypertensive labdane diterpenoid from *Coleus forskohlii* 249
Tanzer L. R. see Pan Y. 967
Tarnus C. see Schirlin D. 651
Taylor C. Quinn R. J. McCulloch R. Nishiwaki-Matsushima R. and Fujiki H. An alternative computer model of the 3-dimensional structures of microcystin-LR and nodularin rationalising their interactions with protein phosphatases 1 and 2A 299
Taylor C. see Nishiwaki-Matsushima R. 673
Taylor E. C. see Shih C. 339
Taylor P. W. see Menear K. A. 285
Taylor R. J. K. see Briggs J. C. 127
Taylor R. J. K. see Briggs J. C. 131
Taylor R. J. K. see Davies A. J. 481
Teall M. see Fletcher S. R. 627
Tecle H. Lauffer D. J. Mirzadegan T. Moos W. H. Moreland D. W. Pavia M. R. Schwarz R. D. and Davis R. E. A rationale for the design and synthesis of m1 selective muscarinic agonists 821
Tedder J. M. see Buckle D. R. 1161
Tedford M. C. see Suckling C. J. 49
Terashima S. see Boger D. L. 759
Terashima S. see Fukuda Y. 755
Terenius L. see Jenmalm A. 1693
Terrett N. K. Bojanic D. Merson J. R. and Stephenson P. T. Imidazo[2',3':6,5]dipyrido[3,2-*b*:2',3'-*e*]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine 1745
Tertiuk W. see Ganellin C. R. 1231
Tessel R. see Doughty M. B. 1497
Thatcher G. R. J. see Campbell A. S. 655
Thérisod M. see Lubineau A. 607
Thiem H.-J. Wiedenfeld D. J. Lee J.-G. and Friesner R. A. AMBER force field parameters for the trimethyl-anilinium cation 291
Thierry D. see Maillard M. 1469
Thirring K. see Schricker B. 387
Thomas A. J. Kester J. A. Butler D. E. Hershenson F. M. Davis R. E. Marriott J. G. Schwarz R. D. Spencer C. J. Symons J. P. and Moos W. H. Acetylcholine-releasing agents as cognition activators. Chemistry and pharmacology of a series of ureas 855
Thomas A. J. see Sanders K. B. 803
Thompson C. M. see Huh N. 1551
Thompson C. M. see Jackson J. A. 1547
Thompson K. R. see Hagmann W. K. 681
Thorn S. N. see Delisser V. M. 421
Tillequin F. see Andrianomenjanahary S. 1093
Timmerman H. see Zhang M.-Q. 1283
Toda F. see Ikeda H. 1581
Todd R. S. see Bone E. A. 223
Tolbert T. J. see Montchamp J.-L. 1349
Tolman R. L. see Chang L. L. 1207
Toma P. H. see Stowell J. G. 185
Tomaszek, Jr T. A. see Grant S. K. 1441
Tomer J. D. see Gregory Shutske M. 865
Toniolo C. see Polinelli S. 453
Toth J. E. Ray J. and Ehlhardt W. J. The synthesis of *o*-aminophenyl sulfate metabolites of the oncolytic sulfonylureas 1013
Tourwé D. Verschueren K. Van Binst G. Davis P. Porreca F. and Hruby V. J. Dermorphin sequence with high δ-affinity by fixing the PHE sidechain to trans at χ_1 1305
Towner R. D. see Yu M. J. 1121
Townsend L. B. see Devivar R. V. 1105
Townsend L. B. see Renau T. E. 1755
Tronchet J. M. J. Zsély M. Capek K. and de VilledondeNaide F. Synthesis and anti-HIV activity of 3'-deoxy-3'-(*N*-hydroxyamino) analogues of nucleosides 1723
Tropper F. D. see Roy R. 911
Truchon A. see Peyronel J.-F. 37
Trybulski E. J. Kramss R. H. Mangano R. M. Brabander H. J. and Francisco G. The synthesis and structure–activity relationships of enantiomerically pure hydroxylated oxotremorine derivatives 827
Tsai Y.-C. see Chen H.-P. 697
Tsay S.-C. see Nicolaou K. C. 1155
Tullman R. H. see Sieburth S. McN. 1585
Tulshian D. B. Gundes A. F. and Czarniecki M. Versatile synthesis of dihydroxy γ and δ amino acids from carbohydrates 515
Tung C.-H. Ebright Y. Shen X. and Stein S. A peptide–acridine conjugate with ribonucleolytic activity 303
Turner D. H. see Hadley M. S. 1293
Turner D. H. see Hadley M. S. 1147
Turner-Brown S. J. see Denyer C. V. 1039

Ueda T. see Murakami N. 149
Ueda Y. Mikkilineni A. and Partyka R. A. Synthesis of α-(*S*)-acylamino-*N*-(hydroxydioxocyclobutenyl)-β-lactams as potential antibiotics 1541
Ueno H. see Hayashi H. 1187
Ulrichová J. Walterová D. Brezina F. and Šimánek V. Inhibition of the yeast alcoholdehydrogenase by Cu(II)-complexes of colchiceine and *N*-deacetylcolchiceine 1097
Uncapher C. see Chang L. L. 1207
Underwood D. C. see Murray M. V. 1775
Ungerank M. see Berger A. 27
Uriarte E. see Zagotto G. 659

Valentine J. J. Nakanishi S. Hageman D. L. Snider R. M. Spencer R. W. and Vinick F. J. CP-70,030 and CP-75,998: the first non-peptide antagonists of bombesin and gastrin releasing peptide 333
Valle G. see Polinelli S. 453
VanAerschot A. see Augustyns K. 945
VanAerschot A. see Herdewijn P. 1057
Van Binst G. see Tourwé D. 1305
van Boeckel C. A. A. see Jaurand G. 897
van Boeckel C. A. A. see Basten J. 901
van Boeckel C. A. A. see Basten J. 905
Van der Eycken J. see D'Halleweyn C. 477
Van der Velde D. see Grunewald G. L. 1681
Van Haver D. see D'Halleweyn C. 477
Vandewalle M. see D'Halleweyn C. 477
van Boom J. H. see Noort D. 583
van der Marel G. A. see Noort D. 583
van Straten N. C. R. see Noort D. 583
Vasseur J.-J. see Debart F. 1479
Venkataraman R. see Groutas W. C. 1571
Venkataraman R. see Groutas W. C. 175
Venuti M. C. see Webb, II R. R. 457
Verschueren K. see Tourwé D. 1305
Villamil C. I. see Flynn D. L. 1251
Villani-Price D. see Djuric S. W. 1367
Vinick F. J. see Snider R. M. 1535
Vinick F. J. see Valentine J. J. 333
Vishwakarma R. A. see Tandon J. S. 249
Vogel Z. see Fisher A. 839
Vorbrüggen H. see Deicke P. 439
Vorbrüggen H. see Klar U. 445
Vreekamp R. H. see Seitz S. P. 171
Vyas D. M. Kadow J. F. LeBoulluec K. L. Saulnier M. G. and Doyle T. W. Etoposide (VP16): chemical reactivity of etoposide *ortho*-quinone with amines and thiols 1111
Vyas D. M. see Kadow J. F. 17
Vyas D. M. see Saulnier M. G. 1213
Wachter M. P. see Murray M. V. 1775
Wadsworth A. H. see Davies A. J. 481
Waelchli R. see Blum E. 461
Walker M. M. see Meunier I. 1575
Wallace L. J. see Ares J. J. 123
Walterová D. see Ulrichová J. 1097
Walton L. see Howson W. 559
Wang C. see Earl R. A. 851
Wang G. T. and Krafft G. A. Automated synthesis of fluorogenic protease substrates: design of probes for Alzheimer's disease-associated proteases 1665
Wang K.-T. see Chen H.-P. 697
Wang K.-T. see Chen S.-T. 1685
Wang K.-T. see Ong G.-T. 161
Wang K.-T. see Ong G.-T. 631
Wang P. see Wasserman H. H. 1137
Wang Y. see Chackalamannil S. 1003
Wang Z. see Labelle M. 1141
Ward J. S. see Sauerberg P. 809
Warren T. G. see Djuric S. W. 1367
Wasserman H. H. Ching T. Y. Lipshutz B. H. Matsuyama H. Scully Jr. F. E. and Wang P. Synthesis and kinetic studies of a novel singlet oxygen donor with acceptor-binding capability 1137
Wasserman H. H. and Niu C. Pyrrole derivatives of 6-APA and 7-ACA. Oxygenation by singlet oxygen 1101
Watkins W. J. see Faull A. W. 1181
Watling K. see Howson W. 559
Watson S. P. see Middlemiss D. 1243
Watts S. D. M. see Hodgson S. T. 1257
Wayne M. see Faull A. W. 1181
Webb M. L. see Misra R. N. 73
Webb M. L. see Misra R. N. 937
Webb, II R. R. and Venuti M. C. Synthesis and biological activity of a 5,6-substituted teleocidin 457
Weber F. H. see Moyer M. P. 1589
Weber H. P. see Pombo-Villar E. 501
Weller H. N. Miller A. V. Moquin R. V. Dickinson K. E. J. Hedberg S. A. Moreland S. Cohen R. B. Delaney C. L. Skwish S. and Williams S. Benzothiadiazine dioxides: a new class of potent angiotensin-II (AT_1) receptor antagonists 1115
Wenting H. see Earl R. A. 851
Wermuth C. G. Bourguignon J.-J. Hoffmann R. Boigegrain R. Brodin R. Kan J.-P. and Soubrié P. SR 46559 A and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome 833
Werner K. M. see Hecker S. J. 533
Werner K. M. see Hecker S. J. 1015
Werner K. M. see Hecker S. J. 1043
Weston H. see Hagmann W. K. 681
Weston J. B. see Crombie L. 13
White A. C. see Cliffe I. A. 245
White I. M. see Bone E. A. 223
White R. E. see Misra R. N. 73
Whittaker M. see Hodgkin E. E. 597
Wiedenfeld D. J. see Thiem H.-J. 291
Wilkerson W. W. see Earl R. A. 851
Williams D. H. see Searle M. S. 993
Williams H. see Labelle M. 1141
Williams J. R. and Boehm J. C. The synthesis and reactivity of β,γ-acetylenic and allenic sulfoxides and sulfones of dehydroepiandrosterone and their reactions with 1-butanethiol and glucose-6-phosphate dehydrogenase 933
Williams S. see Weller H. N. 1115
Williamson J. S. see Chatterjee A. 91
Willis R. J. see Moni R. W. 1631
Wimmer Z. see Rejzek M. 963
Wint L. T. see McCarthy P. A. 119
Wischik C. M. see Resch J. F. 271
Woerner F. J. see Jadhav P. K. 353
Wolfe M. S. see Liu S. 1741
Wolfe M. S. see Aubé J. 925
Wolff-Kugel D. see Navé J.-F. 1483
Wong C.-H. see Dumas D. P. 33
Wong P. L. see Moeller K. D. 739
Woodburn K. W. Phillips D. R. Bellinger G. C. A. Sadek M. Brownlee R. T. C. and Reiss J. A. Synthesis and phototoxicity of a series of haematoporphyrin analogues 343
Woroniecki S. R. see Elson S. W. 1503
Wrasidlo W. see Nicolaou K. C. 1155

Wrigglesworth R. see Delisser V. M. 421
Wright C. D. see Boschelli D. H. 705
Wright C. D. see Kramer J. B. 1655
Wright G. D. and Honek J. F. Synthesis and evaluation of photoaffinity probes directed at lanosterol 14α-demethylase ($P\text{-}450_{14DM}$) 383
Wright J. J. see Balasubramanian N. 99
Wright J. J. see Sit S. Y. 1085
Wright S. W. Pinto D. J. Sherk S. R. Green A. M. and Magolda R. L. Vinylogous hydroxamic acids: 5-lipoxygenase inhibitors 1079
Wright S. W. and Nelson M. J. Episulfide inhibitors of lipoxygenase 1385
Wu J.-P. see Bigge C. F. 207
Wu M. S. see Bugianesi R. L. 181
Wu S.-H. see Chen H.-P. 697
Wu S.-H. see Ong G.-T. 161
Wu S.-H. see Ong G.-T. 631
Wuonola M. A. see Rajagopalan P. 721
Wuonola M. A. see Earl R. A. 851

Xiang Y. B. see Labelle M. 1141

Yamada K. see Hoshino O. 1561
Yamada N. see Murakami N. 149
Yamamura H. I. see Misicka A. 547
Yamanaka G. see Chang L. L. 1207
Yamanishi Y. see Sugimoto H. 871
Yamatsu K. see Sugimoto H. 871
Yang D.-C. see Flynn D. L. 1251
Yang D.-C. see Flynn D. L. 1613
Yang W. see Boger D. L. 1649
Yang W. see Boger D. L. 261
Yang W. see Boger D. L. 959
Yang Y.-B. see Chen H.-P. 697
Yoo S. Suh J. H. Lee S. J. and Jeong N. A new efficient synthesis of Ro-31-6930, a potent potassium channel activator, and its analogs 381
Young P. see Brooks D. W. 1353
Young P. see Brooks D. W. 1357
Young P. R. see Brooks D. W. 1309
Young R. C. see Kaumann A. J. 419
Young R. J. Cortez C. Luna E. Lee H. and Harvey R. G. Synthesis of biologically active dihydrodiol metabolites of 16,17-dihydro-15*H*-cyclopenta[*a*]phenanthrene and its carcinogenic 11-methyl and 17-keto derivatives 23
Young R. N. see Labelle M. 1141
Young R. N. see Prasit P. 1395
Yu L. and Dennis E. A. Kinetic analysis of the competitive inhibition of phospholipase A_2 in Triton X-100 mixed micelles 1343
Yu M. J. McCowan J. R. Bertsch B. Ho P. P. K. Phebus L. A. Ruterbories K. J. Lindstrom T. D. Smallwood J. K. and Simpson P. J. Phenothiazine and phenoxazine derivatives of nafazatrom. *In vitro* evaluation as 5-lipoxygenase and iron-dependent lipid peroxidation inhibitors 59
Yu M. J. McCowan J. R. Towner R. D. Ho P. P. K. Phebus L. A. Ruterbories K. J. Lindstrom T. D. Boyd R. Jackson W. T. Ertel P. J. Steinberg M. I. Murphy A. Breau A. Pollock G. D. and Hahn R. A. Structurally novel antiarrhythmic/antioxidant quinazolines 1121
Yuan C. see Liu S. 1741
Yuasa H. see Fukusaki E. 411
Yun W. see Boger D. L. 759

Zaczek R. see Earl R. A. 851
Zagotto G. Uriarte E. Antonello C. Conconi M. T. Marciani Magno S. and Palumbo M. New hydroxy-amido-anthraquinones as potential antineoplastic drugs 559
Zambias R. A. see Durette P. L. 1033
Zamboni R. see Prasit P. 1395
Zamboni R. J. see Labelle M. 1141
Zappia G. see Misiti D. 1029
Zarevucká M. see Rejzek M. 963
Zerial A. see Maillard M. 1469
Zhang L. see Hansch C. 1165
Zhang M.-Q. Caldirola P. Leysen D. C. Timmerman H. Novel stereoselective calcium channel ligands of the diphenylalkylamine-type 1283
Zhang N. see Babine R. E. 541
Zhang X. see Earl R. A. 851
Zheng C. Pham V. T. and Phillips R. S. Asymmetric reduction of ketoesters with alcohol dehydrogenase from Thermoanaerobacter ethanolicus 619
Zhou G. see Chang W. K. 399
Zjawiony J. K. see Chatterjee A. 91
Zsély M. see Tronchet J. M. J. 1723

Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication for Rapid Dissemination of
Preliminary Communications on all Aspects of Bioorganic Chemistry,
Medicinal Chemistry and Related Disciplines

AIMS AND SCOPE

Bioorganic & Medicinal Chemistry Letters (*BioMed. Chem. Lett.*) presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal will publish preliminary communications in camera-ready form in much the same format as *Tetrahedron Letters* and strives to provide maximum dissemination to a large, international audience, the outstanding advances in bioorganic chemistry, medicinal chemistry, and related disciplines.

Topics relevant to but not limited to the journal include:

- bioorganic chemistry, all aspects
- medicinal chemistry, all aspects
- design, synthesis, and evaluation of enzyme inhibitors
- elucidation of enzyme mechanism and structure
- chemistry of enzymatic and metabolic pathways
- biosynthesis
- kinetic, spectroscopic, isotopic, and stereochemical studies of enzymatic and metabolic reactions
- chemical models for enzymes, peptides, and biological macromolecules
- coenzyme structure and reactivity
- protein/enzyme structure–function studies
- catalyst systems that mimic enzymes
- structure, mechanism, synthesis, and evaluation of pheromones
- chemical modification of nucleic acids
- physical, chemical, biochemical, and biological aspects of nucleic acids
- DNA:agent and DNA:protein interactions
- catalytic antibodies
- enzymes in organic synthesis
- molecular recognition
- isolation, structure determination, and synthesis of bioactive agents
- bioconjugates
- molecular basis for protein function
- design, synthesis, and evaluation of biologically active agents and novel drugs
- structure–activity relationship (SAR) studies
- chemical–biological relationships, all aspects
- development of novel receptor models
- molecular modeling, conformational analysis, QSAR
- physicochemical studies on established drugs pertinent to the mechanism of action
- drug delivery
- drug metabolism, metabolic transformation of drugs
- design, synthesis, and evaluation of diagnostic agents

Printed in Great Britain at BPCC-AUP Aberdeen Ltd.